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1.1. FRACTURE HEALING 
1.1.1. Epidemiology, social and economic burdens of fractures 
Bone fractures are common musculoskeletal injuries 1. Approximately 6.8 million 
fractures occur annually in the United States 2, and an epidemiological study from 2008 
revealed that the incidence rate of fractures in England was 3.6 cases per hundred 
people per year 3. In addition, the study showed that the lifetime prevalence of fractures 
was >50% in males aged 34-55 years and approximately 40% in women over 75 years 
old. Furthermore, it has been observed that the fracture location is associated with age. 
In this context, a study indicated that approximately one-third of hip, vertebral and 
other fractures (pelvis, clavicle, humerus, wrist, forearm and leg) occurred in people 
aged 50-64 years 4, whereas tibial fractures more frequently occurred in adults who are 
less than or close to 50 years old 5. 
The social and economic burdens of fractures are considerable 6, and as the patient 
population continues to age worldwide, the incidence of osteoporosis-related fractures 
is rising 7. Researchers have reported that expenditures on osteoporosis-related 
fractures in the United States range from $10 billion to $17 billion every year, and it is 
estimated that those annual costs could be $25.3 billion by 2025 8. Ström et al. found 
that osteoporosis-related costs in 2011 were approximately €30.7 billion in six 
European countries, including Germany, France, the United Kingdom, Italy, Spain and 
Sweden. It is important to note that the majority of osteoporosis-related medical costs 
in those six countries were attributed to fractures, while only 4.7% of total costs were 
related to pharmacological treatment 9. 
It is obvious that both direct medical healthcare costs and indirect expenditures due to 
disability or loss of work productivity are strongly correlated with the healing time, 
which varies according to fracture location, classification and treatment method 10. 
According to Parziale et al., the healing time ranged from 6-8 weeks for proximal 
humerus fractures to 12-16 weeks for femoral fractures. An additional period of 12-52 
weeks and 15-30 weeks might be added to reach a complete recovery for proximal 
humerus fractures and femoral fractures, respectively. Approximately one-third of 
patients with a unilateral fracture of the lower extremity were unable to return to work 
within one year after initial injury 10. In the last three decades, the rate of fracture 
healing has been greatly improved because of an increased understanding of fracture 
repair and advancements in fixation instruments and techniques. 
According to the Global Burden of Disease Study 2017 11, life expectancy increased 
worldwide by 7.4 years, from 65.6 years (65.3–65.8) in 1990 to 73.0 years (72.7–73.3) 
in 2017. However, in most countries, the increase in the number of years of life expected 
to be lived in good health was smaller than the increase in overall life expectancy, 
indicating more years lived in poor health. Those findings challenge medical science to 
improve Health Adjusted Life Expectancy (HALE) by further improving diagnostics and 
treatments for conditions which have a high burden of disease. At the same time, this 
sharpens the current discussion regarding whether the increasing possibilities of 
medical diagnostics and therapies outweigh the associated increasing costs to society. 
The burden of disease is expressed in disability-adjusted life-years (DALYs), and 
traumatological causes play a considerable role in the overall burden of disease. Among 
the top 30 leading causes of DALYs, road injuries (men: 49.8 million [95% CI 47.3–52.1] 
DALYs; women: 18.0 million [16.6–19.4] DALYs) and falls (men: 21.0 million [17.6–
16
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24.9] DALYs; women: 15.0 million [12.3–18.0] DALYs) have had stable positions over 
the last 30 years for both men and women 11. 
1.1.2. The process of fracture healing 
Contrary to the healing of other tissues, bone tissue in fracture healing regenerates to 
the original tissue with the same biochemical and biomechanical characteristics as 
before the injury. That is one reason why fracture healing takes longer than the healing 
of soft tissues 12. 
The healing of bone is a complex, dynamic process which entails different stages. 
Adequate fracture healing depends on the interaction of many biomechanical and 
biological factors, as described in the ´diamond concept´ of fracture healing by 
Giannoudis and colleagues 13. According to this concept, Giannoudis explains that for 
adequate bone restoration and regeneration to occur, besides growth factors, scaffolds 
and mesenchymal stem cells (triangular concept), the mechanical environment plays at 
least an equally important role. In the fairly complex process of bone repair, the 
coordination of cells and numerous mediators is required 14. Primary (direct) and 
secondary (indirect) bone healing are considered to be the two basic histological routes 
of fracture repair 13. Primary fracture healing is the goal every surgeon wants to achieve 
because the healing period is shorter than for indirect fracture repair 15. However, this 
type of bone fracture healing is rare because it requires certain necessary conditions, 
including a rigid fixation and an anatomic reposition of the fracture fragments without 
a bone gap between both sides of the fracture ends. In fact, most fractures, including 
those treated operatively, heal via secondary healing, including intramembranous and 
endochondral ossification. Generally, the secondary fracture healing process is 
differentiated into four partially overlapping stages: the inflammation stage, the soft (or 
bridging) callus formation stage, the hard (or medullary) callus formation stage and the 
remodelling stage (Figure 1.1.). 
1.1.2.1. Inflammation stage 
The inflammatory response starts with the fracture and the immediate excretion of 
inflammatory exudate into the fracture gap. This phase is necessary to initiate the 
healing process, and it peaks within the first 24 hours and disappears completely about 
5-7 days after fracture. In this stage the fracture haematoma originates, organises and 
forms a link between the fracture fragments. The fracture haematoma consists of 
coagulated bleeding around the fracture sides and provides a template for callus 
formation 16. The platelets in the haematoma are aggregated and degranulated. They 
then release growth factors and stimulate the subsequent chemotactic signals. Different 
cells, including monocytes, lymphocytes and macrophages, are attracted to the 
haematoma, and cytokines including TNF-α (tumour necrosis factor-α) and interleukins 
(ILs) such as interleukin-1 (IL-1), IL-6, IL-11 and IL-18 are secreted and enhanced 
within the first few days following the initial fracture 17. Other inflammatory cells are 
attracted by the pro-inflammatory cytokines mentioned above, leading to the further 
aggregation of platelets and the stimulation of angiogenesis. Hypoxic changes are 
present at both sides of the fracture site and in bone marrow during the first few days 
because the blood supply to the affected bone is disrupted 18. Macrophages participate 
in regulating the early stage of fracture repair as they not only phagocytize and kill 
necrotic tissue but also regulate revascularisation 19. 
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Figure 1.1. A schematic representation of the secondary fracture healing process. (a) Inflammation 
stage: the haematoma is formed as a result of a disruption of blood vessels after trauma, then numerous 
inflammatory cells and biological factors occur to initiate the bone healing process. (b) Soft callus formation 
stage: neovascularization occurs (angiogenesis) and fibroblasts deposit (fibro) cartilage tissue. (c) Hard 
callus formation stage: the immature woven bone is replaced by woven bone through intramembranous or 
endochondral bone formation. (d) Remodelling stage: the woven bone is replaced by lamellar bone and the 
biomechanical properties are restored. [This illustration by Smart Servier Medical Art is licensed under Creative 
Commons CC-BY-SA 3.0 (https://smart.servier.com/)]. 
 
The recruitment, proliferation and differentiation of mesenchymal stem cells (MSCs) 
are also necessary for bone regeneration. First, MSCs are recruited to the fracture site 
by stromal cell-derived factor-1 (SDF-1) and G-protein-coupled receptor CXCr-4 20,21. 
Then, TNF-α stimulates the differentiation of MSCs into osteoblasts and chondrocytes 
by activating the expression of tumour necrosis factor receptor-1 (TNFR-1) and tumour 
necrosis factor receptor-2 (TNFR-2), which are expressed on osteoblasts and 
osteoclasts 22. IL-1 and IL-6 are two essential interleukins for bone repair because either 
the generation of cartilaginous callus or angiogenesis is mediated by IL-1 23,24, while the 
differentiation of osteoblasts and osteoclasts is regulated by IL-6 25. The whole process 
of the inflammatory phase promotes the generation of granulation tissue and the 
formation of new blood vessels. 
1.1.2.2. Soft (or bridging) callus formation stage 
By the end of the first week following trauma, a cartilaginous callus tissue called a ‘soft-
tissue callus’ or ‘pro-callus’ is generated surrounding the fracture site. This soft tissue 
callus consists of different components, including fibrous connective tissue, newly 
generated blood vessels, collagen fibres, cartilage and immature woven bone 26,27. The 
fibroblasts within the granulation haematoma, influenced by different growth factors, 
such as transforming growth factor-β1 (TGF-β1) and platelet-derived growth factor 
(PDGF), deposit fibrocartilage and cartilage tissue, which forms a weak bridge between 
the fracture fragments and reinforces the stability of the fracture site 28-30. This stage of 
fracture healing lasts for approximately 2 -3 weeks. 
18
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1.1.2.3. Hard (or medullary) callus formation stage 
The cartilaginous callus will gradually turn into cartilage because chondrocytes are 
formed under hypoxic conditions in the peripheral callus regulated by cytokines such 
as PDGF, insulin-like growth factor 1 (IGF-1) and bone morphogenetic proteins (BMPs), 
including BMP-2, BMP-5 and BMP-6 31. Numerous molecular signals, including 
transforming growth factor-β2 (TGF-β2), transforming growth factor-β3 (TGF-β3) and 
BMPs, further promote the calcification process. In order to increase the stability of the 
fracture site, the immature woven bone is eventually replaced by woven bone through 
intramembranous or endochondral bone formation 17,26,32. During the process, which 
can take between 6 and 12 weeks depending on the fracture type and the anatomical 
fracture site, the organic matrix (predominantly consisting of collagen) is mineralised 
by the deposition of hydroxyapatite. Due to continuous proliferation, chondrocytes 
become hypertrophic, and the appearance of the mineralised extracellular matrix 
represents the beginning of the process of endochondral ossification 33. 
1.1.2.4. Remodelling stage 
The remodelling of bone is an imperative quality of bone tissue, taking place after 
fractures but also as a lifelong process in normal healthy bone. With regard to fracture 
healing, remodelling is the last stage in bone healing, starting immediately after woven 
bone has formed but perhaps lasting for several years until completion 30. The objective 
of this phase is to achieve the same mechanical strength as normal bones have by 
replacing the woven bone with lamellar bone 16. The substitution of (woven) bone takes 
place according to Wolff’s law, which describes the response of bone transformation to 
mechanical loading and the possibility of altering its mechanical properties according 
to this loading stress 34. Eventually, when the applied mechanical loading is sufficient, 
bone will be restored to its original form and strength, involving bone resorption by 
osteoclasts and the formation of new bone by osteoblasts. This osteoclastic and 
osteoblastic activity is generated via a polarisation of the involved long bone by axial 
loading of the crystalline bone matrix 35. In this polarisation process, one electropositive 
convex side activating osteoclasts emerges and one electronegative concave side 
activating osteoblasts emerges 32,35. After an erosive pit is generated by osteoclasts 
resorbing the woven bone on the calcified surface, also known as ‘Howship's lacuna’, 
osteoblasts deposit the new bone in the eroded pit 36. The remodelling phase is 
complete after a central medullary cavity has formed in the internal callus and the 
lamellar bone has substituted the external callus 35. 
The success of the remodelling stage depends to a great extent on a sufficient blood 
supply and the stability of the fracture site 37. Fractures can be stabilised in two ways. 
Absolute stability can be achieved by anatomic reduction and interfragmentary 
compression, without micro-motion of the fracture parts, which results in primary bone 
healing; relative stability occurs when the fracture parts are reduced in a functional way 
and controlled micro-motion is still possible between the fragments, which results in 
secondary bone healing. 
1.2. DISTURBED FRACTURE HEALING 
Although the understanding of fracture pathology and the treatment of fractures has 
greatly evolved in recent decades, deranged fracture healing in the sense of delayed 
unions and non-unions is still very difficult to predict at the time of injury and during 
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the course of the healing process 38. Considering the number of studies published on the 
topic of non-unions, in our opinion, the clinical and socioeconomic importance of non-
unions is probably underestimated. Most papers on non-unions report a general 
incidence of non-union of approximately 5–10%, but almost all of those papers based 
their figures on the information from one book by Praemer and colleagues on 
musculoskeletal epidemiology 39. On the other hand, in 2017, Mills published a paper in 
which she demonstrated overall non-union rates of 1.9% (men: 1.5%; women: 2.3%) in 
a large patient population 40. For specific fractures in particular age groups, however, 
the risk increased to 9%. The non-union incidence peaked in men aged 25–34 and in 
women aged 65–74, and the overall non-union risk peaked in early adulthood and 
decreased with rising age 40,41. Mills and Simpson also evaluated non-union incidence 
for children and found a very low risk, probably due to the relatively strong periosteum, 
the excellent vascularity and the great healing potential of paediatric bone. The non-
union risk for girls in general and boys aged under 14 years was ≤0.2%. For older 
teenage boys (15–19 years), the incidence raised to approximately 0.5% 41. 
Independent of the exact incidence of non-union, the direct and indirect costs of non-
unions are very high and they are projected to increase over the next 10-20 years as the 
rate of trauma-related morbidity in the young adult population rises 42, the survival rate 
for patients with severe injuries improves 43-46 and the age of the overall patient 
population increases. 
Non-unions consume increasing health care resources and double the median costs of 
care compared with normally healing fractures 47,48. Furthermore, non-unions and 
especially non-unions of the lower extremity are a significant clinical problem with a 
tremendous impact on the quality of life of the patient 48-50. Various studies on quality 
of life show an enormous incapacitating effect on the physical and mental health of such 
patients 50,51. Non-union patients need more opioids and suffer more from pain and 
depression because their physical health is comparable with patients with end-stage 
hip arthrosis and worse than those with congestive heart failure 47,49. That is why 
patients with non-unions on average have longer hospital stays, outpatient treatment 
and rehabilitation periods 51. 
The direct costs to hospital organisations for individual non-union therapy range from 
£7000 to £79,000 per person 41,52. Indirect costs of non-unions are difficult to determine 
as they differ according to each patient’s personal life and occupational circumstances. 
For instance, only 60% of non-union patients return to work within the first year after 
trauma. In addition, they show a significant decrease in productivity 47,48. Hak et al. 
estimated the indirect costs to be 67%–79% of the total costs of a tibia fracture in the 
Canadian health care system and 82.8%–93.3% of all costs for tibia fracture patients in 
European health care systems.53 Furthermore, the costs can even accumulate through 
litigation procedure costs, which are increasing, particularly when there is associated 
residual deformity 38. 
Another difficulty in comparing different studies concerning non-unions is the diversity 
of non-union definitions used in the literature. Despite that diversity, in our opinion, 
exact time frames to define non-union are not the most important measure because 
different bones have different healing times. More important in defining non-union is 
the fact that the healing of the particular bone does not occur in the expected time, that 
there is no progression in the healing process and that a successful union is not 
expected without intervention 54,55. Among all the bones in the human body, long bones 
such as the femur and the tibia need the longest time to heal. and those bones also have 
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among the highest non-union rates (13.9% and 14%, respectively) 56. In general, 
physicians should realise that almost all fractures should heal within 3 to 4 months,55 
and when healing has not occurred within this time range, one should become 
suspicious. Furthermore, the suggested waiting period of 9 months to diagnose the non-
union before intervention may be unrealistic in an economic climate in which 
healthcare and social systems are under more and more strain 57. Patient education and 
expectations must be addressed in conjunction with advancements in techniques and 
surgeons´ competencies to reduce the social and financial burden. 
Besides the definition in terms of time, non-unions can be classified according to Weber 
and Cech, who categorised non-unions into hypertrophic and atrophic 58. Hypertrophic 
or hyper-vascular non-unions have an adequate vascularity and biological activity to 
progress to union, but the healing is limited by bony instability. Conversely, atrophic or 
avascular non-unions lack vascularity and biological healing potential and show no 
evidence of healing. The classic view on this, as Calori et al. described, was that atrophic 
non-unions were associated with factors acting directly on the early phases of fracture 
healing while hypertrophic non-unions relate mostly to factors acting on the ‘re-
organisation’ phase of bone healing 59. The general opinion now is more nuanced and 
not as clear-cut. Avascular non-unions can be further subgrouped by the fracture 
pattern — torsion wedge, comminuted, defect and atrophic — and Weber and Cech 
further subdivided non-unions by radiological appearance (elephant foot, horse hoof 
and oligotrophic) 58. Moreover, it is important to consider the possibility of an infection 
in all cases of delayed union or non-union and particularly in high-energy open 
fractures. 
All conditions which impair fracture healing can lead to non-union and are divers from 
origin 13,40,60. Some conditions arise from injury characteristics, such as mono vs. poly-
traumatisation, fracture localisation (metaphyseal vs. diaphyseal), fracture type (open 
vs. closed, simple vs. comminuted, percent cortical contact), bone quality (juvenile vs. 
osteoporotic), or vascularity of bone, periosteum and soft-tissue condition (impaired 
blood supply, excessive periosteal stripping and fragment denudation, presence of a 
compartment syndrome, need for a flap). Other conditions originate from patient 
characteristics, such as sex, age, general health (malnutrition, adipositas, osteoarthritis 
with rheumatoid arthritis, vitamin D deficiency, hepatic and renal disorders), activity 
level, metabolic status (anaemia, diabetes mellitus, hormone deficiencies), use of drugs 
(anti-inflammatory medication, anti-depressant medication, steroids, anticoagulants, 
bisphosphonates, opioids, anticonvulsants, benzodiazepines, insulin, antibiotics, 
diuretics), alcohol and tobacco. Some conditions ensue from the interventions 
performed, such as fracture treatment (conservative vs. operative, reamed vs. 
unreamed), instability of fixation, axis deviation, and infection 47,56,61-65. As the personal 
and socio-economic consequences of non-unions are so serious, all influenceable 
factors which affect normal bone healing have to be considered as possible research 
targets to improve the treatment of predisposed patients with acute fractures or (non-
predisposed) patients with delayed or non-unions. 
As Giannoudis et al. 13 described in their diamond concept that for adequate fracture 
healing, in addition to biological factors, such as growth factors, scaffolds and 
mesenchymal stem cells, the biomechanical factors are of equal importance, those 
factors should be considered for prophylaxis and treatment of non-unions. First of all, 
excellent biological conditions should be established at the fracture site. In acute 
fractures, that means that the fracture haematoma should not be removed with the 
21
CHAPTER 1 | 
22 
reduction because it contains a significant number of growth factors, cytokines, 
osteogenic and angiogenic factors. Moreover, the disposure of the fracture ends should 
be as limited as possible to retain as much periosteum as possible. Then, the proper 
biomechanical conditions should be created, either with a rigid fixation and 
compression on the fracture fragments or with a biologic osteosynthesis in cases of 
comminuted fractures. In cases of non-union, the following treatment algorithm has 
been established through the years. A debridement and removal of infectious and/or 
necrotic tissue should be performed, a transplantation of autologous bone graft (ABG), 
containing mesenchymal stem cells, with osteoinductive, osteoconductive and 
osteogenic properties is carried out and, if required, a re-osteosynthesis with implant 
replacement and restoration of mechanical stability is accomplished 66. 
1.2.1. Poly-trauma and fracture healing 
In poly-traumatised patients, the pathophysiologic reaction is first predominated by a 
swift development of hypovolemia reaching a shock state in a short period of time. 
Subsequently, the organism attempts to minimise the consequences of the injuries by 
activating different homeostatic mechanisms to save vital organ functions. Ultimately, 
the organism aims to return to the pre-traumatic situation 67. 
Although for several years the prevailing opinion on this pathophysiologic reaction was 
that it consisted of three physiological phases (i.e., a hypodynamic flow phase, a 
hyperdynamic flow phase and a recovery phase) 68, it is now known that the reaction is 
more complex and consists of multiple pathways which constitute a fragile equilibrium 
between inflammatory (systemic inflammatory response syndrome [SIRS]) and anti-
inflammatory (counter anti-inflammatory response syndrome [CARS]) mechanisms 69. 
The inflammatory response of the body caused by major trauma starts with an immuno-
inflammatory reaction in which different cells are activated, which damage the 
endothelial membrane in the vital organs of the body. Those cells, including monocytes, 
lymphocytes, natural killer cells and polymorphonuclear leukocytes (PMN), are then 
able to spread to other organs, injure those organs and fully evolve into SIRS and even 
multiple organ dysfunction syndrome (MODS) 70,71. In cases of major physiologic stress, 
including polytrauma, the dysregulation of the neutrophil response as part of the PMN 
pool is known to be crucial in the origin of SIRS as well as MODS 72,73. Besides cytokines, 
such as Interleukin-1, -6, -8 and -10 and TNF, which are known to play an important 
communicative role in the activation of immune cells and in the origin of SIRS and 
MODS, there is also another group of signalling molecules, which are scrutinised in 
various studies for the part they play in such phenomena 67. Those alarmins or 
endogenous danger cells, as they are called, mainly stimulate the cells (i.e., T cells, 
neutrophils, monocytes, macrophages, natural killer cells and dendritic cells) of the 
natural immune response in the early phases, and they are released at the site of injury 
by necrotic or apoptotic cells 74,75. High-mobility group box 1 (HMGB1) is the most 
important representative of this group besides antibacterial peptides, S100 and heat-
shock proteins 76. The expanse of this SIRS is basically determined by the extensiveness 
of the initial traumatic impact (‘first hit’), but it can be increased by additional treatment 
interventions (‘second hit’) 77,78. An excessive SIRS reaction can lead to complications, 
such as acute respiratory distress syndrome (ARDS), MODS and death. Various studies 
have demonstrated that the inflammatory response in poly-traumatised patients with 
a combination of injuries is magnified compared with the response of the individual 
injuries and thereby affects the outcome 79. 
22
1
| INTRODUCTION 
23 
On the other hand, if the CARS, which develops at the same time, is super-dominant, a 
suppression of the immune system follows, which is related to infectious and septic 
conditions of the patient. 
This improved understanding of the immune-mediated systemic response of the body 
to poly-trauma has led to an important change in the initial treatment of such patients. 
In the pre-hospital setting, the ‘scoop and run’ concept has replaced the ‘stay and play’ 
concept in the vast majority of cases. 
In the emergency department, treatment is directed towards preventing the occurrence 
of the ‘triad of death’, consisting of coagulopathy, acidosis and hypothermia. The triad is 
mainly caused by hypovolemia, hypoxia and heat loss. Therefore, the treatment during 
the ‘golden hour of shock’ seeks to control blood and heat loss, stabilise oxygen 
saturation and restore coagulation. 
For the subsequent treatment options, the physiological condition of the patient leads, 
and the condition can be subdivided into four categories: stable, borderline, unstable 
and extremis 67. For the initial surgical treatment of the patients, except for the stable 
patients, a shift from early total care (ETC) to damage control surgery (DCS) has taken 
place. 
Importantly, traumatic brain injury often represents a major threat for the outcome and 
survival of trauma patients and alters the approach from ETC to DCS in order to reduce 
the secondary hit to the brain. The neuroendocrine axis is activated after trauma by 
pain, fear, by-products of metabolism which cross the blood-brain barrier, and primary 
brain damage itself 67. Subsequently, the hypothalamus and the sympathetic-adrenal 
system together with signals from the renin-angiotensin system increase heart rate and 
vasoconstriction in an attempt to control blood pressure. 
In such poly-traumatised patients, the healing of fractures is often challenging and non-
unions are an established phenomenon 51,80. Hildebrand and colleagues endorse the fact 
that interactions between local and systemic inflammatory reactions play an important 
role in fracture healing in patients with multiple injuries, but they also emphasise the 
influence of concomitant injuries, such as chest trauma, severe tissue injuries and 
haemorrhagic shock, on bone metabolism and fracture healing 64. 
1.2.2. Neuro-trauma and  fracture healing 
The overall prognosis of patients with (concomitant) traumatic brain injury depends 
on both the primary and secondary brain damage. At the time of the initial traumatic 
impact on neuro-cranium and brain tissue, the primary brain injury originates and 
consists of concussion, contusion, shear injuries, lacerations and axonal stretching 81. In 
cases of severe primary brain injury, in which lesions of neurons, axons and microglia 
cells occur, the mortality rate is very high. Subsequent to the primary injury, a delayed 
complex immunological, biochemical and physiological pathomechanism, which 
continues for several days to weeks, results in secondary brain damage 81,82. That 
secondary brain damage is a multifactorial process which is caused and influenced by 
different processes, such as excitotoxicity, inflammation, oedema, cell death, 
mitochondrial damage, magnesium depletion, the production of free radicals and 
damage to the blood brain barrier 82,83. 
The complex pathomechanism which leads to secondary brain damage also influences 
other healing processes in the body such as bone regeneration. According to the clinical 
findings of some experts in the field, patients with concomitant severe TBI often show 
faster and excessive fracture healing. The alleged relationship between TBI and fracture 
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healing has been the subject of clinical and experimental research during the last three 
decades. Despite the long history of studies, in which evidence of a positive correlation 
between TBI and osteogenesis is rising 84-96. there is no conclusive evidence for the 
relationship and there are many clinical and experimental studies taking a stand for or 
against this supposed relationship 97,98. Moreover, the pathophysiologic mechanisms 
underlying the supposed osteogenic phenomena in patients with TBI are multifactorial 
and far from clarified 99,100. In the literature, various possible mechanisms of action have 
been postulated without unambiguous proof of a specific pathophysiologic mechanism. 
The following possible working principles have been discussed in recent years. 
TBI leads to a complex metabolic, inflammatory and neuroendocrine reaction, and 
various authors have assumed that the osteoinductive potential of the serum increases 
as a result. Furthermore, it has been discussed that based on the changes of neuronal 
activity in the injured brain tissue, an increased synthesis of osteoinductive factors 
occurs, which are then transported to the fracture site. Within this frame, important 
significance, without definitive proof, has been attributed to different cytokines, 
proteins, peptides, cells and neurotransmitters (i.e., substance P and calcitonin gene-
related peptide [CGRP]) 84-89,93. 
In recent years, several authors have described a neurogenic inflammatory mechanism, 
which could influence callus formation and the healing of fractures, via different 
neuropeptides, which are released after both TBI and bone fractures 101,102. Although 
the exact pathophysiologic mechanism underlying the interaction is not known, 
Substance P and CGRP are two neuropeptides which are upregulated after TBI and 
released after peripheral nerve injury (by fractures), and they are supposed to be 
involved in the healing of fractures. 
Supportive of this theory are the findings of different authors which demonstrate a 
positive influence of such neuropeptides, released by peripheral sensory nerve endings 
in the bone tissue, on the quality of bone regeneration and the integrity of bone 103,104. 
It is known that bone is innervated via sensory nerves in the periosteum and nerves 
accompanying the nutrient vessels of the Haversian canals in the bone. However, 
although until now ‘classic’ synapses between nerves and bone cells are not proven, 
Jones et al. were able to show that there are nerve fibres with an active expression of 
different neurogenic ligands, which are in close contact with bone cells 103. In case of a 
fracture, those nerve endings are injured, regenerate and grow back into the callus 
tissue. That proliferation of nerves elapses simultaneously with the formation of callus 
tissue and the subsequent bone remodelling, implying the active involvement of 
peripheral nerves in these processes 104. Corresponding to those findings, Santavirta et 
al. demonstrated a lack of peripheral innervation of bone in non-unions 105. 
Moreover, several studies have demonstrated by utilising either combined motoric, 
sensory and autonomic denervation 106,107 or complete sensory nerve-ending blockage 
108,109 that complete peripheral nerve transection 106,107,110 and the selective blockade of 
sensory nerve endings 108,109 can impair fracture healing. 
That negative influence of a blockage of efferent sensory nerves on the quality of callus 
formation and fracture healing is due to the inability to release Substance P and CGRP 
108,109. Further studies have shown that the nociceptive system of sensory nerves is 
essential for the initialisation of the inflammatory process in fracture and wound 
healing 104, that the concentration of sensory neuropeptides are upregulated in the first 
24 hours after fracture 111 and that the number of nerve fibres increases in cases of bony 
defects 106,112. According to those results, it is plausible that neuropeptides, and 
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especially substance P and CGRP, are of significant importance for the healing of 
fractures. 
One neuropeptide of particular relevance to bone healing seems to be Substance P, 
which shows simultaneous effects in neurogenic and osteogenic activities. Substance P 
seems to have a significant involvement in bone metabolism, formation and resorption 
as well as in the osteogenic activity of bone marrow stromal cells and osteogenic cell 
lines 113-116. However, to date, the specific role of single neuropeptides in bone healing 
has not been established 97,98. 
In another concept, which finds support in the literature, the bone morphogenetic 
proteins (BMPs) as members of the transforming growth factor β (TGF-β) superfamily 
play a role in increased bone healing in patients with concomitant TBI. The BMPs 
transfer their signals via binding to the transmembrane receptor complex, which 
incorporates serine-threonine kinase activity 117. The complex is activated after 
neurogenic trauma, and the subsequent activation of the signalling mothers against 
decapentaplegic (SMAD) gene family modifies the cellular transcription activity 118-120. 
Three members of the BMP family (BMP-2, BMP-4 and OP-1 [formerly called BMP-7]) 
have the opportunity to stimulate bone growth in peripheral locations 121,122. 
Furthermore, it is supposed that after bone fractures as well as after TBI, a cascade in 
which MSCs play an important role is initiated. BMPs released from the injured bone 
matrix support that initiation 123. As multipotent cells, the MSCs can differentiate into 
various mesenchymal cell lines, which enables the development of different tissues, 
such as bone, cartilage, fat, etc 124,125. Besides proteins produced by the MSCs 
themselves, other mediators, which are not further specified in studies, released by 
injured brain tissue are described to stimulate MSCs and osteoprogenitor cells 84. 
1.2.2.1. Heterotopic ossification (HO) 
It is in this context that several authors claim that the increased callus formation in 
patients with concomitant TBI is due to the generation of heterotopic ossifications. 
Heterotopic ossification as pathological bone formation in extra-skeletal tissue can 
have a traumatic, neurogenic or genetic genesis. Although the exact pathophysiology of 
heterotopic ossification is not yet known, the idea is that the formation of such 
ossifications shows a similarity to the normal fracture healing process of osteogenesis, 
osteoinduction and osteoconduction. Nauth et al. suggests that osteoprogenitor cells, 
which have a pathologic differentiation in response to dysregulated BMP signalling, 
play a role in the formation of heterotopic ossifications(HOs) 126. The combination of an 
inflammatory response, with increased levels of IL-6 and monocyte chemoattractant 
protein 1 (MCP-1), and dysregulated BMP signalling would mainly be responsible for 
the osteoinduction in HO formation 126. Injured soft tissue forms an ideal environment 
for the development of such ossifications. In contrast to the involvement of the above-
mentioned inflammation response factors in orthopaedic and blast injury patients with 
HO, the knowledge of the pathogenesis of HO in patients with concomitant TBI is still 
exiguous. The involvement of e.g. catecholamines, leptin, CGRP and substance P, has 
been hypothesised 126,127. 
1.3. THE ROLE OF ANGIOGENESIS IN FRACTURE HEALING 
In recent decades, several studies proved that the vascular status is of major importance 
for normal bone homeostasis and restoration of bony defects. The mechanism of 
fracture healing is a multifactorial process in which many different cytokines, 
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hormones, proteins, etc., play a role. Above all, virtually all of those studies emphasise 
the key role of revascularization and angiogenesis as an essential prerequisite for new 
bone formation 128-132. Vasculogenesis and angiogenesis are two basic processes of 
blood vessel formation 133. (Figure 1.2.) Unlike vasculogenesis, in which the vascular 
network is initially formed from angioblastic stem cells, the development of a new blood 
vessel from a pre-existing vascularity is defined as angiogenesis 133-135. 
Revascularization is important for the physiology of bone formation, bone growth and 
remodelling 136,137 because it transports the nutrients, oxygen, hormones, cytokines and 
numerous cells which are required by bone tissues 31,130,138. Those complex processes of 
neovascularization and angiogenesis are regulated by different pro- and anti-
angiogenic mediators, such as vascular endothelial growth factor (VEGF), hypoxia-
inducible factor-1α protein (Hif-1α), fibroblast growth factor (FGF), TGF, IGF, 
interleukins, BMPs and NO 129,132,139.  
 
 
Figure 1.2. The relationship between vasculogenesis and angiogenesis. Endothelial progenitors first 
differentiate into clusters of endothelial cells, and the primary vascular system is formed by the fusion of 
endothelial cells (vasculogenesis). The primary vascular system is remodelled to form a mature vascular 
system through angiogenesis. [This illustration by puttinpurin1108 is licensed under Creative Commons CC-PD 
1.0 (commons.wikimedia.org)]. 
 
The reduction of bone mass and bone formation is correlated with insufficient blood 
supply 132,140. Furthermore, along with the deepening research, surgeons are realising 
that a successful fracture repair critically depends on successful angiogenesis 141-143. 
When fractures occur, the periosteum and blood vessels between the fractured ends are 
damaged, subsequently changing the local microenvironment. One study has shown 
that the overall blood flow of the bone after a fracture or osteotomy is reduced 
immediately 144. The circulation of cortical bone can be reduced by approximately 50% 
due to the physiological contraction of the periosteal and intramedullary vessels 
following trauma, while the partial pressure of oxygen in the centre of the damaged 
tissues can even be decreased to 0%-2% 145. The hypoxic environment around the 
fracture site can induce the release of various cytokines, which promote the 
differentiation of stromal precursor cells in the periosteum, bone marrow and 
surrounding soft tissue towards osteoblasts and chondrocytes. 
The process of intramembranous bone formation occurs in the adjacent ischemic area 
and requires not only the anaerobic metabolism of osteoblasts but also the 
transportation of nutrients and mineral through new blood vessels 146. Chondrocytes 
are located at the centre of the hypoxic region where the complete absence of blood  
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perfusion mostly occurs. The proliferation, differentiation and matrix deposition of 
those cells is associated with angiogenesis in order to achieve successful cartilage 
ossification 147. Moreover, it has been reported that angiogenesis occurs prior to 
osteogenesis, and the latter is a vascular-dependent process 148,149. In case of 
compromised angiogenesis or microcirculation at the fracture site, 50% of such 
fractures will result in a pseudarthrosis or non-union 128. Moreover, in vivo research 
with rat models has shown that delayed fractures or non-unions occur if angiogenesis 
is inhibited 143. This could possibly be explained by the decisive role of angiogenesis in 
every single step of fracture healing, but the vascular network also disposes imperative 
growth factors, such as cytokines, hormones, proteins, amino acids, etc., to the fracture 
site and its surrounding tissue. The endothelium functions as a communication network 
for that surrounding tissue 130. 
1.4. THE ROLE OF BIOLOGICAL FACTORS IN BONE HEALING 
Besides the musculoskeletal system, other biological systems such as the immune 
system play an extremely important role in bone regeneration. In the complex process 
of bone regeneration and fracture healing growth factors, cytokines and chemokines 
play a major role in addition to the cellular involvement of immune cells, osteocytes and 
osteoclasts 28,33,150,151. The inflammation stage at the beginning of fracture healing is 
considered to be a very important phase because that local, non-systemic inflammation 
response has to provide an excellent environment for fracture healing to evolve. That 
is achieved by clearing necrotic debris and forming good granulation tissue 152. The 
coordinated progress of that inflammation response has to be assured by a delicate 
equilibrium between different inflammatory and anti-inflammatory cytokines and 
other biological factors because uncontrolled inflammation can impede the fracture 
healing process 153. 
1.4.1. Genetic factors 
As with almost all other diseases, different genetic factors seem to play a role in bone 
regeneration and fracture healing. 
For instance, the regulation of gene expression associated with numerous biological 
processes is performed by micro-ribonucleic acids (miRNAs), and there is growing 
evidence that miRNAs are also important for bone formation, resorption and 
remodelling and the development of non-unions 154. Waki and colleagues showed that 
there is an upregulation of different miRNAs in adequate healing tissues. In another in 
vivo experiment, they showed that another set of miRNAs are upregulated in cases of 
non-unions 155,156. 
Furthermore, it is suggested that single nucleotide polymorphisms (SNPs), which are 
variations in a single nucleotide that occur at a specific position in the genome, where 
each variation is present to some degree within a population, are responsible for the 
progression of a fracture into a non-union 157. Those SNPs are found in four genes 
encoding for the BMP pathway (BMP-2, BMP-7, Noggin, Smad6) 157,158. Supportive of 
this theory are the findings of different in vivo and ex vivo studies that the distribution 
of BMP genes, amongst others, can increase bone healing 159-161. Ali and colleagues 
suggested the involvement of a single T/G genotype at SNP rs3753793 in the CYR61 
gene, encoding for a widespread signalling molecule, in the development of non-unions 
162. 
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Based on a comparison of the findings with those for patients with normal fracture 
healing, a platelet-derived growth factor (PDGF) haplotype was reported to be 
associated with aseptic non-union 163. 
For the expression of different genes in the fracture healing process, it is of utmost 
importance that the expression is well balanced because an excessive expression could 
damage the structure and function of related cells, leading to impaired bone healing. 
That was demonstrated by Zimmermann and colleagues, who showed an increased 
expression of different genes in non-unions, which normally coordinate the production 
and stabilisation of the extracellular matrix, the induction of cell differentiation and 
proliferation and the cytoskeleton 164. 
The correction or adaptation of some of these genetic changes and the modulation of 
bone metabolism in patients with disturbed fracture healing are possible indications 
for gene therapy. 
Gene therapy for bone repair can be divided into (stem) cell-mediated therapy and 
acellular therapy. The cell-mediated strategy, in which a cellular component is used as 
the carrying vector, is very complex and difficult to implement in the clinical situation, 
because the tissue has to be selected, transduced in vitro and then re-implanted into 
the bony defect, mostly in a second operation 165,166. However, for instance, Xing et al. 
showed some promising results of bone marrow mesenchymal stem cells (BMSCs) 
transfected with IGF-1 gene promoting fracture healing in an in vivo study 167. 
Acellular direct gene therapy comprises of different techniques using viruses (vectors), 
plasmids (extrachromosomal DNA molecule), and gene activated matrices (GAM) 
impregnated with plasmids to transfer therapeutic cDNA (complementary DNA) into 
the host cell 165. These methods have been performed in vivo directly administered as a 
suspension into the bony defect or freeze-dried to an allograft scaffold 165. Main 
advantages of genes over recombinant osteogenic proteins are a sustained secretion of 
therapeutic proteins by transfected cells, a more physiological manner in which the 
therapeutic proteins are presented, due to the posttranslational processing in the host 
cell, the ability of repeated administration, and the low cost of gene production 166,168. 
Concerning the efficacy of transferring genetic information to cells, viral vectors are 
superior to plasmids 169. Vectors from adenoviruses or adeno-associated viruses are 
used to transduce mesenchymal stem cells and chondrocytes and different bone 
morphogenetic proteins (i.e. BMP-2, BMP-4, BMP-7) are used in these vector types to 
enhance osteogenesis 170-172. Although gene therapy is still at an early stage, it has a 
tremendous potential of correcting genetic mutations or improving bone metabolism 
by delivering osteogenic and angiogenic proteins to the fracture site. Therefore, it might 
become the most valuable therapy option for fracture patients with a genetic 
predisposition towards delayed union and non-union development. 
1.4.2. Plasma proteins 
The systemic and local inflammatory responses after trauma are coordinated by three 
cascade systems, which are activated by pro-inflammatory mediators, toxins and/or  
direct tissue damage. Those interrelated systems of plasma proteins are the clotting 
system, the complement system, and the kallikrein-kinin system 173. 
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Figure 1.3. A schematic representation of  the intrinsic, extrinsic and common clotting cascade and 
the fibrinolysis pathway. FDPs: fibrin degradation products, HMWK: high molecular weight kininogen, 
MASP-2: Mannan-binding lectin serine protease 2, PAI-1: plasminogen activator inhibitor-1, SEC: 
subendothelial collagen, TF: tissue factor, tPA: tissue plasminogen activator, uPA: urokinase plasminogen 
activator. [This illustration was created by Martijn Hofman and is licensed under Creative Commons CC-BY-SA 
4.0]  
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1.4.2.1. Clotting system 
Bones are vascularized extensively and in case of a fracture this vascularity is disrupted. 
The clotting system (Figure 1.3.) tries to limit the blood loss by forming an organised 
haematoma, that provides the connection between the different bone fragments 174. 
Furthermore, different components of the clotting system influence the inflammatory 
response to injury and interact with other systems like the Kallekrein-kinin-system and 
the complement system 74. 
Thrombin. Thrombin (coagulation factor IIa) seems to have an anabolic function in bone 
by stimulating the proliferation of different osteoblasts and their functions 175. In the 
study of Sato et al., they suggest that thrombin is another cytokine regulating osteoblast 
function and fracture healing. They demonstrated that thrombin stimulated osteoblasts 
to express proteinase-activated receptor 1 (PAR1 / coagulation factor II receptor), to 
produce monocyte chemoattractant protein-1 (MCP-1), tissue factor (TF), macrophage 
colony stimulating factor (MCSF) and Il-6, and to reduce the expression of plasminogen 
activator inhibitor-1 (PAI-1). 
The production of MCP-1 and MCSF leads to the recruitment of monocytes and 
macrophages into the fracture haematoma and the expression of PAR1 and of TF leads 
to the subsequent production of more thrombin via the extrinsic coagulation pathway. 
Both phenomena are important for the maintenance of inflammation in the early stages 
of fracture healing 176. Vi et al. also showed that the presence of macrophages in the 
fracture healing process is vital for callus formation and the quality of fracture healing 
177. Further, thrombin seems to have an important role in the balance between 
coagulation, through increasing the expression of TF by osteoblasts and fibrinolysis, 
through reducing the expression of PAI-1 by osteoblasts. It further causes a burst of 
prostaglandin E2 (PGE2) and prostacyclin (PGI2) production by osteoblasts via the B2 
receptor 175. 
Fibrin. In the process of fracture healing, fibrin, which is formed by both the intrinsic 
and extrinsic coagulation pathway, has a bimodal function. First of all, fibrin is essential 
for the formation of a stable blood clot surrounding the fracture site. The fibrin matrix 
retains platelets and forms a reservoir for platelet associated growth factors and 
vasoactive molecules. It further promotes the recruitment of inflammatory and 
mesenchymal progenitor cells into the fracture haematoma through specific integrin / 
receptor interactions. Above that, it provides the structural mesh like framework for 
the initial phase of tissue repair. In the in vivo study of Vasconcelos et al. it was 
demonstrated that a fibrinogen-scaffold (fibrinogen is the precursor of fibrin) favours 
a pro-regenerative local environment, followed by changes in the systemic immune cell 
balance and advanced fracture repair 178. Fibrinogen further improves the angiogenesis 
through the binding of VEGF, an important neovascularization factor, with high 
affinity179,180. 
On the other hand, excessive fibrin deposition or an inefficient break down of the fibrin 
clot impairs the vasculogenesis, which occurs from both ends of the fracture site and is 
essential for new bone to form. For instance, Yuasa et al. demonstrated in plasminogen-
deficient mice, in which as a result fibrinolysis was disturbed, that fracture 
vascularisation and bone healing was impaired 181. 
Fibrin stabilizing factor (coagulation factor XIII). Factor XIII is a member of the 
transglutaminase (TG) family, and it is found in many different cells, such as platelets, 
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monocytes, macrophages, chondrocytes, osteoblasts and osteocytes. Factor XIII plays a 
role in the formation of extracellular matrix, by stabilizing the interaction of 
microtubules with the cell membrane, through which collagen and fibronectin, as 
important components of the extracellular matrix, are secreted. Collagen and 
fibronectin form stable interaction with osteonectin, which binds Calcium and 
osteopontin, which is a structural linking protein in bone. TG as a catalyst for this 
interaction plays an essential role in the mineralization and collagen deposition of the 
extracellular bone matrix 182,183. 
Plasmin. Plasmin degrades fibrin into fibrin degradation products and dissolves the 
stable fibrin clot. Primarily, this plasmin-mediated fibrinolysis is necessary for the 
vascularisation of the soft- and hard-callus tissue. The recruitment and direction of 
essential endothelial and osteoblastic progenitor cells to initiate angio- and 
osteogenesis is coordinated by hypertrophic chondrocytes by the release of VEGF-A, 
calcium and phosphate 181. Plasmin also has a role in the clearance of the fracture site 
from debris by the recruitment of monocytes and macrophages into the fracture 
haematoma. Thereby, the inflammatory response in fracture healing is kept within 
limits independently of the fibrin degradation 184. Moreover, plasmin supports the 
release of growth factors, which are important for tissue repair, i.e. TGF-β 185-187 and 
VEGF 187-189. Schoenecker et al. also demonstrated a direct conducive effect of plasmin 
on the maturation of osteoblast precursors to mature osteoblasts during fracture 
healing by stimulation of the mineralization and differentiation of in vitro osteoblast 
cultures 190. 
Plasminogen, the precursor of plasmin, and its activators urokinase and tissue 
plasminogen activator (tPA) are released by osteoblasts and osteoclasts, stimulated by 
cytokines and hormones 191,192. They influence various components of bone 
remodelling, such as the recruitment of macrophages 187 and the osteoclastogenesis and 
the osteoclast / osteoblast interaction 193,194. 
1.4.2.2. Complement system 
The proteins of the complement system are numbered C1 to C9, and they have different 
modes of action within the immune system. Normally those plasma proteins circulate 
inactive in plasma. The activation of this system can be initiated via three different 
pathways. There are 3 intrinsic pathways (classical, alternative, and Mannose-binding 
lectin) to activate the complement cascade, with the key-players C3 and C5 triggering 
the terminal pathway to constitute the Terminal Complement Complex (TCC). 
Interaction between immune cells, the clotting system, the kallekrein-kinin system and 
the complement system exist in that different serine proteases, clotting factors as well 
as serine proteases from macrophages can activate the complement cascade via an 
extrinsic pathway, independently from the intrinsic pathways 195-197. (Figure 1.3.) The 
pore-forming Terminal Complement Complex (TCC) possesses both lytic as well as non-
lytic activities. TCC formation on cell membranes can cause lysis of the cell of pathogens 
and microorganisms. In sub-lytic concentrations the TCC can induce cell signalling 
pathways, stimulation of pro-inflammatory mediators, mobilisation of immune cells, 
production of different peptides, free oxygen radicals and cytokines, and modulation of 
cell cycle and apoptosis 198-201. Besides the early induction of an inflammatory response 
to fracture and the elimination of debris and potentially invasive microorganisms at the 
fracture site, complement factors (C3a and C5a) also recruit polymorphonuclear 
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neutrophils, MSCs, osteoblasts and macrophages to the fracture site 202. Further, C3 and 
C5 play an important role in the Cell-to-cell communication between osteoblasts and 
osteoclasts, which are both very important players in the regulation of the immune 
response after fracture and of the metabolism of bone 202. Bergdolt et al. even suggest 
that via the C5a-receptor on osteoblasts and osteoclasts, C5 upregulates the activity of 
osteoclasts and the expression of osteoclastic factors, such as RANKL and IL-6 with an 
enhanced resorption of bone as a consequence 203. 
 
 
Figure 1.4. A schematic representation of activation pathways of the complement system. There are 3 
intrinsic pathways (classical, alternative, and mannose-binding lectin) to activate the complement cascade, 
with the key-players C3 and C5 triggering the terminal pathway to constitute the Terminal Complement 
Complex (TCC). There is also an independent extrinsic pathway, involving different serine proteases and 
proteins from the coagulation system and from immune cells. [This illustration was adapted by Martijn Hofman 
from ´Figure 1. Complement pathways´ by Zaahira Gani published on https://www.immunology.org/public-
information/bitesized-immunology/systems-and-processes/complement-system (licensed under Creative 
Commons CC-BY-SA 4.0)] 
 
Supportive to these findings Ehrnthaller et al. showed decreased callus volume and 
mechanical strength of healing bone in their in vivo study with C3-/- and C5-/- -knockout 
mice 204. Mödinger et al. also demonstrated a role for C6, as an essential component for 
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TCC assembly, in the inflammatory response to fracture and in the normal fracture 
healing process, because in absence of C6 an increased osteoclast activity was seen with 
a subsequent impaired bone healing 201. Moreover, Mödinger showed that, under 
physiological conditions, human bone cells protect themselves against complement 
attacks by the expression of CD59 glycoprotein, which is able to prevent C9 from 
polymerizing and forming the TCC 201. 
Besides the activation of the extrinsic complement pathway via several serine proteases 
and proteins of the coagulation system, the complement and coagulation cascade are 
strongly interconnected and augment each other via the intrinsic mannose-binding 
lectin pathway. The  binding of MBL to the cell membrane of pathogens causes an 
activation of MBL-associated serine proteases (MASPs), which subsequently activate 
proteins from the complement cascade. At fracture sites, MBL also binds to fibrin-
networks and in turn, fibrin stabilises the MBL-MASP complex, enhancing a further 
activation of complement proteins. MASP-2 (Mannan-binding lectin serine protease 2) 
is consecutively an enzyme, which can cleave prothrombin into thrombin very potently 
and thereby augment the fibrin complex 205. (Figure 1.3. & 1.4.) 
1.4.2.3. Kallekrein-kinin system (KKS) 
The most important mediators of the kallikrein-kinin system are bradykinin and 
kallidin, which are activated in the cascade system via inflammation and tissue damage. 
(Figure 1.5.) Kallikrein has chemotactic functions, and it also plays a role in the clotting 
system by stimulating the activation of factor XII and by counterbalancing the clotting 
cascade by stimulating the conversion of plasminogen to plasmin, activating fibrinolysis 
198. Plasma-kallikrein and factor XIIa are rapidly inactivated by C1-inhibitor from the 
complement system, antithrombin from the clotting system and α2-macroglobulin, 
mainly synthesized by macrophages. Tissue-kallikrein, however, is not affected by 
inhibition.  
In cases of inflammation in the vicinity of bone, the activity of osteoclasts is induced, 
which results in bone resorption. This influence on bone metabolism can be elicited by 
different cytokines, growth factors, and thrombin, but also by the kinins of the KKS. 
Both kinins act on the B1 and B2 receptor expressed by osteoblasts, which elicit a 
stimulation of the prostaglandin production. The expression of these receptors can be 
upregulated by the pro-inflammatory cytokines IL-1β and TNF-α 206. Prostaglandin 
increases the formation and activates the differentiation of osteoclast progenitor cells 
to osteoclasts and these are responsible for subsequent bone resorption 175,206,207. This 
working mechanism is supported by the study of Zhang et al., in which a decreased 
expression of the B1 receptor improved local bone metabolism 208.  
1.4.3. Cytokines 
Many studies, preclinical as well as clinical, have proven the value of cytokines in 
coordinating and modulating bone regeneration and fracture healing in recent years 154. 
The four fracture healing stages are all regulated by the expression of cytokines, matrix-
metalloproteinases (Mmps), and angiogenic factors. The cytokines can be subdivided 
into three categories: (1) proinflammatory cytokines, (2) anti-inflammatory cytokines, 
(3) members of the TGF-β superfamily and other growth factors 16. Cytokines are 
mainly released by lymphocytes and macrophages but also by epithelial, connective 
tissue and endothelial cells. The regulatory mechanisms of cytokines can be easily 
deviated by environmental influencing factors. 
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1.4.3.1. Pro-inflammatory cytokines 
Proinflammatory cytokines are upregulated within the first hours after trauma and 
appear mainly at the first stage of fracture healing but are also imputed to influence the 
remodelling stage of bone regeneration 23,209. The proinflammatory cytokine group 
consists of TNF-α, IL-1β, IL-6, IL-8, IL-12 and IL-17. 
 
Figure 1.5. A schematic representation of the kallekrein-kinin system in bone metabolism. B1: G-
protein-coupled B1-kinin-receptor, B2: G-protein-coupled B2-kinin-receptor, HMWK: high molecular weight 
kininogen, LMWK: low molecular weight kininogen, XII: clotting factor XII or Hageman-Factor, XIIa: activated 
clotting factor XII,. [This illustration was created by Martijn Hofman (licensed under Creative Commons CC-BY-
SA 4.0) using images from Smart Servier Medical Art (https://smart.servier.com/)]. 
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Tumour necrosis factor alfa (TNF-α). Together with IL-1β, TNF-α is released within the 
first 2 hours after fracture. Macrophages are the main source of TNF-α, which can bind 
to two receptors, TNFR1 and TNFR2. The effects of TNF-α on bone regeneration are 
time-sensitive. As one of the first proinflammatory cytokines, the maximum 
concentration is reached within the first 24 hours after injury and reverts to baseline 
levels after 72 hours.16 During that period, TNF-α increases the endothelial permeability 
and the responsiveness of mesenchymal cells to chemokines, thereby facilitating the 
migration of these cells into the fracture site, where they start the osteogenesis 210,211. 
Subsequently, it has a positive effect on bone regeneration by upregulation of the innate 
immune response via support of the production of chemokines, cytokines, growth 
factors and NO 210,211. Besides those effects, TNF-α also enhances the neutrophil 
secretion of VEGF and thereby encourages vasculogenesis at the fracture site 212. Then, 
apoptosis of chondrocytes and recruitment of osteoclasts is triggered by TNF-α, causing 
soft callus resorption and the induction of endochondral bone formation 213,214. In the 
later stages of fracture healing, possibly depending on various expression patterns of 
TNF-α, TNF-α exerts a converse influence on callus mineralisation and fracture healing 
215-218. Moreover, the effect of TNF-α on bone regeneration depends on its concentration 
and is, therefore, dose-dependent. Low-level concentrations of TNF-α lever 
mesenchymal stem cells migration to the site of injury and their osteogenesis, but at 
high-level concentrations, TNF-α is counter-productive for bone formation 219. The 
negative effect of TNF-α on bone regeneration is also supported by different in vitro 
studies 215,217,218,220,221. 
Interleukin 1 beta (IL-1β). Interleukin-1β is another cytokine which appears early in the 
inflammatory stage of fracture healing. Together with TNF-α, IL-1β is one of the most 
important inflammatory cytokines in coordinating the local inflammatory response to 
bone injury 28. Corresponding to TNF-α, IL-1β exerts its effects, which are also time-
sensitive and dose-dependent. That is, IL-1β first influences bone repair at the 
inflammatory stage and further on in the process at the soft and hard callus formation 
stages 23. IL-1β positively influences osteoclast growth 222, osteoblast apoptosis and 
chondrocytic differentiation 223. Furthermore, it stimulates the upregulation of matrix 
metalloprotease 13 (MMP-13) activity via the wingless/int1 (Wnt) signalling pathway, 
which causes the maintenance of bone mass and enhances bone repair 224. However, 
the positive effects of IL-1β are only employed in a narrow concentration range of 0.1 
ng/ml to 0.3 ng/ml; otherwise, IL-1β has the opposite effect 153. 
Interleukin 6 (IL-6). Another important proinflammatory cytokine for bone healing is 
IL-6, produced by a variety of cells (monocytes, macrophages, neutrophils, T cells, B 
cells, endothelial cells, smooth muscle cells and fibroblasts) and executing its effect via 
two signalling pathways. In the IL-6 classic pathway, IL-6 binds to a membrane-
anchored IL-6 receptor present on hepatocytes, epithelial cells and leukocytes, and that 
complex then binds to the receptor subunit gp130, which is a transmembrane 
glycoprotein, which subsequently initiates the intracellular signalling.225 The second 
pathway is called the IL-6 trans-signalling pathway, in which the IL-6 receptor protein 
is cleft and a soluble receptor (sIL-6R) is created. The receptor binds IL-6 and, after 
connecting to the receptor subunit gp130, signalling is generated, even in cells which 
do not express IL-6R 225. 
In poly-traumatised patients, IL-6 is recognised as an important parameter for 
determining the severity of an injury, the favourable moment to perform an operation, 
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and the prognosis after the polytrauma 173. IL-6 is upregulated in two peaks. In the acute 
inflammatory phase (within the first 24 hours after fracture induction), IL-6 initiates 
the recruitment and proliferation of MSCs, which are multipotent stromal cells, and 
their differentiation to the osteogenic cell lines 23,226,227. Another characteristic of IL-6 
is that it promotes angiogenesis, which is important for the delivery of blood and 
nutrients to the bone tissue 228,229. 
The second peak occurs at the stage of hard callus formation in which IL-6 stimulates 
the endochondral and intramembranous mineralisation of the soft callus 230. In this 
stage, IL-6 advances osteoclastogenesis 25,231,232, but it also stimulates the overall 
turnover of healing bone 215,220,228,229. 
On the other hand, some studies have found enhanced fracture healing by suppressing 
the IL-6 activity in mice 233, and others state that only the classic IL-6 signalling pathway 
and not the IL-6 trans-signalling pathway is crucial for fracture healing 234. 
Interleukin 17 (IL-17). This proinflammatory cytokine is yielded by various cells from 
the immune system (i.e., B cells, natural killer (NK) cells and mesenchymal cells), but 
the majority of IL-17 comes from the γδ T cell, a subset of T cells with a specific T cell 
receptor expression 235. The expression of IL-17 can be upregulated by interleukin 12 
and interleukin 23 (a member of the IL-12 family) 153. The IL-17 group mobilises 
neutrophils and releases inflammatory cytokines and consists of the subtypes IL-17A-
F 236. Of those subtypes, IL-17A shows inconsistent effects on osteoblastogenesis, 
depending on the target cells involved 237,238. Positive effects are exerted on immature 
mesenchymal cells at the site of injury, but a negative effect is displayed on pre-
osteoblasts 238-241. Furthermore, Nam and colleagues show that the subtype IL-17F has 
positive effects on the maturation of osteoblasts 242. 
1.4.3.2. Anti-inflammatory cytokines 
Interleukin 4 and 13 (IL-4 and IL-13). Several studies have demonstrated that both 
interleukin 4 and interleukin 13, as well as the combination of these two cytokines, 
downregulate bone resorption 243,244. IL-4 in particular has the capacity to activate the 
transition of macrophages, from the proinflammatory M1 phenotype to the anti-
inflammatory M2 phenotype, which enhances osteogenesis and bone regeneration 245. 
Interleukin 6 (IL-6). Besides IL-6’s proinflammatory function, it also exerts anti-
inflammatory effects through the generation of anti-inflammatory cytokine and 
prostaglandin E2 (PGE2) release by macrophages. Subsequently, PGE2 coordinates the 
synthesis of TNF-α and IL-1β and the release of IL-10 173. 
Interleukin 10 (IL-10). One of the most potent anti-inflammatory cytokines is 
interleukin 10 (IL-10), which is produced by T cells or myeloid cells. Through the 
inhibition of proinflammatory cytokines, such as TNF-α, IL-1, IL-6, IL-8 and free oxygen 
radicals, IL-10 exerts an indirect suppression of bone mass, mechanical strength and 
bone formation 246,247. 
Interleukin 27 (IL-27). As a member of the interleukin 12 family, IL-27 is secreted by 
monocytes, macrophages and dendritic cells. The inflammatory response to fracture is 
substantially antagonised by IL-27. Furthermore, IL-27 has a stimulating effect on the 
remodelling of bone through the enhancement of osteogenesis, the inhibition of 
osteoblast apoptosis and diminishing the proinflammatory response 248,249. 
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1.4.3.3. Members of the TGF-β superfamily and other growth factors 
The TGF-β superfamily is a group of related cell regulatory proteins, which can be 
subdivided into different subfamilies: the TGF-β subfamily; the BMPs and growth 
differentiation factors (GDFs) subfamily; the subfamily of the activins, inhibins and 
Müllerian-inhibiting substance; and a subfamily of various other important growth 
factors, including IGFs, PDGF and FGFs.250 The most relevant mediators for fracture 
healing will be discussed below. 
Transforming growth factor beta (TGF-β). Transforming growth factor beta has value 
mainly in the early stages of fracture healing 251. As a chemotactic modulator of 
osteogenic differentiation, it stimulates the healing and remodelling of bone via cell 
division and mobilisation, matrix synthesis and tissue differentiation 252-255. Interesting 
data have been demonstrated by Zimmermann and colleagues concerning a possible 
predictive value of TGF-β for delayed fracture healing situations because in normal 
fracture healing TGF-β initially peaks at 2 weeks and then decreases over the 
subsequent 4 weeks 256. 
Bone morphogenetic proteins (BMPs). There are about 20 different BMPs, but only BMP-
2 and BMP-7 (or osteogenic protein-1 [OP-1]) are currently used clinically in non-union 
therapy and as an adjuvant treatment 257,258. Their effect on bone healing occurs via two 
pathways. The BMPs trigger the recruitment of MSCs, which then differentiate either to 
osteoblasts depositing bone material directly or to chondrocytes changing to bone cells 
along the way 259. Both BMP-2 and BMP-7 are expressed during the early stages of 
fracture healing, but BMP-2 exerts its effect throughout the entire fracture healing 
process. The BMP pathways are susceptible to environmental influences, through 
which the effect or expression of BMP decreases. For example, nonsteroidal anti-
inflammatory drugs (NSAIDs), which are widely used painkillers in musculoskeletal 
injuries, reduce the response of osteoprogenitor cells to BMP and thereby decrease 
their osteogenic potential 260. Also, the initial hypoxic state of fracture tissue instigates 
reduced scavenging, oxidative stress and enhancement of reactive oxygen species 
(ROS); consequently, BMP-2 expression impairment occurs, leading to insufficient bone 
healing 261. 
In the early stages, BMP-2 is involved in enhancing the inflammatory response, the 
periosteal activation and the differentiation of stem cells to osteoprogenitor cells. At the 
later stages, BMP-2 is involved in regulating chondrogenesis and osteogenesis 16,262. 
BMP-7 exerts its action only after the formation of osteoprogenitor cells in the early 
stages of fracture healing 262. According to the literature, BMP-7 has an osteoinductive 
function 263,264, but Haubruck et al. were also able to demonstrate an angiogenic effect 
of BMP-7 in bone regeneration.265 Although these two BMPs have been established in 
the treatment of non-union and are already on the market, the literature is not univocal 
on their proof of action concerning bone healing. Several studies show positive effects 
of BMPs on bone regeneration and angiogenesis 13,263,264,266-272. Other studies have been 
unable to prove any significant advantage of adding BMP-2 or BMP-7 to autogenous 
bone grafts in non-union treatment, probably due to the initiation of the expression of 
BMP antagonists after local administration of BMPs 273,274. There are even studies which 
mention relevant adverse effects of BMP treatment in non-unions 275. 
Insulin-like growth factors (IGFs). Insulin-like growth factors are frequently found in 
bone tissue. Of the two forms, IGF-I and IGF-II, IGF-I is the most powerful form, and it 
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exerts its stimulating effect on downstream signalling pathways over different binding 
proteins. 
The opinions in the literature on the exact effect of IGFs on bone regeneration are 
bivalent. There are in vivo studies showing a positive effect of the IGF system on 
embryonic and postnatal development of the skeleton 276,277 and on fracture healing 278-
280. Other studies show that IGF-1 functions as a regulator over autocrine activity within 
the bony callus, thereby stimulating the osteoprogenitor cells at the fracture site 281-284. 
Furthermore, Weiss and colleagues show that low IGF-1 concentrations are associated 
with non-union development 282. On the other hand, some studies demonstrate an 
increased fracture healing tendency in IGF-I knockout mice 285 and enhanced IGF-I/II 
gene expression in mice with non-unions 286. 
1.4.4. Matrix-metalloproteinases (Mmp) 
Metalloproteinases are enzymes, some of which degrade the extracellular matrix of 
cartilage and bone. The degradation of the extracellular matrix in newly formed bone 
enables the ingrowth of blood vessels and subsequent osteogenesis 154. In various 
studies, Mmp-9 and Mmp-13 are demonstrated to be relevant for both cartilage and 
bone remodelling 287,288. Wigner and colleagues even showed that Mmp-9 and Mmp-13 
levels in urine have the potential to act as biomarkers for fracture healing 289. 
1.4.5. Angiogenic factors 
1.4.5.1. Hypoxia-inducible factor-1α (HIF-1α) 
As blood supply is damaged at the fracture site due to the initial trauma, an oxygen debt 
arises. In such hypoxic environment, the expression of pro-angiogenic factors, which 
promote angiogenesis during fracture healing, is induced, but also the functions of 
osteoblasts, osteoclasts and chondrocytes are directly regulated towards cell 
proliferation. The oxygen-sensitive transcriptional activator hypoxia-inducible factor-
1 (HIF-1) is a key transcriptional mediator of the response to hypoxic conditions 290. 
HIF-1 participates in the process of fracture repair by triggering angiogenesis, 
facilitating the migration of inflammatory cells, recruiting osteoprogenitor cells and 
promoting the differentiation of cells in the fracture site. 291-293. Subunit HIF-1α 
expression can be induced by a hypoxic environment with an oxygen concentration of 
less than 6% 294,295. The promotion of angiogenesis and osteogenesis takes place by 
upregulating VEGF and other target genes. HIF-1α further facilitates the migration and 
proliferation of MSCs by enhancing the expression of SDF-1 and Twist-related protein 
(TWIST), respectively 296,297. 
1.4.5.2. Vascular endothelial growth factor (VEGF) 
The VEGF group is formed by the isoforms VEGF-A, -B, -C and -D.290 These isoforms are 
produced by endothelial cells, macrophages, chondrocytes and osteoblasts 298,299, and 
their functions are exerted by binding to its receptors VEGFR-1 and VEGFR-2 on the 
target cells 298. Those functions are different for every isoform. VEGF-C and -D are 
closely associated with lymphangiogenesis; the biological significance of VEGF-B, 
however, is still unclear 299. The isoform of VEGF-A predominantly regulates 
angiogenesis and the growth of endothelial cells 299,300. Several studies have 
demonstrated that VEGF is an essential growth factor in bone healing as it is a key 
regulator of angiogenesis. Street et al. have found that a high level of VEGF in fracture 
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haematoma not only promotes the recruitment of endothelial cells and osteoblasts but 
also stimulates the biological function of those cells 301,302. In the intramembranous 
ossification stage, VEGF induces vascular invasion into the fracture site, providing the 
nutrients and numerous cells which are required for bone healing 299. In the 
endochondral ossification phase, VEGF expressed by hypertrophic chondrocytes 
promotes vascular invasion into the cartilage zone, accelerates chondrocytes apoptosis 
and stimulates bone matrix synthesis 303,304. Animal studies have demonstrated that 
exogenous VEGF stimulates blood vessel formation and enhances the formation and 
ossification of a callus, whereas inhibiting the activity of VEGF had the opposite effect 
138,305. 
Platelet-derived growth factor (PDGF). Platelet-derived growth factor is mainly 
synthesised by platelets but can also be set free by other cells, such as macrophages, 
endothelial cells and smooth muscle cells. This group of growth factors exists in 
different forms: PDGF-A, PDGF-B, PDGF-C, PDGF-D and PDGF-AB. The last form plays a 
role in the inflammatory stage of fracture healing and controls the inflammatory 
response 306,307. PDGF-AB is upregulated in the early phases of the inflammatory stage, 
and it has clear angiogenic activity 151,281,308. A positive effect of PDGF-AB on normal 
bone regeneration has been shown 306,308, and conforming to those results, low PDGF-
AB concentrations were detected in patients with non-unions 309. 
1.4.6. Chemokines 
The chemokine group, which plays an important role in the recruitment of immune cells 
into the fracture haematoma, consists of approximately 50 ligands with approximately 
20 corresponding receptors 310,311. 
1.4.6.1. CC Chemokine ligand (Ccl) 2 and CC Chemokine receptor (Ccr) 2 
In particular, the system of Ccl2 and Ccr2 initiates the recruitment of macrophages and 
mesenchymal cells in the inflammatory stage of fracture healing, but this system also 
seems to play a role in the mineralisation process of the soft callus 312,313. 
1.4.6.2. Chemokine CXCL8 (Interleukin-8 or CXC motif chemokine 8) 
This inflammatory mediator is produced by macrophages, fibroblasts and endothelial 
and epithelial cells. This chemokine, also identified as a proinflammatory cytokine, is 
upregulated within the first 24 hours after injury 173,314. It has an essential function in 
the chemotactic mobilisation of neutrophils, leukocytes and other immune cells 315 but 
also has angiogenic and osteoinductive effects 316. 
1.4.6.3. CXC chemokine ligand (CXCl) 12 and CXC chemokine receptor (CXCr) 4 
This system also has a role in the recruitment of mesenchymal stem cells into the 
fracture hematoma 20,220. As chemokine CXCL8, it also seems to contribute to the 
angiogenesis and callus-forming process and promotion of bone regeneration 21,317,318. 
1.4.7. Prostaglandins 
Arachidonic acid as a resource for prostaglandins is metabolised by cyclooxygenase 
(COX) 1 or 2 and prostaglandin synthases. End products of this reaction are different 
prostaglandins (PGs) and thromboxane A2 (TXA2) 319,320. Of those prostaglandins, PGE2 
appears to increase bone regeneration by enhancing the BMP-2, osteocalcin, receptor 
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activator of nuclear factor kappa-Β ligand (RANKL), tartrate-resistant acid phosphatase 
(TRAP) and Mmp9 expression 320,321. 
1.4.8. Other factors 
The arginine-nitric oxide (NO) pathway and the Wnt signalling pathway also play 
important roles in the development of non-union. 
1.4.8.1. Arginine-NO pathway 
Another factor which plays an important role in the healing process of patients is their 
nutritional status. Considering the disastrous effect of malnutrition on bone healing, it 
is likely that not only endogenous depletion but also exogenous supply with protein and 
amino acids is vital for good fracture healing.322 In the population of patients with 
fractures, there are two categories of patients who need special attention concerning 
this factor. First, it has been observed that a malnourished state in elderly patients leads 
to prolonged recovery, complications such as non-union and increased morbidity and 
mortality after fractures 139,323,324. Second, nutritional requirements in poly-
traumatised patients are elevated, and metabolic changes in these patients can lead to 
the loss of muscle mass, impaired healing, immobility and susceptibility to infections, 
regardless of the age of the patient 325,326. As both patient groups are growing due to the 
ageing of society and an increased survival rate of polytrauma patients, dietary 
interventions, such as protein- and amino acid suppletion, to avert impaired bone 
healing could contribute to improved patient outcomes and reduced healthcare costs. 
One of the factors associated with a better nutritional state, which influences bone 
repair, is the arginine-nitric oxide (NO) metabolism. This metabolism is an important 
factor in angiogenesis and revascularization. In the literature, many studies concerning 
fracture healing emphasise the key role of revascularization and angiogenesis and its 
necessity for new bone formation 129-132,139,327-329 because those processes are a 
prerequisite for inducing cell growth, the distribution of cytokines and the delivery of 
nutrients and oxygen to the fracture site. If the blood supply during fracture healing is 
compromised, there is a high probability of developing pseudarthrosis or a non-union 
138,330. 
The complex process of neovascularization, vascular reactivity, angiogenesis and the 
formation of bone cells during fracture healing partly depends on the regulation by 
nitric oxide 323,331,332, in addition to other pro- and anti-angiogenic mediators such as 
VEGF, HIF-1α, FGF, interleukins and BMPs 129,132,139. 
In the inflammatory stage of fracture healing, nitric oxide is a well-established mediator 
which enhances blood flow throughout the fracture site by vasodilation 333-335. NO is 
produced in the human body either via the endogenous nitrate-nitrite-nitric oxide 
pathway 336 or the classic L-arginine-NO-synthase pathway 337. The nitrate-nitrite-nitric 
oxide pathway forms an important alternative to the classic pathway, especially in 
hypoxic states 338. In the classic pathway, NO is produced by the oxidation of L-arginine 
catalysed by the NOS enzyme family 331,333,337,339. A disturbance of the equilibrium 
between the three isoforms of NOS (i.e., neuronal NOS [nNOS/NOS-1], inducible NOS 
[iNOS/NOS-2], endothelial NOS [eNOS/NOS-3]) in this pathway will lead to impaired 
fracture healing 340. There is experimental evidence indicating that sufficient 
production of NO from its precursor arginine is of particular importance for vascular 
reactivity and the healing of fractures, thereby establishing a possible link between 
nutritional status and bone healing 322,323,330,341. Wijnands et al. showed that the 
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citrulline-arginine-NO metabolism is impaired in atrophic non-unions and arginine and 
NO levels are increased in hypertrophic non-unions, suggesting that NO is involved in 
the development of non-unions 322. Supportive of this theory is the finding that arginine 
levels decrease in cases of stress, such as wound healing and sepsis, as possible initial 
circumstances in the pathogenesis of non-union 342,343. Further, in vivo studies have 
demonstrated that the upregulation of NOS expression and thus of NO production 
encouraged fracture healing 331,344. Moreover, evidence has shown that NO can enhance 
the conversion of arginine into ornithine by arginase enzyme, increasing the production 
of polyamine and proline, which are considered to be substrates for collagen synthesis 
345. This could be considered another explanation to clarify the importance of arginine-
NO metabolism in fracture healing. 
The NOS enzymes. The NOS enzymes are subdivided into three isoforms in humans: 
neuronal nitric oxide synthase (nNOS or NOS1), inducible nitric oxide synthase (iNOS 
or NOS2), and endothelial nitric oxide synthase (eNOS or NOS3) 346. The iNOS enzyme 
is Ca2+-independent, which produces a large amount of NO under inflammatory 
conditions and is mainly expressed in macrophages. The Ca2+-dependent enzymes, 
eNOS and nNOS, are constitutively expressed in endothelial and neuronal cells, 
respectively, with low-output NO production 346. During fracture repair, there seems to 
be an appropriate NOS isoform expression equilibrium between NOS isoforms, 
especially in the early stages of fracture healing, which is very important for a normal 
course of callus formation and bone stability after fracture 331,333,334,339. The high output 
of NO generated by iNOS is considered a likely ‘damaging NO’ to bone healing as it 
would increase the osteoclastic bone resorption and reduce the proliferation of 
osteoblasts but promote the apoptosis of osteoblasts. Conversely, the low output of NO 
produced by eNOS is considered a ‘protective NO’, which has the opposite effect 
compared with that produced by iNOS. It has been demonstrated that the NO produced 
by eNOS is a key factor in regulating vascular tone 347. Increasing the activity of eNOS 
may not only directly upregulate the function of osteoclasts and osteoblasts but also 
promote angiogenesis 348. Early upregulation of the NOS enzymes, which mediate the 
conversion of arginine into citrulline and NO, is associated with a normal inflammatory 
phase of fracture healing 333. In addition, artificial stimulation of the NOS enzymes 
results in increased bone stability during recovery after fracture 331. Disturbances in NO 
production, either through insufficient NOS activity or depletion of substrate, is 
associated with an increased incidence of delayed fracture healing and non-union 322,340. 
Arginine as a substrate for NO production. For humans, arginine (or L-arginine) is 
considered to be a semi-essential amino acid, and the vast amount of arginine in the 
body is derived from protein breakdown, accounting for approximately 80% of total 
arginine. Approximately 10%-15% of arginine is converted from citrulline by the 
enzymes arginine-succinate synthetase (ASS) and arginine-succinate lyase (ASL) 346. 
From the arginine taken from proteins in food, approximately 40% is oxidised in the 
intestines by bacteria and arginases during the first passage 349,350. Then, 10%-15% of 
the residual systemic arginine is metabolised during the passage through the liver 
349,351,352. The remaining arginine can be used intracellularly but has to compete with 
other arginine analogues for the transmembrane carrier protein hCAT-2B 339, with the 
result that only ~1% of the ingested arginine is actually used for NO production 353. To 
exemplify these facts on arginine metabolism, Luiking et al. observed that in conditions 
of sepsis, chronic stress, malnutrition and polytrauma, arginine availability is impaired, 
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which may lead to insufficient callus formation and, ultimately, to severe problems in 
the bone-healing process 324,354. Further, Wijnands et al. found that arginine deficiency 
was related to delayed fracture healing or non-union 322, while, in another study, an 
improvement of bone formation was observed by supplying arginine silicate inositol 
complex, indicating that arginine administration might increase bone healing 355. 
Moreover, Meesters et al. demonstrated that disturbances of NO production, either 
through insufficient NOS activity or depletion of substrate, is associated with an 
increased incidence of delayed fracture healing and non-union 322,340. (Figure 1.6.) 
 
Figure 1.6. Metabolic pathways of arginine. Arginine is converted over two relevant pathways. In one 
pathway, arginine is converted by Arginase 1 (Arg-1) into urea and ornithine, which are precursors of 
polyamines and collagens. In the other pathway, arginine is converted by NOS (nitric oxide synthase) into NO 
(nitric oxide) and citrulline. Citrulline is in turn recycled by argininosuccinate synthetase (ASS) into 
argininosuccinate and then by argininosuccinate lyase (ASL) into arginine again. Furthermore, ornithine is 
converted into citrulline by ornithine transcarbamoylase (OTC). [This illustration was created by Martijn 
Hofman and is licensed under Creative Commons CC-BY-SA 4.0]. 
 
Citrulline as a substrate for NO production. Citrulline (C6H13N3O3) is a non-
proteinogenic α-amino acid which was initially isolated from watermelon (Citrullus 
lanatus) in 1914 by Koga and Odake 356. In mammals, citrulline is produced as an 
intermediary product in the urea cycle in a reaction between carbamoyl phosphate and 
ornithine catalysed by the enzyme ornithine transcarbamylase. Subsequently, 
argininosuccinate-synthase (ASS) turns citrulline into argininosuccinate, which is then 
metabolised into arginine and fumerate by the enzyme ASL 333. Thus, citrulline acts as 
a precursor of arginine production. Moreover, citrulline is a secondary product of the 
conversion of arginine into NO by the NOS enzyme family. As mentioned before, 
citrulline can be converted back into arginine 346,357. (Figure 1.6.)  
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Citrulline is normally released by the small intestine, converted to arginine in the 
kidney and released into the circulation. This citrulline-NO pathway appears to be the 
solution for the inefficient NO production via the L-arginine-NO pathway because the 
recycling of citrulline into arginine is a very efficient process 339,358-360. The big 
advantage of the citrulline-NO pathway over the L-arginine-NO pathway is that the 
catabolism of orally taken citrulline is restricted in the intestines 361 and it is not 
extracted by the liver 339,352, leaving the bulk of citrulline for conversion, mainly in the 
kidneys, to arginine 339,352,362. 
Moreover, several studies have demonstrated that, in this way, citrulline 
supplementation is significantly more potent in increasing the level of  
arginine in tissue and plasma in the human body than an equivalent dose of arginine 
322,363,364. 
In adults, the citrulline converted by the kidney is enough to provide the body’s full 
arginine requirements. Arginine synthesised from citrulline represents 60% of the de 
novo arginine synthesis in the organism but only 5% to 15% of the circulating arginine 
365. Various studies have shown that orally administered citrulline supplementation is 
well absorbed 366-368, increases protein synthesis 358 and restores the arginine pool and 
nitrogen homeostasis 339,369. In addition, increased concentrations of citrulline are 
associated with increased activation of iNOS and eNOS 333,370 and thus have positive 
effects on NO production and can improve nitrogen homeostasis. Those effects are 
likely to be mediated through the increased availability of arginine in tissue and plasma 
322,339,369. There are several studies demonstrating the beneficial effects of citrulline 
supplementation on various disorders, such as sickle cell disease 371, hypertension, high 
pulmonary artery pressure 372 and protein malnutrition 358,373 but also on improving 
sports performance 374,375. On the other hand, other authors failed to find biological 
effects of citrulline supplementation in either animal or human studies. For example, 
Bouillanne et al. carried out a randomised, multi-centre study to investigate the effects 
of citrulline supplementation on malnourished elderly patients. They found that oral 
citrulline supplementation for 3 weeks could not enhance protein synthesis in the 
whole body or in the liver 376. Ham and colleagues found that citrulline had no effect on 
preventing the loss of skeletal muscle in 14 days of hind-limb immobilisation in mice 
377. A meta-analysis performed by Mirenayat et al. showed that citrulline 
supplementation could not decrease blood pressure 378. Concerning bone healing, 
Wijnands and colleagues demonstrated a significant change in the concentrations of 
arginine, citrulline and ornithine in non-union patients compared with healed-fracture 
patients 322. More recently, Rajfer and colleagues reported that COMB-4 (a mixture of 
citrulline, paullinia cupana, ginger and muira puama) accelerates the process of fracture 
healing in rats by increasing the expression of iNOS 331. However, because they used a 
compound in their study, the conclusions are not fully transferable and informative on 
the effects of citrulline supplementation on its own. 
1.4.8.2. Wnt signalling 
In the canonical Wnt (wingless/integrated) signalling pathway, a secreted glycoprotein 
passes signals over a membrane receptor into the cell, where the upregulation of β-
catenin levels modulates gene expression. This pathway is shown to be involved in 
fracture healing in mice 379,380. 
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1.4.9. Cells involved in the inflammation response 
Cells from the immune system, derived from hematopoietic stem cells, play a highly 
important role in the process of fracture healing and bone regeneration. A disturbance 
of the cells or their function results in pathologic fracture healing. The cells are recruited 
mainly during the first stage of fracture healing, but their effects are not limited to that 
stage and continue throughout the entire healing process. (Figure 1.7.) 
 
 
Figure 1.7. Immune cells involved in the fracture healing process. Throughout the four fracture healing 
stages, different immune cells are active at different time points. [This illustration was adapted by Martijn 
Hofman (licensed under Creative Commons CC-BY-SA 4.0) using the original illustration from Baht et al.327 and 
images from Smart Servier Medical Art (https://smart.servier.com/)]. 
 
1.4.9.1. Platelets 
Platelets are immune cells of myeloid origin and, besides their essential function in the 
construction of fracture haematomas, they also discharge inflammatory cytokines (IL-
1, IL-6, TNF-α) and growth factors (PGDF, TGF-ß, VEGF and IGF) 381 for the mobilisation 
of neutrophils, monocytes and mesenchymal progenitor cells 382,383. As the 
understanding of the part growth factors play in the fracture healing process grows, the 
importance of the fracture haematoma, containing platelets, is emphasised. On the 
other hand, scientific evidence for a stimulating effect of the application of platelet-rich 
plasma (PRP) in fracture healing is still inconclusive 38.  
1.4.9.2. Neutrophils 
Neutrophils are derived from multipotent haematopoietic stem cells in the bone 
marrow and belong, just as basophils and eosinophils, to a subspecies of leukocytes 
called polymorphonuclear leukocytes or granulocytes. Neutrophils are the most 
abundant immune cells in peripheral blood and the primary first responders to trauma 
72,73. As components of the innate immune system, neutrophils possess a genetically 
programmed defence mechanism, which recognises molecular patterns of offensive 
pathogens or damaged cells by pattern recognition receptors (PRRs). 
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These PRRs identify pathogen-associated molecular patterns (PAMPs), consisting of 
microbial components, and damage-associated molecular patterns (DAMPs), consisting 
of cell components 384. Injury-induced local inflammation activates endothelial and 
immune cells, which produce different cytokines and chemokines, which pre-activate 
circulating neutrophils (‘priming’). The ‘priming’ of neutrophils enhances cytotoxic 
responses evoked by activating agonists, alters the expression and affinity of several 
specific surface receptors, increases the neutrophil oxidative burst and neutrophil 
migratory response to chemotactic stimulation and delays neutrophil apoptosis 384. 
Besides the direct inflow of neutrophils from the bone marrow and damaged vessels at 
the fracture site, the neutrophils are attracted to the injury site by different chemotactic 
signals, produced by activated immune cells and stromal cells. The transmigration 
across the endothelium into the injured tissue, a process called ‘homing’, is preceded by 
the rolling (‘slowing down’) and subsequent firm adhesion of neutrophils to endothelial 
cells 384. At the site of injury, their most crucial attribute is the production of different 
cytokines to mobilise monocytes differentiating into macrophages 327. Furthermore, 
they play a considerable role in the development but also the later breakdown of the 
fibrin thrombus clot at the inflammatory stage of fracture healing. Bastian et al. even 
suggested that neutrophils synthesise a fibronectin+ extracellular matrix within 48 
hours after injury, before stromal cells infiltrate the fracture haematoma 385. In addition 
to those functions, neutrophils also remove other redundant cellular and tissue debris 
at the fracture site 386,387. The phagocytic function of the neutrophils can be exerted in 
the following manners 384. 
- Neutrophils bind either with their immunoglobulin receptors to immunoglobulins 
attached to their targets, or they bind via the αMβ2 integrin (CD11b/CD18 or MAC-1) to 
particles coated with the complement component C3bi5. Subsequently, the 
phagocytosis-process is activated. 
- Neutrophils can release cytotoxic agents (e.g., proteinases, reactive oxidative and 
nitric species) by which pathogens or debris are eliminated. 
- Neutrophils are able to eliminate pathogens by the discharge of so-called neutrophil 
extracellular traps (NETs), which are networks of cytotoxic mediators bound to DNA 
fibres that bind pathogens extracellularly. 
On the other hand, the dysregulation of the neutrophil response plays a key role in the 
origins of various complications after major physiologic stress, such as trauma, burns, 
ischemic reperfusion injuries and sepsis 70,388. Shortly after such major stress events, an 
enhanced and partly undirected immune response, known as systemic inflammatory 
response syndrome (SIRS), causes an accumulation of neutrophils in different organs 
throughout the body and a subsequent massive release of cytotoxic factors, damaging 
the organs and potentially leading to ARDS and MODS 384. 
1.4.9.3. Macrophages 
Like the neutrophils, macrophages are also phagocytic cells from the myeloid lineage, 
but they are differentiated from monocytes. In normal healthy bone, these cells are 
important for bone homeostasis by continuing the balanced bone remodelling. It is 
achieved by providing a niche for osteoblasts and -clasts and by communication 
between different bone cells 327. The role of the macrophages in fracture healing is still 
the subject of research. As monocytes are attracted to the fracture site by CXCL2, IL-1 
and TNF-α, they differentiate into macrophages, which are then one of the first types of 
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cells to emerge in the fracture haematoma 235. Subsequently, the macrophages 
differentiate into M1 macrophages triggered by IL-1 or TNF-α or M2 macrophages 
triggered by IL-4. The M1 macrophages are important in the inflammatory reaction and 
produce different cytokines (IL-1, IL-6, TNF-α, MCP-1, MIP-1 [CXCL2]), which also 
attract monocytes. They also exert their normal phagocytic function in removing debris 
and the fibrin thrombus 235,389. The M2 macrophages appear at a later phase in the 
inflammatory stage and exert anti-inflammatory activities by producing tissue repair 
factors, such as IL-10, TGF-β, BMP-2 and VEGF, mobilising mesenchymal progenitor cells 
and initiating osteochondral differentiation and angiogenesis 390-392. 
1.4.9.4. Osteoclasts 
Another product of the myeloid cell line is the osteoclast cell, which differentiates 
directly from monocytes or from macrophages 392. Triggered by inflammatory signals, 
osteoclasts can also function as immune cells, and they possess the unique function of 
the phagocytosis of bone material. The osteoclasts adhere to the cortex of bone and 
form a ruffled border and a so-called resorption pit. Then, hydrogen ions are secreted 
to dissolve the hydroxyapatite and lysosomal enzymes are set free to resorb the debris. 
Together with activated osteoblasts, the osteoclasts organise bone formation or 
remodelling by resorption of callus tissue, creating bony tunnels for neovascularization 
or nerve ingrowth 393,394. This function of osteoclasts is modulated in two ways. The 
activation of osteoclasts occurs when RANKL, produced by osteoblasts, natural killer 
(NK) cells or T cells, binds to the osteoclast surface receptor RANK. The deactivation of 
osteoclasts occurs when osteoprotegerin (OPG), secreted by osteoblasts and B cells, 
binds to RANK and competes with RANKL binding 327. 
1.4.9.5. T-Lymphocytes (T cells) and B-Lymphocytes (B cells) 
Both T cells and B cells are haematopoietic cells of the lymphoid cell line, and both are 
essential for normal bone homeostasis and adequate fracture healing 242,395. Both cell 
types exert the most important influence on cell signalling in the inflammatory stage 
and the hard callus stage 396. The T cells produce RANKL and thereby activate the 
phagocytic osteoclasts to break down the thrombus and prepare for the soft callus stage 
of fracture healing. Furthermore, the cells produce IL-17, which has an 
immunomodulatory function as described before. 
The B cells, on the other hand, produce OPG and thereby inactivate the osteoclasts. They 
also play a role in the suppression of the inflammatory reaction by inhibiting 
proinflammatory factors, such as interferon gamma (IFN-γ), TNF-α and IL-2 235,397. 
Moreover, the IgM+-CD27+-memory B cell complex has been demonstrated to be 
principally responsible for IL-10 production in fracture healing 397. 
1.4.9.6. Natural killer (NK) cells 
Like T and B cells, NK cells are haematopoietic cells from the lymphoid lineage, which 
normally induce apoptosis of hostile or infected cells. In fracture healing, the most 
obvious role of NK cells, which produce IFN-γ and RANKL, is the mobilisation of 
inflammatory cells and osteoclasts. They also secrete CXCL 7 at a later stage of fracture 
healing and thereby also have a part in the role mesenchymal progenitor cells play at 
the fracture site 398,399. 
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1.4.9.7. Mesenchymal stromal cells (MSCs) 
Mesenchymal stromal cells are cells with multipotent differentiation capacity which 
exert an anti-inflammatory response to inflammatory cytokines, described with the 
term ‘licensing’ 400. The licensing is provoked, for instance, by TNF-α and a combination 
of IL-1α, IL1β and IFN-γ 401. Furthermore, MSCs can also have an immunosuppressive 
effect, initiated by IL-17 or IFN-γ 402,403. 
1.4.9.8. Communication between cells in the inflammation response 
In general, there are three methods of intercellular communication between the cells of 
the immune system. The main interaction between cells occurs via direct membrane 
contact. Soluble mediators can also transfer information from one cell to another. Some 
of those mediators are described in our introduction, and they include cytokines, 
chemokines, hormones and nitric oxide. In recent years, a third method of 
communication between cells has come to the fore. In that method of intercellular 
communication, small vesicles loaded with different proteins, mRNAs and miRNAs are 
budded directly from the cell surface membrane itself (ectocytosis) or from an intra-
cellular membrane (exocytosis) in certain physiological or pathological conditions. In 
general, three groups of vesicles have been identified: exosomes, which are 40nm–
100nm in size and are produced in intracellular multi-vesicular bodies; micro-vesicles, 
which are 100nm–1000nm in size and are produced by outward budding from the 
plasma membrane; and apoptotic bodies, which are 500nm–4000nm in size and are 
produced by blebbing from the plasma membrane in apoptotic cells. In the literature, 
many different names are randomly circulated for these vesicles (micro-particles, 
exosomes, ectosomes, nano-vesicles, etc.); however, the function of modulating cell 
functions through transferring their content is more or less the same 404,405. Further, the 
lipid bilayer of the vesicles provides stable physical and chemical properties, which 
protect the incorporated substances from degradation 406. With respect to bone 
regeneration, the vesicles are shown to exert their influence mainly through the 
regulation of osteoblast proliferation and apoptosis. In the early phases of fracture 
healing, the proliferation of osteoblasts is upregulated and further bone formation 
depends to a great extent on the prevention of osteoblast apoptosis 405,407. To exert 
certain effects on processes in the human body, such as the induction of bone formation, 
micro-vesicles can be loaded with cells or coated with bioactive agents 408,409. In that 
respect, Orth et al. were able to show that VEGF-loaded micro-vesicles improved the 
healing tendency of non-unions in vivo 410. Zhang et al. demonstrated that micro-
vesicles derived from umbilical cord mesenchymal stem cells improved angiogenesis 
and fracture healing in vivo 411. Other authors have also shown positive influences of 
different micro-vesicles on bone metabolism, osteogenesis and angiogenesis in both in 
vivo and in vitro experiments 412-414. 
1.4.10. The neurohumoral response in fracture healing 
Inflammation is the physiological response of an organism to any injury affecting its 
integrity. It applies both to primary systemic conditions, such as sepsis and poly-
trauma, and to local trauma such as fractures. As described above, the inflammatory 
response is regulated by multiple processes. Therefore, neurohumoral systems also 
play a crucial role in the response as they provide an interactive communication 
network in addition to various local effects. In case of a systemic or a local trauma, the 
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homeostasis of the organism is disturbed, and the readjustment of the homeostasis is 
regulated and can be influenced by the modulation of the neurohumoral systems. 
Neurohumoral modulation of fracture healing is suggested by several studies, which 
support the observation of accelerated fracture healing in patients with concomitant 
traumatic brain injury. All of the studies suggest an underlying neurohormonal or 
neurohumoral mechanism as a cause for the improved fracture healing in the patients 
93,415-417. Circulating humoral factors released by the damaged brain and direct neural 
pathways are both thought to be partly responsible 97,418. 
It is generally recognised that the central and peripheral nervous systems affect the 
immune system and vice versa 419. That bi-directional communication increases the 
efficiency of both systems in the inflammatory response to injury. 
In case of an injury, sensory information is sent from the site of injury to the cerebral 
cortex. Subsequently, the activated hypothalamic nuclei stimulate different neuro-
humoral pathways, which then expose the target organs to a cocktail of ligands, which 
influence the local angiogenesis, inflammation and immune reactions and coordinate 
the metabolic changes in situ 420. 
Briefly, both humoral and neuronal mediators contribute to the regulation of the 
inflammatory response to injury. Humoral mediators reach their target cells in distant 
organs by diffusion or transport by blood flow. Substances which are released by nerves 
(e.g., norepinephrine and acetylcholine) rapidly reach specific cell groups of distant 
organs 421. 
The four neurohumoral pathways, which are well represented in the literature, are the 
autonomic nervous system, the Hypothalamic-Pituitary-Adrenal axis (HPA) system, the 
neuroendocrine system and the Renin-Angiotensin-Aldosterone System (RAAS). 
(Figure 1.8.) However, the main focus in research is on the influence of these systems 
on systemic diseases and conditions, such as cardiovascular diseases, sepsis and poly-
trauma, and only a negligible number of studies address the influence of these systems 
on fracture healing and bone regeneration. 
1.4.10.1. The autonomic nervous system 
The autonomic nervous system exerts a direct regulation of the bone marrow cellularity 
and especially of the lymphoid tissue. Lymphocytes in turn express different receptors 
for many neurotransmitters, neurohormones and neurohumors, such as steroids, 
catecholamines, enkaphalines, endorphins, vasoactive peptides and substance P. The 
denervation of bone causes an impaired cellularity of the marrow and impairs the 
transport of osteoprogenitor cells into the circulation 422. 
The autonomic nervous system, with its parasympathetic and sympathetic division, 
plays an important role in the regulation of the inflammatory response of the body to 
bone injury. 
The parasympathetic nervous system. The parasympathetic nervous pathway plays an 
important role in the anti-inflammatory response to injury. The sensory input created 
by an injury reaches the brainstem via the afferent vagus nerve, where the signals are 
transmitted via efferent nerves and the release of the parasympathetic 
neurotransmitter acetylcholine to the different organs occurs 423. Subsequently, 
acetylcholine reduces the release of various proinflammatory cytokines, such as TNF-
α, IL-1β, and IL-6, by 50%-75% 421,424,425. This cholinergic anti-inflammatory pathway 
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is a regulatory mechanism for controlling the proinflammatory and immune response 
to injury 426,427. 
In addition to its role as a neurotransmitter of the parasympathetic nervous system, 
acetylcholine is also located as a paracrine and autocrine signalling molecule in various 
non-neuronal cells, such as endothelial, mesothelial, epithelial, immunocompetent and 
smooth muscle cells. In those cells, acetylcholine regulates basic cell functions, 
including proliferation, differentiation and intercellular communication 428. 
Moreover, osteoblasts have nicotinic acetylcholine receptors (nAChR), which are 
upregulated during fracture healing after exposition to BMP-2, and those cells express 
different important enzymes for the synthesis of acetylcholine 429. By binding to 
nicotinic receptors expressed by fibroblasts, acetylcholine can modulate the 
biomechanical aspects of newly formed bone, as those cells can upregulate the collagen 
expression 429. 
Through binding to the other muscarinic receptor, acetylcholine exerts a vasodilative 
effect and enhances bone perfusion in the course of fracture healing because the 
muscarinic receptor stimulates the synthesis of nitric oxide (eNOS) 430. 
Kliemann and colleagues also showed that acetylcholine has a positive effect on fracture 
healing by improving the cancellous bone microarchitecture, the mechanical strength 
and the bone matrix synthesis 431. 
In case of a fracture, Prasad et al. and Udupa showed that the first neurotransmitter 
which increases immediately after injury is acetylcholine. Subsequently, acetylcholine 
stimulates the adrenal medulla to produce catecholamines, and so the parasympathetic 
nervous system has a clear interaction with the sympathetic nervous system 432,433. 
The sympathetic nervous system. The hypothalamus-sympathetic nervous system 
pathway influences the regeneration of bone through various neuromediators, such as 
neurotransmitters, neurotrophins and neuropeptides.422 That influence is possible 
because of a good innervation of bones with sympathetic and sensory nerves, which are 
especially represented in the periosteum, around blood vessels within the bone tissue 
and around osteogenic cells 434,435. Several studies have shown that if that sympathetic 
innervation is absent, bone metabolism is disturbed 436,437. For instance, the perfusion 
of all organs is modulated swiftly by the sympathetic discharge of catecholamines, 
whereby adrenaline mainly causes systemic effects and noradrenaline mainly causes 
local effects. The intended vasoactive effect, vasodilation or vasoconstriction is 
executed by means of the activation of various receptors 420, which have been 
demonstrated by several studies to be present in mammalian bone cells 438,439. That 
presumed influence of the sympathetic system on bone regeneration is further 
reinforced by the findings of Bjurholm et al. and Oshima et al. 440,441. Furthermore, Grills 
and colleagues showed an enhanced level of catecholamines (noradrenaline and 
adrenaline) in callus tissue and an increased biomechanical strength of healing bone 
after the application of nerve growth factor at the fracture site in an in vivo experiment, 
showing an increased innervation of callus tissue 442. In addition to the stimulation of 
sympathetic innervation, the application of nerve growth factor also has a stimulating 
effect on the axonal growth of sensory nerve fibres 437, which play a role in both 
angiogenesis and osteogenesis during fracture healing through their neurotransmitters 
CGRP and substance P 112,435. The sympathetic nervous system and the sensory nerves 
are thought to have an opposite effect on bone metabolism. The sympathetic nervous 
system has a rather catabolic effect on bone metabolism by increasing the bone 
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resorption by osteoclasts and decreasing the bone formation by osteoblasts 443. That 
finding is strengthened by studies which show a positive effect of β-adrenergic receptor 
blockage on the bone mass density in postmenopausal women, thereby decreasing the 
risk of osteoporotic fractures 444. CGRP and substance P, as neurotransmitters of the 
sensory nerves, rather have the opposite effects to β-adrenergic receptor blockage on 
osteoclasts and osteoblasts, causing an anabolic effect on bone metabolism 443. 
In patients with long bone fractures and concomitant traumatic brain injury in which 
increased bone healing is presumed, a relative inhibition of the sympathetic nervous 
system via neuromediators in the hypothalamus could be a possible explanation for the 
phenomenon. That inhibition instigates the mobilisation of mesenchymal stem cells and 
osteoprogenitor cells in the systemic blood pool, which could induce enhanced fracture 
healing 422. 
The neurotransmitters of the sympathetic nervous system can also exert an influence 
on the innate immune system via α- or β-adrenergic receptors, which are expressed on 
various cells of the immune system 445,446. By way of the interaction of catecholamines 
with the α-adrenergic receptors, macrophages are stimulated to discharge TNF-α and 
thereby exert a proinflammatory effect 447. The stimulation of the β-adrenergic 
receptors causes diminished IL-1 and TNF-α releases and increased IL-10 releases by 
macrophages and so has an opposite anti-inflammatory effect 448,449. 
1.4.10.2. The neuroendocrine system 
The neuroendocrine system is made up of special cells, which respond to signals from 
the autonomic nervous system by producing and releasing different hormones. Nearly 
every organ of the human body contains such neuroendocrine cells, and the 
neuroendocrine system plays an important role, amongst others, in the growth and 
remodelling of bone tissue. Examples of neurohormones and neurohumors which play 
a role in the homeostasis of bone tissue are growth hormone (GH), parathyroid 
hormone (PTH), follicle stimulating hormone (FSH), thyroid hormones, testosterone, 
oestrogen, vasopressin, angiotensin, neuropeptide Y, noradrenaline, adrenaline, insulin 
growth factor (IGF), and vitamins A and D. Even the bone tissue itself produces 
hormones, which perform important functions in the mineralisation process of bone 
matrix, such as osteocalcin and fibroblast growth factor 23 (FGF23) 450,451. 
In a study on bone healing in patients with concomitant brain injury, Khallaf and 
colleagues were able to confirm the stimulating effects on bone healing of some 
neurohormones (i.e., parathyroid hormone, growth hormone, noradrenaline and 
adrenaline) and the anti-osteogenic effects of the neurohormone produced in the 
adrenal cortex (i.e., glucocorticoids) 422. 
Furthermore, the role of histamine is discussed in the literature in connection with this 
topic because the long-term inhibition of histamine could lead to increased bone 
resorption and decreased bone formation and, therefore, to an increased fracture risk 
452. 
In addition to the hormones produced throughout the human body, cytokines also play 
a major role in activating different neuro-humoral pathways, such as the sympathetic 
nervous system and the HPA system 453,454.  
Cytokines, which are released after an injury, can activate multiple areas in the brain. 
The hypothalamus, the rostroventral medulla and the locus coeruleus can be activated 
via afferents of the vagal nerve, but the hypothalamus can also be activated by 
inflammatory molecules released by stimulated perivascular cells of the blood brain 
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barrier. Further, cytokines can also activate circumventricular organs without a blood 
brain barrier such as the area postrema. Subsequently, those activated areas of the 
brain can activate the sympathetic nervous system and the HPA pathway. 
1.4.10.3. The hypothalamic-pituitary-adrenal (HPA) system 
After activation of the hypothalamic nuclei via circulating cytokines, vagal stimulation 
or central stimulation over the postcentral gyrus, the hypothalamus expresses 
corticotropin releasing hormone (CRH) and antidiuretic hormone (ADH), also called 
arginine vasopressin (AVP). CRH stimulates the anterior pituitary gland or 
adenohypophysis to produce adrenocorticotropic hormone (ACTH), which in turn 
stimulates the release of glucocorticoids and mineralocorticoids in the adrenal cortex 
454. Cortisol exerts mainly anti-inflammatory effects by stimulating the synthesis of the 
anti-inflammatory cytokines IL-4 and IL-10 and by the downgrading of nuclear factor-
kappa B (NF-κB) as an important transcription factor. Moreover, in the hypothalamus 
and the hypophysis, the prohormone pro-opiomelanocortin (POMC) is produced as a 
precursor to both adrenocorticotropin hormone (ACTH) and alpha-melanocyte-
stimulating hormone (α-MSH). The latter hormone also has anti-inflammatory activity 
by suppressing NF-κB and stimulating the discharge of IL-10 455. 
The importance of α-MSH is mainly known from studies concerning the inflammatory 
response in septic shock 456 and systemic immune responses 457, but it can also affect 
bone metabolism directly by increasing bone turnover 458,459. 
AVP produced in the hypothalamus plays a role in the stimulation of the ACTH release 
from the anterior pituitary gland, but it also stimulates the posterior pituitary gland or 
neurohypophysis to release vasopressin to the kidneys and oxytocin to the breasts and 
uterus 454. 
Another way to activate the HPA pathway, which has been demonstrated in various 
clinical studies, is via the direct stimulation of the HPA system by cytokines, which in 
turn stimulates the release of anti-osteogenic cortisol 460. 
The importance of the HPA pathway in fracture healing is further emphasised by the 
findings of Khallaf et al. in their study of patients with long bone fractures and 
concomitant brain injury. They found normal levels of corticosteroids in the patients as 
an expression of the neuronal inhibition of the adrenal cortex and of its anti-osteogenic 
corticosteroid production, inducing a normal inflammatory response to  
fracture 422. In addition to these effects on neuro-hormones, the anterior pituitary gland 
can also stimulate the sympathetic nervous system directly in a stress response.  
1.4.10.4. The renin-angiotensin-aldosterone system (RAAS) 
The systemic effects of the renin-angiotensin-aldosterone system (RAAS) as a 
regulating system of blood pressure and of fluid and electrolyte homeostasis are well 
known and described in the literature. Disturbances in this regulatory system can cause 
a variety of diseases, such as cardiovascular diseases and hypertension 461, renal 
diseases 462 and metabolic syndrome 463. 
In recent years, evidence has grown to indicate that local skeletal RAAS activity is 
detrimental for bone metabolism. Those effects are exerted via para- and endocrine 
stimulation, which induce different pathological implications in the bone 464. In 
particular, angiotensin II, the bioactive peptide of the system, could lead to decreased 
bone formation, bone injuries and osteoporosis 465,466. 
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Figure 1.8. Regulatory systems of the neurohumoral response in fracture healing. In case of an injury, 
sensory information is sent from the site of injury to the cerebral cortex. Subsequently, the hypothalamic 
nuclei are activated and stimulate various neuro-humoral pathways, which then expose the target organs to 
a cocktail of ligands, which influence the local angiogenesis, inflammation and immune reactions and 
coordinate the metabolic changes in situ, thereby influencing the fracture healing process. In this figure, 
neuro-humoral systems are highlighted: (1) the HPA system (green), (2) the RAA system (blue), (3) the 
autonomic nervous system (red), and (4) the neuroendocrine system (yellow). [This illustration was created 
by Martijn Hofman (licensed under Creative Commons CC-BY-SA 4.0) using the original illustrations from 
Wikimedia commons (https://commons.wikimedia.org/) and images from Smart Servier Medical Art 
(https://smart.servier.com/)]. 
 
Interestingly, the effect of RAAS activity on osteoporosis can be influenced by other 
therapeutics in osteoporosis treatment. For instance, regular exercise and vitamin D 
treatment inhibit skeletal RAAS activity and, therefore, osteoporosis development 
467,468. On the other hand, cortisol treatment and obesity may enhance tissue RAAS 
activity and, therefore, increase the risk of osteoporosis 469. 
Moreover, several studies have been able to demonstrate that there is an interaction 
between RAAS activity and the kallikrein-kinin system in which bradykinin plays a 
decisive role 470. Other studies have shown that bradykinin negatively influences 
osteoblast differentiation and enhances osteoclast formation, by which mechanism 
bone resorption increases and bone mass decreases 471-473. 
Various studies in which RAAS blockers were used have demonstrated such effects in 
systemic 474 and bone diseases 464,470. 
1.5. AIMS AND OUTLINE OF THE PRESENT THESIS 
1.5.1. Aims of the present thesis 
First of all, the aim of this thesis was to obtain a better understanding of the 
pathophysiological mechanism of fracture healing in general and of delayed-/non-
union in particular. Another important trigger for initiating this research project was 
the need to know if the prevailing clinical expert opinion that fracture healing is 
enhanced in patients with concomitant TBI was based on solid research. Therefore, 
first, a systematic review of the literature on fracture healing in patients with 
concomitant TBI was conducted. Second, a retrospective study in which the influence 
of TBI on the healing of long bone fractures was investigated was performed (Part I). 
Through the results of those studies, points of departure were acquired for further 
research on fracture healing in which neurohumoral pathways play a central role. The 
influence of various neurohumoral mechanisms were elaborated by clinical studies and 
several experimental in vivo and in vitro animal studies (Part II). 
Following on from the introduction of the present thesis, it has to be concluded that the 
pathomechanism of the inflammatory response to fracture healing is still a giant puzzle 
with a lot of missing pieces. The complexity of the regulation mechanisms and the subtle 
interaction of the neuro-humoral pathways makes it difficult to regulate single 
modulators of the different pathways in a favourable direction.420 That complexity was 
the inspiration to perform this research project and to compose this thesis in an attempt 
to find answers to the following questions concerning the neuro-humoral modulation 
of fracture healing: 
1. Does concomitant traumatic brain injury definitely enhance fracture healing? If 
so, what pathophysiological mechanisms are underlying this effect? (Chapters 2 
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and 3) 
2. Does the blockage of the substance P neurokinin-1-receptor influence fracture 
healing in rats? (Chapter 4) 
3. How does the gait pattern and muscle weight evolve during fracture healing in 
rats? (Chapter 5) 
4. Can arginine availability in reamed intramedullary aspirate predict the outcome 
in non-union healing? (Chapter 6) 
5. What is the impact of serum-derived micro-vesicles on osteoblast function after 
femoral fractures in rats? (Chapter 7) 
6. How does neutrophil homeostasis change during the early phases of fracture 
healing in rats? (Chapter 8) 
7. Is the pulmonary neutrophil pool affected by intramedullary stabilised femur 
fractures in rats? (Chapter 9) 
1.5.2. Outline of the present thesis 
Part I 
The first part of the thesis focusses on the influence of TBI on fracture healing. 
In Chapter 2, the results of a systematic review of the influence of concomitant 
traumatic brain injury on the healing of fractures are described. The aim of that review 
of the literature was to test the common disseminated opinion that concomitant brain 
injury enhances bone regeneration and fracture healing. In that review, the evidence 
provided by both clinical and experimental research throughout the period from 2005 
to 2015 was evaluated. 
In Chapter 3, the results of a retrospective clinical study we performed to further 
identify the influence of TBI, chest injury and fracture stabilisation strategy on the 
development of non-unions in long bone fractures is presented. In that retrospective 
study, patients with lower extremity long bone fractures were identified and followed 
until healing of the fractures. Further, concomitant diseases and complications were 
recorded and the healing of the fractures was assessed according to the bridging of ¾ 
cortices on the X-rays and by way of the fracture healing response according to Spencer. 
The influence of different fracture stabilisation strategies applied in the treatment of 
long bone fractures were also highlighted. The main outcome parameter was the 
occurrence of non-union. 
Part II 
In the second part of this thesis, the focus will be on the neuro-humoral modulation of 
fracture healing in the experimental setting of a femur fracture model in rats. 
According to the literature, many possible influencing substances have been studied in 
respect of fracture healing and bone regeneration. Of that immense number of 
substances, we selected substance P and citrulline for comprehensive critical 
evaluation. Also, the cellular immune response in fracture healing and the influence of 
fractures on the neutrophil function was investigated. 
In Chapter 4, the effect of a selective blockage of the neurokinin-1-receptor in rats with 
an intramedullary stabilised femur fracture is described. This blockage eliminates the 
influence of substance P on the inflammatory response to fracture. In this study, the 
gene expression of important proteins in the first crucial phases of fracture healing was 
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evaluated and the fracture healing process was further assessed with micro-computed 
tomography (CT) imaging and biomechanical testing up to three months after fracture 
induction. The primary outcome parameter was biomechanical strength and the 
secondary outcome parameters were the gene expression and the callus dimensions in 
the micro-CT evaluation. 
In Chapter 5, the influence of an intramedullary stabilised femur fracture on in vivo gait 
pattern and muscle atrophy in rats is identified. The improvement of mobilisation and 
gait parameters are very important for the (long-term) clinical outcome of patients 
after lower extremity fractures. Gait analysis is gaining attention and importance in 
different medical disciplines. However, in small animal fracture research models, gait 
analysis is still under-studied. Therefore, in this chapter, we expand on an experimental 
gait analysis method, the CatWalkTM-system, which we introduced for the first time in 
gait analyses of a lower extremity fracture in a small animal model. 
In Chapter 6, the focus is on the neuro-humoral arginine-NO pathway in fracture 
healing. In the clinical study reported in this chapter, the predictive value of biomarkers 
of the arginine-nitric oxide metabolism in trabecular bone harvested during RIA 
procedures for non-union treatment of long bones was evaluated. 
In Chapter 7, the effect of micro-vesicles or microparticles as important links in the 
intracellular communication on osteoblasts in the inflammatory response of fracture 
healing is featured. In this in vitro study, the effect of those micro-vesicles was evaluated 
using a growth assay and quantitative real-time polymerase chain reaction (qRT-PCR). 
In Chapter 8, the influence of a femur fracture and its intramedullary treatment on 
cellular immune response and, more particularly, on neutrophil homeostasis is 
presented. As dysregulation of the neutrophil response plays a key role in the 
pathogenesis of inflammatory complications in trauma, we analysed the expression of 
selectins and integrins on the surface of neutrophils to assess their functionality in the 
fracture healing process. 
In Chapter 9, the pulmonary neutrophil pool is considered in more detail as 
dysregulation of this pool after trauma is associated with systemic inflammatory 
response syndrome and the development of acute respiratory distress syndrome. More 
specifically, the behaviour of the pulmonary neutrophil pool in the first inflammatory 
phase after femoral fracture and its intramedullary stabilisation was studied. 
In Chapter 10, the findings from the studies performed in the context of the thesis are 
discussed and we present recommendations for possible future research questions, 
which could build on our findings and could further elucidate the neuro-humoral 
pathways of the inflammatory response in fracture healing. 
In Chapter 11, a summary of the conclusions of the thesis, discussion and future 
perspectives in English are provided.  
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ABSTRACT 
Over the last 3 decades, scientific evidence advocates an association between 
traumatic brain injury (TBI) and accelerated fracture healing. Multiple clinical and 
preclinical studies have shown an enhanced callus formation and an increased callus 
volume in patients, respectively, rats with concomitant TBI. Over time, different 
substances (cytokines, hormones, etc.) were in focus to elucidate the relationship 
between TBI and fracture healing. Until now, the mechanism behind this relationship 
is not fully clarified and a consensus on which substance plays the key role could not 
be attained in literature. In this review, we will give an overview of current concepts 
and opinions on this topic published in the last decade and both clinical and 
pathophysiological theories will be discussed. 
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2.1. INTRODUCTION 
Outline of the review. In the last 3 decades, there are numerous studies published that 
either support or reject the hypothesis of enhanced callus development and fracture 
healing in patients with concomitant traumatic brain injury (TBI). Research on the 
development of heterotopic ossifications in paralytic patients goes back even further. 
The first studies on this subject, with the question whether fracture healing is 
influenced by accompanying TBI, were published in the early 1960s. Despite this 
history of studies, there is still no hard proof whether there is a relationship between 
TBI and enhanced callus formation. Moreover, the pathophysiological background of 
these phenomena is not clarified in the literature. A first review on these subjects 
was published by Morley and colleagues in 2005 1. They reviewed the literature on 
this topic until 2001, but they did not find a definite answer to their main question if 
traumatic brain injury results in accelerated fracture healing. The aim of our review 
is to evaluate the current status of knowledge and to compile an update on this topic. 
Evidence of a relationship between TBI and fracture healing could be important as a 
basis for further research to clarify the mechanism of normal and pathologic fracture 
healing. 
2.2. METHODS 
The following criteria were used to determine eligibility of a study to be included in 
this review. A literature search was carried out on Medline, Embase and Cochrane 
for studies published from January 2001 till December 2012 on the topic of fracture 
healing in subjects with concomitant traumatic brain injury. The following search 
terms were used in different combinations: “head trauma”, “brain injury”, “cerebral 
injury”, “fracture healing”, “bone healing”, “pseudoarthrosis”, and “peri-articular 
ossifications”. The search was limited to manuscripts in English, German, or Dutch 
language. Letters to the editor and case reports were excluded. The references of 
selected studies were also pursued for articles that may have been missed via the 
electronic search.  
2.2.1. Study selection 
The title and abstract of all identified studies (n = 2880) were examined by one 
reviewer (Martijn Hofman). Then, the entire article was obtained and assessed for 
suitability by two of the authors (Martijn Hofman and Philipp Kobbe). Any issue 
pertaining to eligibility of studies was solved via discussion with the senior author 
(Hans-Christoph Pape). This resulted in 26 relevant articles, which were not included 
in the review of Morley and colleagues. Thirteen articles described clinical studies, 
of which 6 were prospective and 7 were retrospective cohort studies. An additional 
thirteen studies were preclinical (in vitro/in vivo) studies, including one review. 
2.3. FRACTURE HEALING  
Fracture healing occurs either by direct intramembranous healing or by indirect 
intramembranous and endochondral healing. Indirect fracture healing is the most 
common form and can be subdivided into multiple stages (Figure 2.1.). The first 
stage, named the Inflammation stage, starts with fracture and can last for ca. 5 days. 
In this stage, the fracture haematoma organizes and forms a link between the 
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fracture fragments. This haematoma consists of blood cells, mesenchymal stem cells, 
fibroblasts, osteoclasts, osteoblasts, cytokines, growth factors, and other hormones.  
 
Figure 2.1. Indirect fracture healing. 
 
The second stage is called soft (or bridging) callus formation stage and lasts for 2-3 
weeks. Fibroblasts within the granulation haematoma deposit fibrocartilage and 
cartilage tissue which forms a weak bridge between the fracture fragments. The 
duration of the third stage of fracture healing, the hard (or medullary) callus 
formation stage, depends on the anatomical fracture site and will take between 6 and 
12 weeks. In this stage, the fragile bridging callus is expanded to hard callus by the 
deposition of minerals. In the last stage of remodelling, which can last up to 5 years 
after injury, bone adaptation according to Wolff’s law occurs. This law explains that, 
as a response to external loading, bone will be restored to its original form, involving 
bone resorption by osteoclasts and the formation of new bone by osteoblasts. 
In the acute inflammatory reaction of fracture healing cytokines, such as tumour 
necrosis factor-α (TNF-α), interleukin-1 (IL-1) and interleukin-6 (IL-6), are involved. 
TNF-α acts as a proinflammatory mediator and a chemotactic agent. Furthermore, it 
enhances the osteogenic differentiation of mesenchymal stem cells (MSC’s) 2. TNF-α 
peaks at about 24 h and returns to baseline at about 72 h after injury 3. IL-1 is 
produced in the acute phase by macrophages in a biphasic mode. IL-1 induces the IL-
6-production by osteoblasts, the forming of cartilaginous callus, and the angiogenesis 
2,4,5. 
IL-6 which is only active in the acute phase enhances also angiogenesis, the vascular 
endothelial growth factor- (VEGF-) production and osteoblasts and -clasts 
differentiation 6. 
After traumatic brain injury, the cytokine levels rise both in the cerebrospinal fluid 
and in the serum. Although the group of Kossmann found an approximately 10 to 100 
times higher level of posttraumatic IL-6 and IL-8 levels in the cerebrospinal fluid 
opposed to the plasma 7,8,9,10, it is not clear whether this gradient is caused by a quick 
peripheral metabolism in the liver 11 or by an initially higher local production in 
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microglia, astrocytes, and macrophages 10,12. Furthermore, there are no studies 
finding an evidence of a direct correlation between the increased levels of cytokines 
and enhanced fracture healing or callus formation. 
Indispensable for fracture healing is the recruitment of skeletal stem cells from 
surrounding tissues to the fracture site. Skeletal stem cells are mesenchymal stem 
cells which can differentiate to skeletal cell types including osteoblasts, 
chondrocytes, adipocytes, fibroblasts, and adventitial reticular cells 13. These skeletal 
stem cells have three main functions, that is, they function as signalling centres, they 
provide a supportive microenvironment for haematopoiesis, and they stabilize and 
maintain the sinusoidal network within a fracture site. Although the mechanism of 
recruitment of these cells is still unclear, the recent opinion is that the stromal cell-
derived factor-1 and its G-protein-coupled receptor CXCR-4 axis (SDF-1/CXCR-4-
axis) play an important role 14-16. Other concepts of recruitment impute a role to 
transforming growth factor-β (TGF- β), bone morphogenetic proteins (BMPs), 
insulin-like growth factor-1 (IGF-1), cellular retinol-binding protein 1 (CRBP-1), 
osteoblast stimulating factor (OSF-1), and hypoxia inducible factor-1α (HIF-1α) 10. 
Following activities of the MSC’s at the fracture site, another immunological cascade 
occurs, in which the transforming growth factor-β (TGF-β) superfamily, especially 
TGF-β2, TGF-β3, GDF-5, BMP-5, and BMP-6 seems to be involved 17,18. TGF-β 
stimulates growth of cells of the osteoblastic lineage and acts as a chemo-attractant 
for osteoblasts. Another supposed function of TGF-β is to increase the endogenous 
production of morphogens, such as bone morphogenetic proteins 19. As members of 
the TGF-β superfamily, three members of the BMP-subfamily enhance bone growth 
in peripheral locations, that is, BMP-2, BMP-4 and OP-1 (formerly BMP-7) 20-22. The 
work of Spector and colleagues shows that these three BMP’s are expressed in early 
as well as advanced stages of bone healing and remodelling and as soon as mature 
bone has formed, the concentration of the BMP’s normalize again 23.  
The revascularization of the fracture and callus site is regulated by the angiopoietin-
dependent pathway in which the first vascular ingrowth occurs from existing vessels 
from the periosteum. However, the main part of the revascularization is regulated  
by the VEGF pathway, which transforms the cartilaginous avascular matrix into 
vascularized osseous tissue 24. In the transformation of soft into hard callus, the Wnt-
protein family modulates the differentiation of MSC’s into the osteoblastic lineage 
and later on the osteoblastic bone formation. Another cascade of immune-factors, 
such as macrophage colony-stimulating factor (M-CSF), receptor activator of nuclear 
factor kappa B ligand (RANKL), osteoprotegerin (OPG), and TNF-α, starts the 
resorption of cartilage and the conversion in calcified bone tissue 25. 
The last remodelling stage of fracture healing is regulated by IL-1, TNF-α, and some 
BMP’s, especially BMP-2, and by the pressure applied to a crystalline environment 26. 
2.4. TRAUMATIC BRAIN INJURY 
The prognosis of traumatic brain injury depends on both the primary and secondary 
brain damage. At the time of the initial traumatic impact on neurocranium and brain 
tissue, the primary brain injury originates and consists of concussion, contusion, 
shear injuries, lacerations, and axonal stretching 27. In cases of severe primary brain 
injury, in which lesions of neurons, axons, and microglia cells occur, mortality rate is 
very high. 
2
77
CHAPTER 2 | 
78 
Subsequent to the primary injury, a delayed complex immunological, biochemical, 
and physiological pathomechanism, which continues for several days to weeks, 
results in secondary brain damage 27-29. This secondary brain damage is a 
multifactorial process which is caused and influenced by different processes, such as 
excitotoxicity, inflammation, oedema, cell death, mitochondrial damage, magnesium 
depletion, the production of free radicals, and damage to the blood brain barrier 
27,28,30.  
2.4.1. Excitotoxicity 
After primary and secondary brain injury excitotoxicity derives from the breakdown 
of neurons loaded with excitative neurotransmitters 28,31. Of these released 
neurotransmitters, glutamate is the most prominent neurotransmitter throughout 
the brain. This secretion of glutamate starts several minutes after the primary 
trauma, peaks about 10 minutes after trauma, and stays increased for several days 
31. Through this glutamate discharge, an auto-destructive cascade is initiated by way 
of a calcium influx followed by a calcium overload, resulting in a stimulation of 
calcium-dependent enzymes, such as proteases, lipases, and endonucleases 27. 
2.4.2. Inflammation 
Generally after trauma, classical or neurogenic, an inflammation cascade follows and 
the immune system is dysregulated, which influences the neurologic injury 
negatively 28. Cytotoxic and inflammatory events with infiltration of leukocytes, 
macrophages, lymphocytes, and natural killer cells will occur. There are a lot of 
mediators, which influence the inflammation process after TBI. Amongst others, 
these are complement components, chemokines, and cytokines 32. 
The complement system is upregulated after TBI by passive leakage across the 
damaged BBB or by intracerebral synthesis 33-35. As a “first line of defence”, this 
system promotes the inflammation by recruiting proinflammatory molecules, 
phagocytosis, apoptosis, and damaging the BBB. 
Other important proinflammatory modulators are chemokines. These heparin-
binding proteins, which are produced by inflammatory cells, promote the infiltration 
of leukocytes in the traumatized brain tissue and thereby enhance the inflammatory 
reaction after TBI.  
There are also many cytokines which have a proinflammatory role in the process 
after TBI. By the release of neuropeptides from sensory neurons, in case of 
neurogenic inflammation, extravasation of plasma, vasodilatation, and neuronal 
hypersensitivity results 36. The most prominent neuropeptides involved are 
members of the bradykinin- and tachykinin-family of which CGRP (calcitonin gene-
related peptide) and substance P are the most distinguished exponents 37.  
However, several studies in the last decade impute a dual role for some mediators 
supposing a proinflammatory and an anti-inflammatory effect in the post-TBI 
inflammatory process. This dual role is often demonstrated by a time-dependent 
pro- and anti-inflammatory characteristic of the different immune modulators, such 
as for IL-1, IL-6, TNF-α, and chemokine (especially fractalkine (CX3CL1)) 38-41. 
For TNF-α, which appears to be synthetized in the brain tissue itself, as a endogenous 
response to TBI in the first few hours, such a dual function is demonstrated in several 
studies 39,41-43. These studies demonstrate an early proinflammatory (1-2 d) and a 
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late anti-inflammatory (2-4 wks.) role for TNF-α. TNF-α increases vascular 
permeability leading to swelling of brain tissue and leukocyte infiltration. It also 
induces necrosis and apoptosis via intracellular pathways and it up-regulates the 
inflammatory mediator anaphylatoxin (C5a) on neurons 44. 
An important role in the inflammation after TBI is reserved for the interleukin-1-
family. IL-1 induces neuronal apoptosis and VEGF, an important mediator for the 
generation of posttraumatic oedema. The exact effect of IL-1, neurotoxic or 
neuroprotective, depends on the environment in which this cytokine resides. Also, 
IL-18 has raised concentrations in the cerebrospinal fluid after TBI 45 and by 
inhibiting both IL-1 and IL-18, the secondary brain damage after TBI could be 
reduced 41. The dual role of the interleukin-family shows a proinflammatory phase 
in the first hours and days after TBI followed by a reparative phase lasting for days 
to months 46. 
Also IL-6, which is produced by neurons and macrophages early after TBI (1 h after 
injury), can promote the inflammatory response but also has anti-inflammatory 
effects 42,43. These anti-inflammatory effects are increased by the capacity of IL-6 to 
inhibit TNF-α synthesis, induce nerve growth factor (NGF), promote survival and 
differentiation of neurons, and antagonize N-methyl-D-aspartate-mediated toxicity 
42. Another aspect of IL-6, as a VEGF-agonist, is its quality to enhance angiogenesis 
and revascularization and thereby promote brain tissue repair 47-50. 
TGF-β, which increases within the first days after injury, may be produced by 
virtually all cells of the central nervous system (CNS). This growth factor counteracts 
the inflammation process by suppressing the release of  IL-1, TNF-α, IFN-γ 
(Interferon-γ), oxygen radicals, MHC class II antigen expression, T-cell activation, 
and proliferation of various cells 51-55. On the contrary, the chemotactic function of 
TGF-β leads to leukocyte invasion and deposition of extracellular matrix (ECM) and 
scar tissue formation. These latter functions are more proinflammatory 56,57. 
2.4.3. Oedema 
Although many factors contribute to the morbidity and mortality, the extent of 
cerebral oedema seems to be the supreme predictor of functional outcome after TBI 
37,41,58. There are two forms of oedema identified after TBI. The vasogenic oedema, 
which is caused by the extravasation of fluid from the vasculature, has an early onset 
after trauma and is associated with an increased permeability of the BBB. The 
subsequent cytotoxic oedema originates from an osmotic shift of extracellular fluid 
to the intracellular compartment. The latter form has neurotoxic qualities and 
accounts for most of the brain swelling after TBI 37,59. Key players in the development 
of postinjural oedema are aquaporins (AQPs), Matrix metalloproteinases (MMPs), 
and vasoactive agents. The expression of several AQPs, which are integral membrane 
proteins,  is upregulated after TBI and promotes oedema formation 60. The MMPs are 
zinc-dependent endopeptidases involved in the process of tissue remodelling 
following various pathologic conditions. The regulation of the MMP expression is 
complex and in cases of dysregulation by TBI, stroke, or neurodegeneration synaptic 
loss and breakdown of the BBB is identified, causing a vasogenic oedema and 
subsequent cell death 61-64. The most important vasoactive agents are members of 
the bradykinin- and tachykinin-families and are produced in the neurogenic 
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inflammation process. In particular, substance P is thought to enhance oedema 
formation 37.  
In case of posttraumatic oedema formation, the swelling of cells as well as 
parenchyma swells and leads to an elevation of the intracranial pressure (ICP), with 
a subsequential decrease of cerebral perfusion pressure (CPP). Eventually a 
herniation of the brain stem can occur 37.   
2.4.4. Cell Death 
Cell death after TBI occurs in the first 24 h foremost via necrosis, in which swelling 
of mitochondria and other organelles and subsequent membrane degeneration 
occurs. In the subsequent days, cell death occurs also via apoptosis, in which DNA 
condensation and fragmentation, cell shrinkage, and the ultimate formation of 
apoptotic bodies occurs 65. Another complicating factor is that the inhibition of one 
mechanism of cell death can exacerbate the other mechanism of cell death and vice 
versa 66,67. Furthermore, beside the release of multiple proinflammatory modulators 
by the neurogenic inflammation cascade as described above, apoptotic and necrotic 
cells will set free multiple cytotoxic cytokines, growth factors, and interleukins, 
which will lead to a vicious circle of inflammation and cell death, which can last for 
months after the initial trauma 41,42,68. 
2.4.5. Mitochondrial Damage 
Brain and nerve tissue have a high energy demand and therefore the mitochondria 
are of utmost importance for the survival of these tissues. Severe injuries to the 
mitochondria can elicit devastating alterations to the mitochondrial respiration, 
respiratory coupling, and energy production 69-71.  
2.4.6. Magnesium Depletion 
A universal aspect of central nervous system (CNS) injury is a decrease of 
intracellular free magnesium, which plays normally a crucial role in normal cell 
function by regulating numerous physiological and biochemical processes within the 
cell 72. Magnesium is a required cofactor in all energy producing and consuming 
reactions and over 300 enzymes involved in these processes are magnesium-
dependent 27. Beside these effects on enzymes, plasma membrane integrity, and ion 
channel activity are also influenced by magnesium 73.  
2.4.7. Production of Free Radicals 
In the oxidative metabolism, free radicals are produces as normal by-products. The 
production of these highly reactive molecules is significantly enhanced by traumatic 
injuries 74-76. Proteins, DNA, and lipids can be damaged by high concentrations of 
these free radicals, which lead to cell death via apoptosis 77.  
2.4.8. Blood-brain-barrier damage 
If a cerebral mediator is released by TBI, which influences bone healing, it has to 
cross the blood brain barrier (BBB). The BBB is formed by the neurovascular unit, a 
conjunction of cerebrovascular endothelial cells, pericytes, astrocytes, and the basal 
lamina 78. The BBB strongly regulates the exchange of substances between plasma 
and the cerebral interstitium 32. After TBI, there occurs a biphasic BBB disruption, 
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with hyperpermeability in the beginning with a maximum at 4-6h after injury, 
followed by a transient restoration and a prolonged period of hyperpermeability 
37,79,80. Both small and large molecules are able to cross this barrier in and around the 
injury site 81. The restoration of the BBB lasts from ca. 4 hours for large molecules to 
ca. 4-7 days for small molecules 37,81. There are many factors influencing the 
permeability of the BBB. In the beginning, the disruption is caused by a mechanical 
force, but in the later course of TBI other mediators are responsible for influencing 
the BBB, such as VEGF, angiopoietins, IL-1β, IL-8, TNF-α, reactive oxygen species, 
kinins, histamines, nitric oxide, elastase, matrix metalloproteinase (MMP) 82-90. 
Furthermore, this permeability is also influenced by hypoxia after TBI, mostly after 
ca. 6h post-injury and it can delay the restoration of the BBB by up to 72h 91. 
2.5. REVIEW OF THE LITERATURE 
When we consider all studies on the topic of TBI and bone healing in the last decades, 
more than 50 different cells, hormones, growth factors, cytokines, chemokines, and 
so forth are reviewed and in a few cases there are some promising results (Table 
2.1.). 
 
Table 2.1. Investigated substances. 
 
 
In the review of Morley and colleagues, they conclude that there is evidence for an 
accelerated osteogenesis associated with TBI. They found a relationship between 
TBI, rapid callus development, and stimulation of bone forming cells 1,92,93. However, 
they could not differentiate between heterotopic ossification and accelerated 
fracture healing 1. 
In the last decade, there were 26 studies on this topic after the publication of Morley 
and colleagues. About 50% of these studies 94-107 find evidence for increased callus 
formation in cases with concomitant TBI; the other studies are not conclusive. 
There are only 7 of these studies which also postulate a possible working mechanism 
for this correlation. These are the studies we focus on in our review (Table 2.2.). 
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Table 2.2. Studies with evidence for a certain mechanism of action. 
 
 
2.5.1. Human Mesenchymal Stem Cells (hMSCs) 
Kanczler and Oreffo stress the importance of angiogenesis in combination with 
osteogenesis to optimize bone growth 108.  In fracture healing angiogenesis precedes 
osteogenesis. Xiao and colleagues show that bone marrow stromal stem cells 
(BMSCs) have the possibility to express both BMP-2 and VEGF and so these 
mesenchymal stem cells enhance fracture healing more explicit compared to the 
addition of any single factor 109. Also Yamada and colleagues confirm the importance 
of a combination of osteogenic and angiogenic factors in the regeneration of bone. 
They found that a mixture of platelet-rich-plasma and mesenchymal stem cells can 
elicit better bone regeneration with good vascularization 110. In the cascade after 
fractures, mesenchymal stem cells play an important role. These MSCs originate from 
bone marrow, periosteum, and so forth and are in case of a fracture generated to 
migrate to the fracture site in response to BMPs set free from the injured bone matrix 
111,112. 
At the fracture site these MSCs produce different proteins and these proteins can 
differentiate the mesenchymal stem cells at their turn to enhance the fracture healing 
process 23.  
As multipotent cells, the MSCs can differentiate into different mesenchymal lineages  
which support the formation of distinct tissues, such as bone, cartilage, fat, tendon, 
muscle, and bone marrow stroma 110,113. 
This differentiation takes place under influence of different factors. Beside the 
proteins coming from the mesenchymal stem cells self as described above, Boes and 
colleagues propose an influence of unknown factors released by injured brain tissue, 
which exert their proliferative effect specific to mesenchymal stem cells 96. In their 
in vitro analysis, they showed that the serum of rats with a fracture and concomitant 
TBI stimulated a multipotent mesenchymal stem cell line (C3H10T-cells) to 
proliferate at a significantly higher level (p = 0.0002), resulting in a 76% increase in 
cells in the fracture/TBI group compared to the fracture-only group. They also 
investigated an osteoblastic (MC3T3-14-cells) and a fibroblastic (NIH 3T3-cells) cell 
line, but here they did not find any difference in proliferation rate 96. Boes and 
colleagues compared the callus in rats with a femur fracture with concomitant TBI 
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and without concomitant TBI. It was shown that after 21 days, the callus in the TBI 
and fracture group was reduced in diameter (p = 0.030), but it is significantly stiffer 
(0.306 N/mm compared with 0.120 N/mm; p = 0.02) than in the fracture-only group. 
The torsional strength was equal in both groups (258.4 Nm compared with 231.4 
Nm; p = 0.472) 96. 
The group of Cadosch and Gautschi investigated a human foetal osteoblastic 
mesenchymal stem cell line (hFOB1.19 cells) in an early stage of its differentiation 
98,99. In an earlier study, they saw that the cerebrospinal fluid of patients with a 
traumatic brain injury had an osteoinductive potential and therefore they expected 
that any osteoinductive factor in the serum of patients with a traumatic brain injury 
would have a stimulating effect on the hFOB1.19 cells in vitro 114,115. This potential 
reaches its maximum as soon as 6h after injury, it remains at the same level for about 
3 days and decreases after about 1 week 98. They also observed an increased 
proliferation rate of osteoblasts exposed to sera from patients with TBI during the 
first week after injury 98. 
The time window of this effect is possibly explained by the traumatic disrupture of 
the blood brain barrier, permitting leakage of cerebrospinal fluid and the recovery 
of the blood brain barrier after about 1 week. Another explanation for the decreased 
osteoinductive potential after 1 week is a decreased production of osteogenic factors 
by the injured brain 98,99. 
Another result reported by the group of Cadosch and Gautschi was an increased 
expression of the osteoblastic differentiation marker gene in the serum of brain 
injured patients, such as ALP, CATK, RUNX-2, macrophage colony-stimulating factor 
and SP-7 99,116,117. 
In the clinical part of their research, Gautschi and colleagues observed, in the TBI and 
fracture group in 41.7% of the cases, clinical and radiological evidence for 
hypertrophic callus formation. None of the cases in the fracture-only group 
developed hypertrophic callus. Moreover, Cadosch and colleagues found a positive 
correlation between callus ratio and proliferation of hFOB1.19 cells. On the contrary, 
they found an inverse correlation between fracture union time and callus ratio as 
well as between Glasgow Coma Scale (GCS) and callus ratio 99. 
In a recent in vitro study of Yang and colleagues increased levels of arachidonic acid 
(AA) were noted in serum metabolites of rats after TBI. They showed that in the 
presence of arachidonic acid the expression and proliferation of bone gamma 
carboxyglutamate protein (BGLAP or osteocalcin) is beneficially influenced and 
thereby the proliferation of the mouse osteoblastic cell line MC3T3-E1 was 
increased. They suggest a key role for arachidonic acid in the process of enhanced 
callus formation in rats with a TBI 106. 
2.5.2. Leptin and CGRP 
In the metabolic, inflammatory, and neuroendocrine stress response occurring after 
TBI serum levels of leptin, an adipose-derived hormone, are significantly increased 
97. The level of leptin is further influenced by different cytokines and hormonal 
factors, but the exact pathway of how leptin influences bone formation is not fully 
understood. It is postulated that the pro-inflammatory cytokine IL-1 increases 
rapidly after brain injury and this might cause an increased serum level of leptin 
118,119. 
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Moreover, Wei and colleagues 97 found a positive correlation between leptin 
concentration in serum and volume of callus formation in patients with a fracture 
and a traumatic brain injury. Leptin, mainly produced by adipocytes, can influence 
bone metabolism by two pathways. In the first central pathway, leptin increases the 
sympathetic output by the hypothalamus which exerts an anti-osteogenic effect via 
β2-adrenoceptors on osteoblasts. In the second peripheral pathway, leptin acts 
directly on peripheral tissues and then it has the opposite effect and promotes bone 
mineralisation and osteoblast-to-osteocyte differentiation 97. They suggested several 
tracts for the serum level increase of leptin. First of all, the mobilization of free fatty 
acids as a result of hyper-metabolism in traumatic brain injury patients results in 
elevated serum leptin levels by a neuroendocrine feedback mechanism 120. Secondly, 
hypoxia, caused by the adult respiratory distress syndrome or a pulmonary 
inflammatory response in traumatized patients, augments adipocyte expression of 
leptin 121. Finally, the release of bone marrow at the fracture ends, containing mainly 
haematopoietic cells, induces leptin delivery at tissue level 122. Furthermore, the 
complex neuroendocrine inflammatory response after TBI, with the release of 
multiple cytokines and hormones, influences the production and levels of leptin. 
Wei and colleagues have shown that the serum leptin concentration reach a 
significant increased level only from the 4th until the 12th week after injury. This can 
be explained by the fact that in the acute posttraumatic period the stress response 
increases the sympathetic outflow, which down-regulates leptin expression and 
secretion by adipocytes. The secretion of leptin by adipocytes is also decreased due 
to the fasting state of a trauma patient in the acute posttraumatic stage. After the 
initial posttraumatic period, the peripheral effect of increasing leptin may outweigh 
the sympathetic inhibition of leptin on bone formation 123,124. 
The results of Wei and colleagues confirm the concept of Rayner and Trayhurn in 
2001 and of Takeda and colleagues in 2002 that injury to the hypothalamus may 
result in a decreased sympathetic outflow, resulting in a subsequent decreased 
inhibition of peripheral leptin expression and a decreased anti-osteogenic effect via 
β2-adrenoceptors on osteoblasts. In this way, injury to the hypothalamus 
contributes to the enhanced bone regeneration observed in rats with fractures and 
TBI 97. 
In their evaluation of callus formation, Wei and colleagues show a significantly 
increased callus volume in rats with TBI and fracture compared to rats with only a 
fracture from the 4th till the 8th week after injury. This increase subsides at 12 weeks 
after injury, but in the histological analysis they can still proof thicker lamellar bone 
formation in the TBI and fracture group at 12 weeks after injury 97. 
Another possible mode of action of leptin on fracture healing is via calcitonin gene-
related peptide (CGRP). Zhang and colleagues 125 showed in 2011 that peripheral 
administration of leptin alleviated injury-evoked brain damage by promoting CGRP 
expression, improving regional cerebral blood flow, and reducing local infarct 
volume and neurological deficits. Furthermore, leptin also promoted bcl-2 
expression and suppressed caspase-3 in vivo and vitro after injury. Administration 
of CGRP(8-37), an antagonist of the CGRP receptor, partly abolished the beneficial 
effects of leptin and restored the normal expression levels of bcl-2 and caspase-3 in 
neurons, which indicated that leptin-induced protection of neurons was correlated 
with release of CGRP. 
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Results of Song and colleagues showed in vivo a significantly elevated concentration 
of CGRP in rats with a femoral fracture and a concomitant traumatic brain injury. 
These concentrations were found both in the brain tissue and muscle tissue 
surrounding the fracture. They concluded that there was reciprocity between 
traumatic brain injury and enhanced fracture healing and they suppose that the 
CGRP is produced by the brain tissue. This conclusion was based on the observation 
that CGRP was expressed in the cerebral cortex and around the fracture site in the 
TBI and fracture group and not in the fracture-only group 105. 
In their micro-CT-analysis of callus formation, they observed a significantly 
increased bone mineral density (BMD) and bone mineral content (BMC) of the newly 
formed callus in the TBI and fracture group compared to the fracture-only group in 
the 4th week after injury. The same measurement in the 8th week post-injury 
revealed that the BMD was indifferent and the BMC was significantly lower in the 
fracture-only group when compared to the TBI and fracture group. According to Song 
and colleagues, this indicated that fracture healing occurs earlier in cases with 
concomitant TBI 105. 
In 2000 Garcia-Castellano and colleagues 126 already confirmed a great effect of CGRP 
on  angioectasia to capillary, which is, as discussed before, of extreme importance for 
the acceleration of bone formation. According to Zhang and colleagues 101 CGRP can 
exert this haemangiectasic role at the fracture site due to an axoplasmic transport of 
CGRP from the central nerve system. 
2.6. DISCUSSION 
For years physicians declare, according to their clinical experience, that callus 
formation/heterotopic ossification and fracture healing are accelerated in patients 
with accompanying traumatic brain injury. However, these statements are not based 
on hard evidence according to the literature, because the level of evidence in all of 
these clinical studies is not very high.  
Before the review of Morley et al. 1 in 2005, there were only 5 clinical studies which 
found proof of enhanced callus formation in patients with TBI. These studies 
included one prospective study 92 and 4 retrospective studies 93,127,128,129.  
In the last decade, six clinical studies were published, which found proof of an 
accelerated callus formation or fracture healing in patient with TBI and concomitant 
fractures. Five of them were prospective matched-control studies 95,98,99,100,106 with 
an average patient population of 65.2 (range 28-86) patients and one study was a 
retrospective, matched-control study 94, with a patient population of 67 patients.  
In the period before 2003, there were 4 clinical studies which objected to this clinical 
experience because these studies did not find significant differences in callus 
formation or fracture healing between patients with and without traumatic brain 
injury. Of these 4 studies, there is only one prospective matched-control study 130, 
but with 8 patients which is rather a case series. The other 3 studies are retrospective 
studies 131,132,133, of which only one study is matched-control.  
In the last decade, there are no studies published which refute this enhanced callus 
formation in patients with concomitant TBI, but here publication bias must be 
considered. 
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When we consider the studies which demonstrate a mechanism of action for the 
enhanced callus formation in patients with concomitant TBI, there are two 
mainstreams in the last decade. 
The first mainstream is represented in 4 96,98,99,106 of the 7 considered articles and 
puts the human mesenchymal stem cells/skeletal stem cells in focus.  
In the study of Boes et al. 96, adult rats were investigated, which were 7-9 months of 
age. The traumatic brain injury was administered when the animals showed signs of 
normal recovery after the administered femoral fracture and subsequent 
osteosynthesis, but the timing between administering the two lesions was not 
mentioned. The fact that the TBI and the fracture are not administered at the same 
time, as is the case in normal trauma patients, could be a confounding factor. 
The biomechanical analysis and in vitro analysis of cell proliferation were both 
performed at 21 days after injury. This time point is very early because it is known 
that full recovery of mechanical properties of fractured femora in rats takes about 4 
weeks in young and about 12 weeks in adult rats 134. Nevertheless, they already 
found a significant increased stiffness of the fracture site in the fracture and TBI  
group compared to the fracture only group. This probably could be even more 
distinct in a later stage of fracture healing. Boes et al.96 conclude that the reduced 
callus diameter in the fracture and TBI group contradicts the concept that TBI 
increases endochondral ossification and they suggest that the fractures already have 
progressed into the remodelling phase. Regarding the early time point at which these 
investigations are performed, this does not, in our opinion, contradict the above-
mentioned concept because fracture healing has not finished yet and the remodelling 
phase probably has not started yet.  
Also, the increase in the proliferation of the mesenchymal stem cell line C3H10T½ of 
76% is an impressive result of the study group, which attribute this enhancement to 
a yet unknown soluble factor from injured neural tissue. Although the group of Boes 
et al.96 could not show an increased proliferation of a more advanced osteoblastic 
cell line (MC3T3-14), the group of Yang et al. did observe an increased proliferation 
of a more differentiated osteoblastic cell line of MC3T3-E1 cells. Of note, the analysis 
was performed with serum of TBI rats which was taken only at one time point, that 
is, 24 h after injury. In the bone healing process, the first few days are mainly 
determined by the inflammation phase in which the osteoblasts maybe play a 
subordinate role.  
The results of the clinical part of the study of Gautschi et al. 98 are convincing with 
>40% of hypertrophic callus formation in the TBI and fracture group in comparison 
with the fracture only group, although the study groups are considerable small 
(respectively n = 12 and n = 19). They refer to pre-clinical studies of Boes et al. 96, 
Mandelin et al. 116, and Camozzi et al. 117 in which proof is found for brain-derived 
factors with mitogenic and osteogenic effects on stromal stem cells and molecular 
mechanisms of sera from brain injured patients which mediate a mitogenic effect on 
osteoprogenitor cells. Cadosch et al. support these findings because they find a 
negative linear relationship between GCS and callus ratio on one site and time to 
union and callus ratio on the other site 99. The proof of decreased time to union in 
patients with concomitant TBI is decisive in contrast with many other studies 
because time to union was an endpoint in their study and it was determined by two 
independent blinded radiologists.  
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In their cell proliferation assay with primary human osteoblasts, they harvested the 
osteoblasts from 20 patients in which an osteosynthesis was performed. At what 
time these osteosyntheses were performed and from which group these samples 
were taken is not described. As a consequence, it remains unclear whether these 
osteoblasts were already stimulated in the body of the patients before harvesting. 
They also show that the osteoinductive effect of serum from TBI-patients on the 
hFOB-cell line is increased as soon as 6 h after injury until 3 days after injury. This 
effect fades after about 1 week. This could mean that this effect functions as a trigger 
for an enhanced callus formation. Whether this callus formation starts earlier 
through this trigger or evolves at a greater speed is still unsolved.  
In the other study of Cadosch et al. 102, the increased proliferation lasts even longer 
until the last measurement at 168 h after injury. 
Because the observation period in both studies only lasted for 1 week after injury, it 
is unclear if this osteoinductive effect returns to normal levels after this week or that 
it has an analogous fluctuation as several cytokines in their dual function, with an 
additional effect later on in the fracture healing process. The fact that the disruption 
of the BBB lasts for about one week and therefore, the leakage of influencing factors 
produced by injured brain tissue will last for this period could be supportive to the 
findings of Gautschi and Cadosch 98,99,102. 
Gautschi et al. 98 show an interesting pattern in the expression of osteoblastic 
markers (alkaline phosphatase (ALP), runt-related transcription factor 2 (RUNX-2), 
cathepsin K (CATK) and serine protease 7 (SP 7)), measured by the expression of 
mRNA in hFOB cells. ALP and RUNX-2 expression is significantly increased in the TBI 
and TBI and fracture group compared to the fracture-only group and the expression 
of SP 7 and CATK is significantly increased only in the TBI and fracture group 
compared to the TBI and the fracture-only group. This could mean that the 
expression of SP 7 and CATK is even more specific to the relationship between TBI 
and enhanced fracture healing than the expression of ALP and RUNX. 
Furthermore, the fact that the results of the publications from Gautschi and Cadosch 
98,99,102 are very similar should be put in the perspective that both studies come from 
the same group of researchers.  
The second mainstream is represented by Wei et al. 97, Zhang et al. 101, and Yang et al. 
104 and they focus on the role of leptin and CGRP in the healing of fractures in patients 
with TBI. 
In the study of Wei et al. 97, which links serum leptin levels and leptin expression in 
callus cells to increased callus formation, they suggest a relationship between 
hypothalamic damage and reduced inhibition of peripheral leptin secretion and 
increased callus formation. This increase in leptin levels is reached only after 4 
weeks after injury. In contrast to the studies on mesenchymal stem cells of Cadosch 
and Gautschi 98,99,102, Wei et al. 97 extended the time slot of their histomorphological 
and histochemical analysis until 12 weeks after trauma. Considering the fracture 
healing process in adult rats, this is better suitable then a period of only 1 week. 
Zhang et al. 101 showed the link between increased leptin levels and an enhanced 
expression of CGRP and its haemangiectasic role at the fracture site. 
Song et al. support these results and found proof for a correlation between increased 
fracture-healing tendency secondary to traumatic brain injury and high CGRP. They 
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found a higher level of CGRP in the brain and muscles of traumatic brain injury rats 
and they suggest this CGRP is produced by brain tissue 105. 
According to their micro-CT analysis of callus formation, Song et al. conclude that in 
rats with concomitant TBI fracture healing occurs earlier as in the fracture-only 
group. This earlier healing appears in their population around the 4th week after 
injury and while these experiments are done with adult rats, this seems almost too 
early for fully developed callus formation 134. 
Another important finding of Zhang et al. is that different types of neural injury 
affected fracture healing in a different way. That is, peripheral nerve damage in 
combination with fractures can decelerate the healing process, and central nerve 
damage in combination with fractures can accelerate the healing rate. This increased 
healing rate as well as the inflammatory reaction following central neural injury is 
more intense and distinct for spinal cord injuries than for cerebral injuries 68,101, 
which could be of importance for future research. 
2.6.1. Future Perspectives 
The basic prove of enhanced fracture healing in patients with concomitant TBI is not 
yet substantiated by a large prospective clinical study. If this phenomenon can be 
proven, the interesting question is whether this mechanism is cellular or hormonally 
induced. 
Important for future research is that the time course of mediator upregulation 
following TBI will be elucidated as well as for spinal cord injury by Donnelly and 
colleagues 68. As the osteoinductive reaction after spinal cord injury is more 
pronounced as after TBI, it could be an interesting approach to look at accelerated 
callus formation in patients with spinal cord injury. 
In case of the mesenchymal/skeletal stem cells as well as for the hormonal cascade, 
it is important to look at the fluctuation and influence within the fracture healing 
process over a longer period than 1 week after injury. Furthermore, the idea that 
enhanced callus formation in patients with fractures and concomitant TBI is nothing 
more than a form of heterotopic ossification, is also supported but not substantiated 
by several authors and studies in the last decades. This also could be an interesting 
reference point for further research. 
2.7. CONCLUSIONS 
In 2005 Morley and colleagues 1 concluded that the question whether traumatic 
brain injury results in accelerated fracture union could not be answered at that time. 
Today, more than three decades after the first publications on this subject, the 
consensus in all published papers after 2005 is that traumatic brain injury indeed 
accelerates fracture healing. However, the greater part of studies on this topic are 
preclinical (in vitro/in vivo) studies, which indeed find some evidence for certain 
mechanisms, but the clinical studies with relatively small populations cannot, 
hitherto, support the hypothesis of accelerated fracture healing in patients with TBI. 
Moreover, in the last decade, the possibility of publication bias cannot be eliminated.  
Furthermore, elucidation of the very complex mechanism of enhanced callus 
formation in patients with TBI is still in its infancy. Also in the last years there is very 
little revealed of the complex mechanism by which cytokines, chemokines, hormones 
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and growth factors influence the signalling pathway leading to accelerated fracture 
healing. 
The studies discussed in this review indicate that both serum and cerebrospinal fluid 
(CSF) from patients with fractures and concomitant TBI have osteoinductive 
potential. It also seems to be a consensus in the literature that these osteoinductive 
factors are released from the injured brain and from there spread in the body and to 
the fracture region. 
In the literature published after the review of Morley and colleagues, there are two 
mainstreams which impute key roles in the complex mechanism of enhanced callus 
formation for mesenchymal stem cells on one side and for the leptin-CGRP-axis on 
the other side.  
Nevertheless, because callus formation originates from a complex multifactorial 
cascade, it is possible that all described factors have their role in this phenomenon.  
In our opinion, first of all these findings should be an incentive to design a large 
prospective clinical study to prove or reject the hypothesis of accelerated fracture 
healing in patients with concomitant TBI. The research on the pathophysiological 
relationship between TBI and callus formation should also be elaborated to reveal 
possible pathways of this assumed affiliation. 
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ABSTRACT 
Purpose: Concomitant chest injury is known to negatively affect bone metabolism 
and fracture healing, whereas traumatic brain injury (TBI) appears to have positive 
effects on bone metabolism. Osteogenesis can also be influenced by the timing of 
fracture stabilization. We aimed to identify how chest injuries, TBI, and fracture 
stabilization strategy influences the incidence of non-union. 
Methods: Patients with long bone fractures of the lower extremities who had been 
treated between 2004 and 2014 were retrospectively analysed. Non-union was 
defined as fracture healing not occurring in the expected time and in which 
progression of healing nor successful union is expected without intervention. 
Diverse clinical and radiological parameters were statistically analysed using the 
Statistical Package for the Social Sciences (SPSS). 
Results: The total number of operations before consolidation was an independent 
predictor (odds ratio [OR] = 6.416, p < 0.001) for the development of non-union in 
patients with long bone fractures. More specifically, patients treated according to the 
damage control orthopaedics (DCO) principle had a significantly higher risk of 
developing a non-union than patients treated according to the early total care (ETC) 
principle (OR = 7.878, p = 0.005). Concomitant chest injury and TBI could not be 
identified as influencing factors for non-union development. 
Conclusion: Our results indicate that the number of operations performed in patients 
with long bone fractures should be kept as low as possible and that the indication for 
and the timing of DCO treatment should be meticulously noted to minimize the risk 
of non-union development. 
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3.1. INTRODUCTION 
Fracture healing depends on the interactions of many biomechanical and biological 
factors 1. Disturbances in this process might result in non-union with an overall 
incidence of 1.5–10%, increasing up to 40% in case of open fractures. In particular, 
non-unions of the lower extremities have been identified to significantly impair the 
post-traumatic quality of life 2, and have been associated with high direct and indirect 
costs 3,4. 
The risk factors for non-unions might either arise from injury characteristics, 
patient-specific factors, or from parameter associated with surgical fracture 
stabilization 5,6. Interactions between local and systemic inflammatory responses 
have been considered as the potential reasons for delayed fracture healing in chest 
trauma, 6. In contrast, TBI seems to be positively correlated with osteogenesis 7-9. 
However, this association has not been found in all studies 10,11. Furthermore, 
potential pathophysiological mechanisms for TBI-related impact on osteogenesis 
seem to be multifactorial (humoral, hormonal, and cellular) and are far from clarified 
7,12,13. 
Because of the enormous incapacitating effect of non-unions on the physical and 
mental health of patients, knowledge about the relevance of potential risk factors is 
of upmost importance. As the impact of several patient- (e.g. abuse of substances, 
long-term use of steroids) and injury-specific (e.g. open fracture Type III) factors has 
already been well described 5, we focused on the influence of chest injury, TBI and 
fracture stabilization strategies in patients with long bone fractures of the lower 
extremities. Identifying the risk and predictive factors of non-union can help further 
develop prophylactic and therapeutic strategies for its treatment. 
3.2. MATERIALS AND METHODS 
3.2.1. Study design and exclusion criteria 
We retrospectively analysed patients with diaphyseal femoral or tibial fractures who 
had been admitted and treated definitively with a reamed intramedullary locking 
nail at the department of Orthopaedic Trauma and Reconstructive Surgery, 
University Hospital RWTH Aachen (Germany), or the Department of Trauma 
Surgery, Maastricht University Medical Centre (The Netherlands) between 2004 and 
2014. Clinical records and X-rays were retrieved for analysis. The patients’ clinical 
course was followed until the last outpatient appointment. Patients who developed 
a non-union were placed in the NU group and those with normal fracture healing 
were placed in the control group. Non-union was defined as fracture healing not 
occurring in the expected time and in which progression of healing nor successful 
union is expected without intervention. 
To restrict the number of previously described factors influencing non-union 
development and to focus on chest injury, TBI, and fracture stabilization strategy 
(ETC vs. DCO) as the influencing factors, we applied the following exclusion criteria: 
17 < age (years) < 80, substance abuse 
(alcohol, tobacco, drugs), morbid obesity (BMI > 30), mental deficiency, pregnancy, 
long-term use of steroids, bisphosphonates, or thyroxin, lost to follow-up <1 year 
after trauma, Severe soft tissue damage (Gustilo & Anderson > 2), Comminuted 
fracture, Bone defect > 3 cm, Pathological fractures, fractures of an adjacent joint, 
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bilateral fractures, definitive treatment other than reamed intramedullary locking 
nail, and primary definitive treatment elsewhere. 
3.2.2. Treatment algorithm 
All the patients were managed according to the principles of Advanced Trauma Life 
Support® (ATLS®) and the S3 guidelines on the treatment of patients with severe 
injuries. For fracture treatment, patients underwent ETC with an antegrade 
intramedullary reamed locking nail, and if necessary, DCO at the earliest possible 
opportunity with an external fixator, which was subsequently converted to definitive 
osteosynthesis as soon as it was tolerated by the patient’s clinical condition. 
Intravenous antibiotic prophylaxis was given in closed fractures as a single dose and 
for 3 days in open fractures. As soon as their clinical state allowed it, patients were 
mobilized with partial and consecutive increase to full weight-bearing, according to 
the fracture type. After discharge, the patients were seen in the outpatient clinic at 2, 
6, 12, 26, and 52 weeks postoperatively. If union was not achieved at that time point, 
further controls took place until union was achieved or a revision was indicated. 
3.2.3. General health status and injury severity 
The general health status of the patients was estimated according to the American 
College of Anaesthesiologists (ASA) classification system and the Charlson 
comorbidity index (CCI) 14, which calculates an estimated relative risk of death based 
on the patient’s age, cardiopulmonary and cerebro-vascular condition, the presence 
of metabolic, gastrointestinal and infectious diseases as well as malignancies. Overall 
injury severity was determined with the 2005 revised edition of the Abbreviated 
Injury Scale (AIS) and summarized to the Injury Severity Score (ISS) 15. 
3.2.4. Classification of chest injury 
Concomitant chest injuries were classified according to the AISthorax, and patients 
were considered as having a concomitant chest injury when the AISthorax was ≥2. 
3.2.5. Classification of TBI 
TBIs were prehospitally classified according to the Glasgow coma scale (GCS) 16 and 
after computer tomography scanning. TBI was additionally classified according to 
the AIShead. Patients were only considered as having a concomitant TBI when they 
had a prehospital GCS ≤ 12 and an AIShead ≥ 2. 
3.2.6. Fracture classification and fracture healing assessment 
Only patients with diaphyseal femoral (AO32.A-C) or tibial (AO42.A-C) fractures 
according to the AO (Arbeitsgemeinschaft für Osteosynthesefragen) classification 
system, were included in the analysis. It was registered if these fractures were open 
(grade I or II according to Gustilo & Anderson) or closed. 
Radiological imaging was reviewed and evaluated by two independent observers 
(HA and PK), who were blinded to concomitant injuries. A fracture was considered 
to be consolidated when both observers determined that three out of four cortices 
were bridged by a callus. Further, callus formation was quantified according to the 
fracture healing response described by Spencer 17. 
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Table 3.1. Clinical and radiological parameters. 
 
 
3.2.7. Outcome & complications 
In addition to our primary outcome parameter of non-union, further neurological, 
cardiopulmonary, vascular, urinary tract, orthopaedic, and systemic complications 
were registered. 
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3.2.8. Statistical methods 
Data were analysed using SPSS (version 25; IBM Inc., Somers, NY, USA). Incidences 
are presented with counts and percentages, while continuous values are presented 
as mean ± standard deviation. Differences between the groups were evaluated with 
Mann-Whitney’s U test for continuous data, and Pearson’s χ2 test was used for 
categorical values. The nonparametric Spearman rank test was used for statistical 
correlation. Multivariate logistic regression analysis was performed with non-union 
as the dependent variable to adjust for confounding variables. The results were 
reported as odds ratio with 95% confidence intervals (95% CI). In general, a two-
sided p value < 0.05 was considered to be significant. 
3.3. RESULTS 
3.3.1. Demographic data 
A total of 136 and 68 patients were treated at the University Hospital RWTH Aachen 
(Germany) and the Maastricht University Medical Centre (The Netherlands), 
respectively. Of these, 100 patients (49.0%) had femoral fractures and 104 (51.0%) 
had tibial fractures. Overall, 25 (12.3%) patients had a concomitant chest injury and 
27 (13.2%) had a concomitant TBI. A total of 98 patients (48.0%) underwent ETC, 
and 106 (52.0%) underwent DCO. Conversion to definitive osteosynthesis was 
performed 6.2 ± 5.7 days after trauma (Table 3.1.). 
3.3.2. General health status, injury severity, and clinical course 
The general health status and the injury severity, distribution, and characteristics did 
not significantly differ between the two study groups. Over the clinical course, 
significant differences for the time period until definitive fracture stabilization (p = 
0.012), the total number of operations performed before consolidation (p < 0.001), 
and the ratio of ETC to DCO (p = 0.016) were observed between the control and NU 
groups (Table 3.1.). 
3.3.3. Nonparametric correlation analysis referring to non-union 
Non-union was diagnosed in 11.3% (n = 23) of our patient population. 
Nonparametric correlation analysis showed a correlation between the fracture 
healing response and non-union development (r = –0.424, p < 0.001). Also, the CCI 
was correlated with the incidence of non-union (r = 0.148, p = 0.034). For TBI and 
chest trauma, no correlation was found. (Table 3.2.) 
3.3.4. Multivariate regression analysis referring to non-union 
The multivariate regression analysis referring to non-union showed that only the 
total number of operations before consolidation was an independent risk factor for 
non-union development (OR = 6.416; p < 0.001; Table 3.3.). 
Most patients underwent one or two operations and only seven patients underwent 
more than two operations, which were performed due to hardware failure (n = 3) or 
infection (n = 4), and not because of disturbed healing. Therefore, we focused on the 
patients who underwent either one or two operations. Of these patients, 96 
underwent ETC and 86 of the 101 patients who had 2 operations (85.1 %) underwent 
DCO. In the multivariate regression analysis referring to non-union in DCO vs. ETC, 
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DCO represented an independent risk factor for non-union development with an 
odds ratio of 7.878 (p = 0.005; Table 3.4.). 
 
Table 3.2. Non-parametric correlation analysis of DCO treatment. 
 
 
3.4. DISCUSSION 
Non-unions of long bone fractures represent a challenging problem in trauma 
patients. Patient-, injury- and treatment-specific factors have been previously 
described to influence the occurrence of non-unions. Independent from the already 
well-known risk factors for non-union development, we aimed to focus on the impact 
of chest injury, TBI, and the fracture stabilisation strategy on the occurrence of non-
unions in diaphyseal long bone fractures. Our main results can be summarised as 
follows: 
1. The DCO fracture stabilisation strategy represents an independent risk 
factor for the development of non-unions in long bone fractures. 
2. Chest injury and TBI were not identified as influencing factors for non-union 
development in diaphyseal long bone fractures. 
Although DCO treatment is well accepted to be beneficial in certain subgroups of 
trauma patients, we found that this treatment strategy is associated with a higher 
risk of non-union. Our findings were in accordance to those reported in a previous 
study by Rixen et al. 18. In particular, the timing of conversion from external fixation 
to definitive stabilization has been suggested as an indispensable factor for non-
union development 19,20. In this context, late conversion (>10 days after the initial 
treatment) has been associated with an increase of fracture-associated 
complications, such as non-union 21. Therefore, it is of utmost importance to plan 
definitive surgery meticulously. In this context, Pape and Pfeifer revitalized the 
3
101
CHAPTER 3 | 
102 
discussion on the DCO treatment strategy by introducing the concept of safe 
definitive surgery (SDS). In this concept, the time point of definitive fracture 
stabilization is based on a regular re-evaluation and assessment of the patient’s 
physiological condition and not on a suggested time point like in the DCO concept 
(e.g. not before day 5). The SDS concept therefore might lead to a dynamic 
combination of the advantages of both the DCO and ETC treatment strategy 22. Our 
findings support the philosophy of this approach. Furthermore, approaches to 
identifying patients who could potentially benefit from DCO should be improved to 
avoid the increased risk of non-union development. To assess the relevance of 
concomitant injuries, we focused on chest injuries and TBI. 
 
Table 3.3. Multivariate regression analysis referring to non-union analysing age, gender, ASA, CCI, ISS, 
GCS, AIShead, AISthorax, concomitant injuries, AO-classification, open/closed fracture, period between trauma 
and definitive osteosynthesis, and the total number of operations before consolidation as potential 
predictors (Nagelkerke: R2 = 0.294). 
 
 
However, both entities did not significantly influence the development of non-
unions. In contrast to our study, Recknagel et al. suggest that chest trauma has a 
negative effect, particularly on the late phases of bone regeneration and fracture 
healing 23. A chest trauma-associated hypoxemia-induced enhancement of local and 
systemic inflammation has been suggested as a potential pathomechanism by 
Kemmler et al. 24. The differences between the results of our study and these 
experimental studies might be explained with different aspects. First, data obtained 
in animal experiments under standardized conditions might not be point-to-point 
transferable to the clinical situation with different confounding factors. Second, it has 
been postulated that the strategy for fracture fixation is an even more important 
factor for fracture healing than concomitant injuries 23. This would be in line with our 
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results and might explain why we did not observe an impact of chest trauma on the 
incidence of non-unions. 
TBI did not have a significant influence on fracture healing. Therefore, the findings 
of this study are in contrast to the findings of the majority of studies that TBI has a 
positive influence on bone regeneration 11. In this context, a retrospective study 8 
found shorter healing time and increased callus dimensions in patients with 
concomitant TBI. In contrast to our study, they excluded patients treated according 
to the DCO principle. As fracture fixation represented an independent risk factor for 
disturbed fracture healing in our study, this might be one explanation for the 
different results of the studies. This assumption would also support the finding of the 
aforementioned experimental study that fracture fixation has more impact on 
fracture healing than concomitant injuries 23. Another clinical study demonstrated 
shorter healing times, greater callus volumes, and higher fracture healing rates in 
patients with concomitant TBI 25. Contrary to our study, they included all long bones 
fractures (including humeral and fibular fractures) treated either with 
intramedullary nailing or plate osteosynthesis. Furthermore, they included only 
patients with severe TBI (GCS < 8). These differences are likely to contribute to the 
differences between that study and our present study. 
 
Table 3.4. Multivariate regression analysis referring to non-union analysing age, gender, ASA, CCI, ISS, 
GCS, AIShead, AISthorax, concomitant injuries, AO-classification, open/closed fracture, period between trauma 
and definitive osteosynthesis, and DCO vs. ETC as potential predictors (Nagelkerke: R2 = 0.215). 
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3.4.1. Strength and limitations 
A strength of our study design is that by strict inclusion and exclusion criteria, we 
were able to analyse a specific patient cohort with smaller parameter variance and 
better comparability, in which we could focus on the influence of chest injury, TBI, 
and fracture stabilisation strategy on non-union development by eliminating other 
possible confounding factors as much as possible. 
One limitation of this study is its retrospective design. Second, a large number of 
patients (114) were lost to follow up. Some of those patients may have had 
complications from the treatment and went for care elsewhere. On the other hand, 
patients with a straightforward healing process may have disengaged from the 
follow-up because they did not think it was essential. These phenomena could lead 
to possible selection bias. 
Third, the treatment evaluated was limited to reamed intramedullary nailing and in 
consequence we cannot assess the influence of the studied parameter on non-unions 
in diaphyseal long bone fractures following other treatment strategies. However, 
reamed intramedullary nailing is an established technique and is the preferred 
therapy for long bone shaft fractures of the lower extremities in adults 5. 
3.5. CONCLUSION 
Our results demonstrated that fracture stabilisation strategy is a far more powerful 
factor than concomitant injuries influencing non-union development in long bone 
fractures. Based on our finding that DCO stabilisation strategy is an eminent 
predictor for non-union development, it is of utmost importance in the clinical 
situation to critically review both: the indication for DCO and the time period until 
conversion to definitive treatment to minimize the risk of disturbed fracture healing. 
Our study further counterweights the rising evidence of concomitant chest injury 
predisposing and concomitant TBI protecting for non-unions in the specific situation 
of diaphyseal long bone fractures of the lower extremities. These findings could 
contribute to the improvement of the treatment principles and to the reduction of 
the treatment costs of non-union and its sequelae. Furthermore, reliably predicting 
the risk of non-union in certain fractures at the time of initial treatment would be a 
great advantage and could possibly modify treatment management. 
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ABSTRACT 
Neurologic injury and selective blockage of sensory nerve endings is associated with 
impaired fracture healing, however, the role of specific neurotransmitters has not 
been sufficiently investigated. Our aim was to investigate the impact of specific 
Substance P-receptor blockage on fracture healing, since the neuropeptide 
Substance P has both neurogenic and osteogenic activity. After intramedullary 
stabilization, an isolated femur fracture was induced in 72 Sprague-Dawley rats. In 
the NK1-R group, the neurokinin-1-tachykinin receptor for substance P was blocked 
by a specific antagonist (SR140333) for the first two weeks after fracture induction. 
The control group only received vehicle. Histology, micro-computed tomography, 
biomechanical tests, and gene-expression analysis were performed. NK1-receptor 
blocking suppressed osteocalcin expression at one week, collagen 1A2 expression at 
one and two weeks and collagen 2A1 expression at 2 weeks after fracture induction. 
Biomechanical testing revealed a significant reduction in maximal load to failure in 
the NK1-R group at 6 weeks (69.78 vs. 155.45 N, p = 0.029) and at 3 months (72.50 
vs.176.33 N, p = 0.01) of fracture healing. Blocking the NK1-receptor suppresses gene 
expression in and reduces biomechanical strength of healing bone. Therefore, we 
assume a potential therapeutic relevance of Substance P in cases of disturbed 
fracture healing. 
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4.1. INTRODUCTION 
Fractures are frequently associated with either central (e.g., traumatic brain injury 
[TBI]) or peripheral neurological injuries, and these injuries are well known to affect 
fracture healing. This phenomenon has partly been explained by the close anatomical 
relationship between bones and nerves (e.g., innervation of periosteum with close 
contact between nerve endings and bone cells). It also reflects the chronological 
association between callus formation, bone remodelling, and the regeneration of 
damaged nerve endings and ingrowth into newly formed bone 1,2. Disturbances of 
this re-innervation have therefore been associated with the incidence of non-unions 
3. Hukkanen and colleagues provided the first evidence for a role of nerve-mediated 
bone formation in fracture healing by showing that a complete denervation of a leg 
by sciatic nerve section had negative effects on the mechanical integrity of the bony 
callus after fracture 4. Similarly, Offley and colleagues found that capsaicin-sensitive 
neurons contribute to cancellous bone integrity and bone homeostasis in the 
uninjured bone. They concluded that osteoclast numbers, osteoblast activity, bone 
formation, and bone strength were mediated by transmitters released from efferent 
sensory nerve endings in bone tissue 5. 
Further, complete peripheral nerve transection 6-8 and selective blockade of sensory 
nerve endings 9 can impair fracture healing, as demonstrated by previous studies 
utilizing either combined motoric, sensory, and autonomic denervation 7,8 or 
complete sensory nerve ending blockade 5,9. 
The exact pathophysiologic mechanism underlying this interaction between fracture 
healing and nerve injuries is not known. Neuropeptides are produced by nerve 
endings after TBI and fractures, so neuropeptides potentially have major relevance 
in the process of fracture healing 1,2,10,11. However, no precise role has been 
established for specific neuropeptides in bone healing 12,13. 
One neuropeptide of particular relevance to bone healing is Substance P, which 
shows simultaneous effects at the neurogenic and osteogenic activities. For example, 
Apel et al. showed that sensory denervation, which shut down the transmission of 
both calcitonin gene-related peptide (CGRP) and Substance P, resulted in an 
impaired upregulation of collagen I and II in fracture callus and a negative influence 
on osteoclast function and mechanical strength and maturation of fracture callus. 9 
Neurotransmitters were therefore postulated to play a central role in the interaction 
between the nerves and the osseous system 8;31, and especially substance P seems to 
have a significant involvement in bone metabolism, formation, and resorption, as 
well as in the osteogenic activity of bone marrow stromal cells and osteogenic cell 
lines 14-22. However, the relevance of specific neurotransmitters remains unclear in 
these previous studies and the specific effects of Substance P on the process of 
fracture healing have not been elucidated. Therefore, the aim of this study was to 
investigate the effects of specific Substance P-receptor blockage on gene expression, 
callus formation, and the mechanical strength of healing fractures in an isolated 
femur fracture model in rats. We hypothesize that specific substance P receptor 
blockage impairs mechanical strength of healing fractures, decreases gene-
expression in the early fracture healing stages and reduces callus quantity and 
quality. 
 
4
109
CHAPTER 4 | 
110 
4.2. METHODS 
All methods were performed with the approval of the institutional animal committee 
and of the regulating authority (LANUV) North Rhine-Westphalia, Recklinghausen, 
Germany (AZ 84-02.04.2015.A078). All animal experiments were performed in 
accordance with the guidelines and regulations of the Federation of European 
Laboratory Animal Science Associations (FELASA) and the German Society of 
Laboratory Animals (GV-SOLAS). 
 
Figure 4.1. Subgroup division and time points of analyses. Subdivision of study cohort in two study 
groups (NK1-R group and Control group) and subsequent division of animals according to performed 
analysis at different time points. Every analysis is performed in 6 animals of both study groups at every 
time point. At DPO (days post-operative) 42 both µCT imaging and biomechanical testing was performed 
in the same animals. 
 
4.2.1. Housing 
Our study cohort consisted of 72 adult, female Sprague-Dawley rats, weighing 
approximately 250 g, obtained from Harlan Industries (Indianapolis, Indiana, USA). 
The animals were housed and the experiments were performed in facility approved 
by the Federation of European Laboratory Animal Science Associations (FELASA) 
and the German Society of Laboratory Animals (GV-SOLAS). The animals were 
housed under conditions of controlled temperature (20 ± 2°C) and air humidity (45–
65%), with a 12h light-darkness cycle and a light intensity of <200 lux. Food and 
water were offered ad libitum. Prior to study inclusion, all animals were kept in 
groups for one week in the laboratory premises to allow acclimatization. Throughout 
the entire experiment, all animals underwent physical examinations according to a 
‘score sheet’ documentation and  the ‘Body condition scoring’ according to Hickman 
23 to obtain the general health of the animals.  
Because of the protective effects of female hormones in cases of inflammatory 
stimuli, all animals were confirmed to be in the same ´metestrus´ phase of the 
menstrual cycle, as this phase is characterized by low oestrogen and progesterone 
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levels 24,25. The menstrual cycle phase was identified by the assessment of vaginal 
swabs according to Marcondes and colleagues 26. 
4.2.2. Experimental Design and Power Analysis 
In all animals an intramedullary pin was inserted and a standardized femoral 
fracture was induced. The animals were then randomly assigned to 2 groups (36 
rats/group), according to their order number (odd or even). The first group 
underwent a selective blockage of the NK1-receptor (NK1-R group). The second 
group served as the control group and only received vehicle (Control group). 
Depending on the experimental subgroup to which an animal was randomly 
assigned, the femur was harvested and the following analyses were executed at 
different time points: gene expression analysis, histological analyses, micro-CT 
scanning, and biomechanical testing. (Figure 4.1.)  
Our primary outcome parameter was the load to failure of the rat femora; therefore, 
our power analysis was based on an average load to failure of 131.3 ± 4.9 N for 
normal rat femora, as described by previous studies 9,27. Our calculation indicated 
that a minimum of 4 rats per group was needed to achieve a 95 % power for detecting 
a difference of 10 N with α = 0.05. Therefore, a sample size of six animals per group 
was chosen to compensate for any potential loss of animals. The power analysis was 
performed with G*Power. Secondary outcome parameters were fold change in gene 
expression of osteocalcin and collagen 1A2 and 2A1 and callus-volume, -density and 
-diameter in micro-CT-analysis.  
Reasons for excluding animals were: death from anaesthetic complications, open 
fracture, comminuted fracture, implant failure, wound dehiscence or infection, gross 
technical failure, inadequate RNA for analysis, and unintended displacement of the 
femur during biomechanical testing. 
4.2.3. Anaesthesia and Pain Management 
Thirty minutes preoperatively, the animals received 0.03–0.05 mg/kg 
buprenorphine hydrochloride s.c. as pain medication. The operative procedures 
were performed under general anaesthesia induced with ketamine (100 mg/kg i.p.) 
and xylazine (2 %; 10 mg/kg i.p.) and if necessary, extended with 2–2.5 Vol.% 
isoflurane inhalation. The toe pinch reflex was used to assure adequate anaesthesia. 
Post-operative analgesia was assured with buprenorphine hydrochloride (0.03–0.05 
mg/kg s.c.) every 6 h for the first 24–48 h. Subsequently, buprenorphine 
hydrochloride was given twice daily during the first 3 weeks. Furthermore, in the 
first postoperative week, the drinking water was supplemented with metamizole (1 
ml/300 ml). The animals were evaluated postoperatively three times per day for 
signs of acute deterioration. 
4.2.4. Standardized Femoral Fracture 
After anaesthesia induction, the animals were placed on a heated pad (37 °C) and 
their eyes were covered with moistening ointment. The right rear leg was shaved, 
disinfected, and draped. Then, a para-patellar incision was made, the patella was 
everted laterally and a 1.0 mm stainless-steel intramedullary Kirschner wire was 
inserted in a retrograde manner. Its placement was confirmed by fluoroscopy. The 
K-wire was cut flush with the intercondylar notch and the proximal end was bent 
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over the greater trochanter, cut, and hidden subcutaneously. The patella was 
repositioned and the wounds were closed in layers. Fracture induction was 
performed with a blunt guillotine according to the method of Bonnarens and Einhorn 
28. A fluoroscopic evaluation of the fracture site was performed.  
4.2.5. Substance P Receptor Blockage 
Substance P activity was blocked through selective blockage of the neurokinin-1-
tachykinin-receptor (NK1-R) by subcutaneous administration of SR140333 once 
daily for the first 14 days, beginning 30 min preoperatively. This period was chosen 
because it is the most vulnerable period in the fracture healing process in rats in 
terms of gene expression and the influence of cytokines, chemokines, growth factors, 
etc. 29,30. SR140333 is a non-peptide antagonist of tachykinin NK1 receptors that 
potently, selectively, and competitively inhibits substance P binding to NK1 
receptors 31. SR140333 was administered at a concentration of 1 mg/kg dissolved in 
a vehicle of 10 μl DMSO (dimethyl sulfoxide) and 0.2 ml of sterile water 32,33. The 
animals of the control group received the same amount of vehicle for the same 
period. 
4.2.6. Gene Expression 
The up-regulation of most genes associated with fracture healing in rats takes place 
in the first two weeks after fracture induction 29,30; therefore, gene expression was 
measured at 3, 7, and 14 days post-operative (DPO).  
At each time point, 6 animals from each group (NK1-R group and control group) were 
euthanized with an overdose isoflurane and subsequent cervical dislocation. The 
intramedullary K-wire was removed and bone and callus at 0.5 cm on each side of 
the fracture was harvested, frozen in liquid nitrogen, pulverized, and used for RNA 
extraction. The fold changes of osteocalcin, collagen 1A2, and collagen 2A1 mRNA 
expression were determined by the reverse transcription polymerase chain reaction 
(RT-PCR). The cDNA was transcribed from total RNA using a Maxima H Minus cDNA 
synthesis kit (Thermo Scientific, US). Real-time quantitative RT-PCR was performed 
with Power SYBR Green Master Mix (Applied Biosystems, US) using the 
StepOnePlus™ Real-Time PCR System (Invitrogen, CA, USA). The 2-ΔΔCT method (a 
method to analyse the relative changes in gene expression from real-time qPCR 
experiments) was used to calculate gene expression with peptidyl prolyl cis-trans 
isomerase (PPIA) as an internal housekeeping gene reference. The NK1-R and 
Control groups were compared for their expression of collagen-1A2, collagen-2A1, 
and osteocalcin mRNA.  
4.2.7. Histological Analysis 
At DPO 28, 10 animals underwent histological analysis (6 of the αNK1-R group and 
4 of the Control group, due to drop out of 2 animals, see Results section). The animals 
were euthanized, the Kirschner wire was removed, and the femora were harvested 
and fixed in 4% neutral buffered formalin for 48 hours. Decalcification was 
performed with ethylenediaminetetraacetic acid (EDTA) and dehydration with 
alcohol. The tissue was embedded in paraffin and 10μm sagittal sections of the callus 
area and the surrounding soft tissues were cut. The sections were stained with 
haematoxylin eosin (HE) and assessed with an Olympus BHS System Microscope. 
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Images were viewed at 40× and 200× magnification, and measurements of the bone 
were performed. 
 
 
Figure 4.2. Comparison of fold changes in gene expression. The fold changes of osteocalcin (a), 
collagen 1A2 (b), and collagen 2A1 (c) mRNA expression were determined by the reverse transcription 
polymerase chain reaction (RT-PCR) at 3 days, 1 week, and 2 weeks after fracture induction. 
 
4.2.8. Micro-Computed Tomography (μCT) 
Micro-CT imaging was obtained at DPO 42 in 6 euthanized animals from each group 
using a dual-energy gantry-based flat-panel microcomputed tomography scanner 
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(TomoScope 30s Duo, CT Imaging, Erlangen, Germany). The dual-energy X-ray tubes 
of the μCT were operated at voltages of 40 and 65 kV, with currents of 1.0 and 0.5 
mA, respectively. Coverage of the entire leg of the rats was achieved by performing 
three sub-scans; each sub-scan acquired 720 projections with 1,032 × 1,012 pixels 
during one full rotation, with durations of 90 s. After acquisition, volumetric data sets 
were reconstructed using a modified Feldkamp algorithm with a smooth kernel at an 
isotropic voxel size of 35 μm. The bone, K-wire, and fracture callus regions were 
segmented using an automated segmentation method with interactive correction of 
segmentation errors (Software Imalytics Preclinical 34). (Figure 4.4.) The total bone 
volume, callus volume, bone density, callus density, and transverse diameter of the 
fracture callus were analysed quantitatively. The mid-part of the femoral shaft of the 
unfractured side of the animals from the Control group were taken for reference. 
 
Figure 4.3. Microscopic imaging of callus tissue. Callus tissue (arrows) between muscle cells (above) 
and bone (below) in control group (a; calibration = 500 µm) and NK1-R group (b; calibration = 500 µm) 
in 5× magnification using haematoxylin-eosin staining. Callus tissue in control group (c; calibration = 100 
µm) and NK1-R group (d; calibration = 100 µm) in 20× magnification using haematoxylin-eosin staining. 
 
4.2.9. Biomechanical Testing 
Biomechanical testing was performed at two time points in the healing process to 
analyse the strength of the callus and/or newly formed bone. The first test was 
performed at DPO 42 in 6 animals of both groups; the second test was performed at 
DPO 84 in 6 animals of both groups. These time points were chosen because normal 
callus formation is completed after 6 weeks and the remodelling process is advanced 
or completed after 3 months. The fractured right as well as the unfractured left femur 
were tested in all animals. After euthanizing the animals and removing the K-wires, 
both ends of the femora were embedded, closely to the callus / fracture site in a two-
component resin (Technovit® 3040 powder + Technovit® Universal Liquid),35,36 
which quickly hardens at low temperature. The embedded femora were tested in the 
biomechanical testing device (Retroline from Zwick Roell AG, Germany), over two 
cardan yokes, by which the force was conducted perpendicular to the femur axis. The 
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biomechanical traction test was performed with a traction rate of 1 mm/s = 0.1 N/s 
and a measurement interval of 0.1 s. Digital set-up and control was performed using 
TestXpert II software (Zwick Roell AG, Germany), which enabled real-time 
measurement of the traction force. The obtained parameters were used for the 
calculation of average load to failure in Newton (N). 
4.2.10. Data Analysis 
The data were analysed using the Statistical Package for the Social Sciences (SPSS; 
version 22; IBM Inc., Somers, NY, USA) and GraphPad Prism 5.0 (San Diego, CA, USA). 
Continuous data are presented as mean ± standard deviation, while incidences are 
presented as counts and percentages. Differences between the groups were 
evaluated with a two-tailed unpaired Student’s t-test and with analysis of variance 
(ANOVA with post hoc Tukey) for continuous data. In general, Pearson’s χ2-test was 
used for categorical values. The gene expression and biomechanics data were 
analysed with the Mann–Whitney U test as a non-parametrical test. Potential 
statistical associations were evaluated with Pearson’s correlation. In general, a two 
sided p-value < 0.05 was considered statistically significant. 
4.3. RESULTS 
4.3.1. Animal Mortality 
At the beginning of the experiments, all animals were in good general health, 
according to the ‘score sheet’ and ‘Body condition scoring’ described in the methods 
section. No rats died during our study due to impacts of the operative procedure or 
its sequelae. In the course of the experiments, 2 rats (2.78 %, planned for histological 
analysis) had to be excluded according to our exclusion criteria; one animal had to 
be removed due to wound dehiscence and the other animal due to anaesthetic 
complications. In total, this left 70 rats (97.22 %) for inclusion in the final analyses. 
4.3.2. Gene Expression Analysis (Collagen 1A2- and 2A1- and Osteocalcin-
mRNA) 
Osteocalcin expression was significantly impaired at 1 week in the NK1-R group 
compared to the Control group (2.6 ± 0.1 fold vs. 13.5 ± 0.4 fold, p = 0.0002 for α = 
0.05). Collagen 1A2 also showed a significant depression of expression at 1 week 
(59.5 ± 2.5 fold vs. 228.2 ± 33.45 fold, p = 0.00148 for α = 0.05), as well as at the 2-
week time point (86.2 ± 7.3 fold vs. 170.3 ± 3.2 fold, p = 0.00028 for α=0.05). Collagen 
2A1 expression showed a significant reduction only after 2 weeks (1.9 ± 0.4 fold vs. 
106.9 ± 2.1 fold, p = 0.000041 for α = 0.05) (Figure 4.2.). 
4.3.3. Histological Analysis 
The haematoxylin-eosin staining 4 weeks after fracture did not reveal any significant 
differences in terms of vascularity or angiogenesis. The number and diameter of 
vessels were similar in both groups. We performed three microscopical 
measurements in each animal, but neither in trabecular diameter nor in callus 
diameter significant differences between both study groups were found (Figure 4.3.). 
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Figure 4.4. Micro-CT imaging shows the process of ossification and remodelling of the fracture site 
in the control group and NK1-R group. Micro-CT-imaging of the unfractured control left femur as 2D 
cross-sectional image in sagittal plane as well as 3D volume renderings resulting in a spatial resolution of 
35µm voxel side length before (a) and after segmentation of the bone (blue) (b); micro-CT-imaging of the 
fractured right femur as 2D cross-sectional image in sagittal plane as well as 3D volume renderings 
resulting in a spatial resolution of 35µm voxel side length before (c) and after segmentation of the bone 
(blue), callus (green) and K-Wire (red) (d). 2D cross-sectional images in sagittal plane for one unfractured 
and fractured side of both study groups (yellow line as example for callus length and diameter) (e). Micro-
CT-based quantification of the total bone volume (f) and bone density (g) of the whole femur in both the 
fractured side and the control side of both study groups. Diameter at the fracture side compared to the 
diameter at the correspondence level of the unfractured side (h). Micro-CT-based quantification of the 
total callus volume (i), callus density (j), callus length (k) and callus diameter (l) in the fractured side of 
both study groups. Significance: * p<0.05, ** p<0.01, *** p<0.005. 
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4.3.4. Micro-CT Scanning 
The micro-computed tomography analyses conducted six weeks after fracture 
induction showed an almost completed process of ossification and remodelling of the 
fracture site in the Control group, whereas the healing process in the NK1-R group 
was still in progress, based on the visual analysis of the µCT-scanning images, 
preceding the quantitative computer tomography analyses. In the quantitative 
computer tomography analyses, six weeks after healing, the total bone volume did 
not significantly differ between the fractured side with callus formation and the 
unfractured side without callus formation in both study groups. This implies that the 
comparability of the two study groups is warranted. The bone density was 
significantly lower for the fractured femur compared to the femur on the unfractured 
side in both groups (NK1-R group, p < 0.01; Control group, p < 0.05). Furthermore, a 
significant difference was noted in the transverse diameter between the fractured 
side (callus) and the unfractured side in both groups (NK1-R group, p < 0.01; Control 
group, p < 0.005). No significant differences were observed between the Control and 
the NK1-R groups. The callus formation analysis did not reveal any significant 
differences between the two groups in terms of the volume, diameter, length, or 
density of the callus. (Figure 4.4.) 
4.3.5. Biomechanical Tests  
Both study groups demonstrated a decreased load to failure of the fractured femora 
compared to the unfractured side at 6 weeks and 3 months after fracture. By 
contrast, biomechanical analyses at 6 weeks (Control group 251.84 ± 8.87 N vs. NK1-
R group 254.48 ± 9.95 N) and 3 months (Control group 247.00 ± 28.66 N and NK1-R 
group 224.67 ± 19.10 N) after fracture showed no significant differences in the load 
to failure for the unfractured side in both groups. The fractured side showed a 
significant (p = 0.029) difference in the load to failure between the NK1-R group 
(69.78 ± 8.51 N) and the Control group (155.45 ± 9.32 N) after 6 weeks. This 
difference was even greater at 3 months after fracture (NK1-R group: 72.50 ± 12.09 
N vs. Control group: 176.33 ± 13.44 N, p = 0.010) (Figure 4.5.). 
4.3.6. Summary of study results 
Our main results can be summarized as follows: 
(1) Blocking of the NK1-receptor for Substance P was associated with a reduced 
expression of different osteogenic proteins (osteocalcin, collagen 1A2, and collagen 
2A1) in the early phase (the first two weeks) of fracture healing. 
(2) NK1-receptor blocking impaired the normal improvement in biomechanical 
strength of the bone in the late phase (6 weeks and 3 months) after fracture. 
(3) Since the quantitative callus extensions showed no significant differences, but 
the biomechanical strength of the healing bone was impaired, NK1-receptor blocking 
decreased the quality of the callus formed. 
4.4. DISCUSSION 
Fracture healing is well recognized as a complex process that is still not completely 
understood. However, the relationship between fracture healing and neurologic 
injury is well described and implies an influence of neurological neurotransmitters. 
12,13 Among the various neurotransmitters, Substance P in particular is believed to 
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play a central role in bone metabolism. In this context, Substance P has been shown 
to stimulate bone formation by osteoblastic cells through interaction with the NK1-
receptor 37, whereas blockage of the NK1-receptor enhanced widespread 
osteoporotic processes 17. In the present study, our aim was to investigate what 
influence blocking the NK1-receptor for substance P might have on fracture healing.  
The important role of Substance P in bone metabolism was especially supported in 
the present study by the demonstration, for the first time, that selective blockage of 
Substance P activity by a NK1-receptor antagonist impairs the gene expression, 
biomechanical strength, and callus quality of a healing fracture.  
Figure 4.5. Biomechanical testing of the femora. Significant decrease in maximal load to failure (Nmax) 
of the femora in the NK1-R group at (a) 6 weeks (* p = 0.029) and (b) 3 months (* p = 0.01) after fracture 
induction. 
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The decreased gene expression observed in the present study for osteocalcin, 
collagen 1A2, and collagen 2A1 in the early phase of callus formation after Substance 
P receptor blockade underscores the relevance of Substance P in fracture healing. 
These results are in line with previous RT-PCR studies that showed a similarly 
impaired expression of osteocalcin and collagen during fracture healing in 
tachykinin-deficient mice14, in sensory denervated rats 9, and in rat osteoblastic cells 
37. 
However, beside this role in early fracture healing, Substance P seems also to have 
relevance for the later stages of fracture healing and remodelling of bone. In this 
context, we were able to show an association between NK1-receptor blockade in the 
first two weeks of fracture healing and a significant decrease in bone strength at 6 
weeks and even at 3 months after fracture.  
In previous studies, Niedermair and colleagues showed that tachykinin-1-deficient 
mice (Substance P knockout mice) have a reduced mechanical strength of callus after 
3 weeks of fracture healing, while Apel and colleagues showed that sensory 
denervated rats have a reduced mechanical strength of callus after 6 weeks of 
fracture healing 9,14. However, none of these studies analysed the biomechanical 
strength at the end of the remodelling phase, as we did after 3 months. If these effects 
of NK1-receptor blockage are exerted in the remodelling phase or are a result based 
on the earlier effects of NK1-receptor blockage on fracture healing has to be explored 
in future studies. 
Contrary to the results presented by Apel and colleagues, our findings did not 
indicate any significant histological differences in trabecular or callus diameter. We 
also did not find any significant radiological differences in quantitative callus 
dimensions in the µCT-analyses between our two study groups, although Apel and 
colleagues did report significant radiological differences. Our results agree with the 
observations of Niedermair and colleagues, who found no radiological differences in 
callus dimensions between tachykinin-deficient mice and a control group 14. These 
comparable quantitative callus dimensions between our study groups, in 
combination with the decrease in biomechanical strength of the bone in the NK1-R 
group, can only occur if the blockage of the NK1-receptor for Substance P impairs the 
quality of the soft and hard callus formed, although we could not substantiate this 
presumption with histological proof. In this context, the quality of callus is 
determined by the biomechanical strength of the callus and later of the remodelled 
bone, because the objective of fracture healing is to restore the original strength of 
the bone. Since Apel and colleagues performed a denervation that blocked both CGRP 
and Substance P, this might indicate that CGRP has a greater influence on the amount 
of callus formed, while Substance P regulates the strength and quality of callus. 
The findings presented here demonstrate the indispensability of Substance P for 
normal and appropriate callus formation and fracture healing. Nevertheless, 
clarifying the exact role of Substance P in fracture healing and bone formation will 
require further research. Additional research is also required to assess previously 
postulated mechanisms of action. For instance, Niedermair and colleagues proposed 
crucial trophic effects of neurotransmitters on bone healing via an endogenous callus 
signalling loop in which chondrocytes producing Substance P and its NK1-receptor 
play an important role. 14 They consider that the absence of Substance P results in a 
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net decrease in bone formation, leading to the observed decrease in the quality of the 
callus.  
Another interesting theory introduced by Davis and colleagues assumed that bone 
morphogenetic proteins (BMPs) released at the fracture site enter peripheral 
neurons through the damaged blood–nerve barrier. There, they induce a 
neuroinflammation with a release of substance P, as well as a subsequent release of 
osteoprogenitor cells in cases of heterotopic ossifications. 38 The results of our study 
could also point to a possible lead for further research into enhanced fracture healing 
in patients with concomitant TBI 13,39-41, because Substance P is released early 
following acute injury to the CNS. This promotes a neurogenic inflammatory 
response that is characterized by an increase in the permeability of the blood–brain 
barrier 42.  
Our study also has some limitations. As our findings were derived from an animal 
model, they are not directly translatable to humans. We chose a rat model because 
the blockage of a neurotransmitter can only be performed in laboratory animals and 
because adequate blockage of the substance P-receptor with the NK1-receptor 
antagonist SR140333 has been previously demonstrated in this species 33. 
Furthermore, the fracture model in rats is well documented in the existing literature, 
and the influence of NK1-receptor blockage on the complex, multifactorial process of 
fracture healing cannot be simulated in an in vitro experiment. Moreover, the volume 
measurements conducted using µCT analyses might be inaccurate due to obscuring 
by the intramedullary Kirschner wire, which in turn would reduce the volume 
measurement in the fractured bones. Therefore, the segmentation of the bone, the K-
wire and the fracture callus regions was performed with a very advanced interactive 
method (Software Imalytics Preclinical) to minimize the error range. Even if we had 
removed the K-wire shortly before the µCT analysis, this removal would have left an 
empty space, which would not be filled with new callus tissue and therefore would 
probably lead to the same results. Conversely, our histology findings concerning 
trabecular and callus dimensions conform to our µCT findings, indicating that these 
results are probably reliable. Another possible limitation, was that we did not follow 
up the blocking capacity of SR130444 after finishing the administration after two 
weeks of fracture healing. We assume that the effect of SR130444 is depleted > 24 
hours after application, but we did not verified it with immuno-histological tests. 
In conclusion, our study findings show that blocking the NK1-receptor for substance 
P suppresses gene expression of important proteins in the early phases of fracture 
healing, decreases the quality of callus formed, and lessens the biomechanical 
strength of bone in the late phases of fracture healing. Therefore, based on our 
results, further research should be focused on the exact mechanism of action of 
Substance P in fracture healing to provide a better understanding of its potential 
therapeutic relevance in cases of disturbed fracture healing. 
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ABSTRACT 
Background: Besides adequate healing of bone and soft tissues, mobility represents 
a significant factor in functional outcome after lower extremity fractures. Although 
gait analysis is gaining clinical interest and importance in the rehabilitation of 
patients with fractures, it is rarely used in experimental fracture healing research. 
The aim of this study is to establish an accurate gait analysis method for fracture 
healing research in small animal models and to evaluate the influence of a lower 
extremity fracture on gait pattern and muscle atrophy in rats. 
Research question: How does an intramedullary stabilized femur fracture influence 
the gait pattern and muscle atrophy during fracture healing in rats? 
Methods: An isolated femur fracture with intramedullary stabilization was induced 
in 26 Sprague Dawley rats. Different gait parameters (e.g. intensity, print area, stand 
duration, duty cycle, and swing speed) were evaluated with the CatWalk gait analysis 
system during the fracture healing process. Furthermore, muscle weight analysis 
was performed at different time points. 
Results: The gait analyses with the CatWalk system showed a high correlation with 
the osteogenesis of fracture healing in this model. Muscle atrophy increased during 
the early fracture healing stages and then decreased in the later stages. 
Significance: We are the first to show that the CatWalk system is a useful tool to 
perform gait analyses after lower extremity fractures in a murine model. These 
results could form a basis for future gait analyses research in fracture healing studies 
to improve knowledge about bone regeneration and rehabilitation after lower 
extremity fractures. 
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5.1. INTRODUCTION 
Gait analysis is gaining clinical interest and importance in different medical 
disciplines. It can be of great importance especially for patients with lower extremity 
fractures in order to evaluate rehabilitation and mobility, thereby improving their 
quality of life after injury. Although gait analyses are established and integrated in 
large animal research protocols, they are not well established yet in small animal 
models. This is remarkable, as small animal models are most commonly used for 
fracture healing studies and are particularly suitable for them because of the general 
accessibility and availability of gene targeted animals and knockout models 1-3. 
Although the CatWalk gait analysis system (Noldus Information Technology, 
Wageningen, Netherlands) is widely used in small animal models to investigate the 
impact of central and peripheral neurological injuries, neurodegenerative diseases, 
pain, and degenerative locomotor diseases on mobility, it has not been evaluated in 
a fracture healing model. However, the CatWalk system is of great interest in this 
field, as several clinically relevant dynamic and static gait parameters can be 
evaluated in a longitudinal and non-invasive way. Both gait parameters and 
functional outcomes are significantly influenced by muscle strength, which is often 
decreased after fracture and osteosynthesis because of direct damage to muscles and 
immobilization-triggered muscle atrophy 4. Moreover, this muscle destruction is also 
associated with impaired bone regeneration 5-8. Because of the aforementioned 
aspects it is important to gain experience with gait analysis methods in small animal 
models of fracture healing. In this study, we analysed the CatWalk system as a gait 
analysis method in a rat fracture model, with the aim to evaluate the influence of an 
intramedullary stabilized femur fracture on gait pattern and muscle atrophy over the 
entire fracture healing process. 
5.2. METHODS 
5.2.1. Housing 
Our study cohort consisted of 26 adult, female Sprague Dawley rats, weighing 
approximately 250g, obtained from Envigo B.V. (Horst, Netherlands). All the animals 
were specifically pathogen free according to the Federation of European Laboratory 
Animal Science Associations recommendation. The animals were housed, and the 
experiments were performed at the Institute of Laboratory Animal Science, 
University of Aachen Medical Center, Germany, with the approval of the 
Governmental Animal Care and Use Committee (Landesamt für Natur, Umwelt und 
Verbraucherschutz, North Rhine-Westphalia, Recklinghausen, Germany; Protocol 
No. 84-02.04.2015.A078). The animals were housed under controlled temperature 
(20 ± 2°C) and air humidity (45–65 %), with a 12h light–dark cycle and a light 
intensity of<200lx. Food and water were offered ad libitum. Prior to study inclusion, 
all the animals were kept in groups for 1 week in the laboratory premises to allow 
acclimatization. Throughout the entire experiment, they underwent physical 
examinations according to a score sheet documentation 9 and the Body Condition 
Scoring system by Hickman and Swan 10 to obtain their general health. Because of 
the protective effects of female hormones in cases of inflammatory stimuli, all the 
animals were confirmed to be in the same ‘metestrus’ phase of the menstrual cycle, 
as this phase is characterized by low oestrogen and progesterone levels 11. The 
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menstrual cycle phase was identified by the assessment of vaginal swabs according 
to Marcondes and colleagues 12. 
5.2.2. Experimental design 
In all the animals, an intramedullary pin was inserted after anaesthesia induction 
and a standardized femoral fracture was induced at the right side. The animals were 
then randomly divided into 2 study groups: one in which gait analyses were 
performed (n = 6) and one in which muscle weight analyses were performed (n = 
20). All the animals from the gait analysis study track underwent gait analysis at 7 
time points during the fracture healing process, including a baseline measurement 
before the intervention. The muscle weight analyses were performed in randomly 
assigned subgroups of 5 animals at 4 time points during the fracture healing process 
(Figure 5.1.). The reasons for excluding animals were as follows: death from 
anaesthetic complications, open fracture, comminuted fracture, implant failure, 
wound dehiscence or infection, impossibility to perform 3 adequate runs in the 
CatWalk system. 
5.2.3. Anaesthesia and pain management 
The animals received buprenorphine hydrochloride (0.03–0.05mg/ kg s.c.) as a 
multimodal analgesic 30min preoperatively. The operative procedures were 
performed under general anaesthesia induced with ketamine (100mg/kg i.p.) and 
xylazine (2 %; 10mg/kg i.p.) and, if necessary, extended with isoflurane inhalation 
(2.0–2.5 Vol.%). The toe pinch reflex was used to assure adequate anaesthesia. 
Postoperative analgesia was assured with buprenorphine hydrochloride (0.03–
0.05mg/kg s.c.) every 6h for the first 24–48h. Subsequently, it was given twice daily 
during the first 3 weeks. Furthermore, in the first postoperative week, the drinking 
water was supplemented with metamizole (1ml/300ml). 
Figure 5.1. Subgroup division and time points of analyses. Subdivision of study cohort in 2 study 
groups (gait analysis and muscle weight analysis) and subsequent division according to performed 
analysis at different time points. (DPO: days postoperative) 
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The animals were evaluated postoperatively 3 times per day according to the score 
sheet evaluation 9. 
5.2.4. Standardized femoral fracture 
After anaesthesia induction, the animals were placed on a heated pad (37°C) and 
their eyes were covered with a moistening ointment. Their right hind leg was shaved, 
disinfected, and draped. Then, a parapatellar incision was made, the patella was 
everted laterally, and a 1mm stainless-steel intramedullary Kirschner wire 
(Königsee Implantate GmbH, Allendorf, Germany) was inserted in a retrograde 
manner. Its placement was confirmed by fluoroscopy. The Kirschner wire was cut 
flush with the intercondylar notch, and the proximal end was bent over the greater 
trochanter, cut, and hidden subcutaneously. The patella was repositioned and the 
wounds were sutured (Ethicon Inc., Somerville, NJ, USA) in layers. Fracture induction 
was performed with a blunt guillotine according to the method of Bonnarens and 
Einhorn 13. A fluoroscopic evaluation of the fractured side was performed directly 
after fracture induction. Fracture healing, defined as bridging of 3 out of 4 cortices, 
was assessed radiologically at 42 days postoperative (DPO). 
5.2.5. Gait analysis 
5.2.5.1. Description of technique and measured parameters  
Gait analysis was carried out using the CatWalk system (version XT 8.1) – an 
automated gait analysis system which can measure dynamic (i.e. stand duration, 
duty cycle, and swing speed) and static (i.e. print area and intensity) gait parameters 
of small animals. The system consists of an enclosed 1.3-m-long walkway of an 
enlightened glass plate. The animal crosses this walkway from left to right, and each 
individual footprint on the enlightened glass plate is detected by a camera placed 
below and registered by the CatWalk software 14,15 (Figure 5.2.). From the registered 
gait data, the following parameters were calculated for both hindlimbs and their 
ratios between the hindlimbs: intensity (average pressure of print for the given paw 
(arbitrary units)); print area (total print area for the given paw (mm2)); stand 
duration (time spent bearing weight per step for the given paw (s)); duty cycle 
(percentage of the time spent bearing weight in each walk cycle for the given paw 
(%)); and swing speed (phase(s) of the limb between steps for the given paw). These 
data were collected from the CatWalk software after performing the ‘auto classify’ 
function. Additionally, these data were edited according to the systematic manual 
classification method described by Chen and colleagues 15. 
5.2.5.2. Pre-traumatic treatment and time point of measurements 
Preoperatively, the animals were trained twice daily on the CatWalk system for 2 
weeks to get used to the test situation. Their cages were put at the end of the corridor 
with reward food pellets, and they were set at the other end of the corridor. They 
were able  to walk freely to their own cages. The goal of this training was that the 
animals could perform 5 successful runs. A successful run is a passage with no 
explicit stops, with a velocity variation of no more than 60 % and a maximum velocity 
of no more than 400 mm/s. For the final analysis, the animals needed to perform 3 
successful runs at each time point. To guarantee a standardized environment, they 
were trained by the same person and the room set-up was the same during all the 
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runs. Post-traumatic gait analysis was performed throughout the entire fracture 
healing process at DPO 3, 7, 14, 28, 42, and 84. A baseline measurement was 
performed preoperatively at DPO 0. 
 
Figure 5.2. CatWalk gait analysis system. CatWalk walkway device (left) and footprint identification 
from the real-life imaging of the CatWalk system. (From Noldus Information Technology, www.noldus.com.) 
 
5.2.6. Muscle weight analysis 
Muscle weight analyses were performed at 4 time points (DPO 3, 7, 14, and 42) 
throughout the fracture  healing process. At each time point, 5 rats were euthanized 
with an overdose of isoflurane and subsequent cervical dislocation, the lateral vastus 
muscle was harvested in toto on  both sides (the fractured right leg and unfractured 
left leg), and then the ‘dry’ muscle weight was measured after 3 days of 
dehumidifying in an incubator at 50°C. The ratio of the muscle mass at the fractured 
side compared to the unfractured side in each animal was evaluated. 
5.2.7. Endpoint and power analysis 
The main endpoint of our study was a normal gait pattern according to the different 
parameters of the CatWalk system. As these gait analyses with the CatWalk system 
were never performed before in rats with femur fractures, we based our power 
analysis on the study by Apel and colleagues 16. In this study, the rats in which a 
femoral fracture was induced after intramedullary stabilization were also evaluated 
for fracture healing parameters. Their power analysis was based on an average 
maximal load to failure of rat femora of 131.3 ± 4.9N, which was described as the 
load to failure of normal rat femora by Takee and colleagues 16,17. According to this 
calculation, the animal groups were required to include a minimum of 4 rats to 
achieve a 95 % power for detecting a difference of 10N, with α=0.05. In order to 
compensate for the potential loss of animals, a sample size of 6 animals per group 
was chosen. The power analysis was performed with G*Power (version 3.1; 
University of Düsseldorf, Germany). The secondary outcome parameter was the 
extent of muscle weight loss during the fracture healing process. 
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5.2.8. Data analysis 
The data were analysed using SPSS (version 25; IBM Inc., Somers, NY, USA). The 
continuous values were presented as median with interquartile ranges (25-IQR and 
75-IQR). The muscle weight was described by mean and standard deviation. 
Differences between the groups were evaluated with Mann–Whitney’s U-test for 
continuous data. The power analysis was performed with G*Power. In general, a 
2sided p-value < 0.05 was considered to be significant. 
 
Table 5.1. Gait parameters. Percentage change to baseline values of gait parameter (intensity, print area, 
stand duration, duty cycle, and swing speed) median (MED) and interquartile range (IQR). Relative 
changes to baseline values for the fractured hind leg (above) and for the ratio of the fractured to 
unfractured side (R/L; bottom) in percentages. 
 
 
5.3. RESULTS 
The radiological evaluation of fracture healing at DPO 42 showed bridging of 3 out of 
4 cortices and no significant dislocation in all subjects. No animals were needed to be 
excluded according to our exclusion criteria. 
5.3.1. Gait analysis 
The results were represented as relative changes to baseline values in percentages. 
We evaluated 5 gait parameters (intensity, print area, stand duration, duty cycle, and 
swing speed) for the fractured hind leg and also for the ratio of the fractured to 
unfractured hind leg (marked with ‘R/L’). In the early fracture healing stages (DPO 
0–14), the fractured hind leg demonstrated significant changes to baseline values for 
all gait parameters. In the later fracture healing stages (DPO 14–84), these values 
normalized to baseline values (stand duration and duty cycle) or even exceeded 
these values (intensity, print area, and swing speed) (Table 5.1.; Figure 5.3.). 
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5.3.2. Muscle weight analysis 
The muscle weight of the unfractured side increased constantly from DPO 3 to 42, 
whereas the muscle weight of the fractured side showed a depression in the first 
week after fracture induction, with a subsequent increase over the next 5 weeks. 
Comparing the fractured with unfractured side we could demonstrate a significant 
decreased muscle weight of the fractured side from DPO 7 throughout the entire 
fracture healing process (Table 5.2.; Figure 5.4.). 
5.4. DISCUSSION 
From clinical experience it is well known that the period of immobilization after 
stabilization of lower extremity fractures depends on different patient- and fracture-
specific factors. Generally, postoperative weight bearing is increased as soon as 
possible to prevent complications, stimulate fracture healing, and regain mobility, 
muscle strength, and function. However, objective gait analysis methods are not 
widely integrated in the rehabilitation of patients with lower extremity fractures. 
Because data on post-traumatic or -operative gait patterns are important to improve 
the recovery of patients after lower extremity fractures, it is gratifying to see that 
gait analysis after lower extremity fractures is gaining increased interest and 
importance. Therefore, it is even more remarkable that the gait analysis methods in 
the most commonly used small animal models of fracture healing are almost absent. 
About 50 % of all animal fracture healing studies are performed in small animal 
models 2, but only 1 study describes a gait analysis method for lower extremity 
fractures in rats 3. However, this study by Histing and colleagues performs gait 
analysis with a treadmill at only 1 time point in the fracture healing process. In the 
present study, we therefore introduced for the first time – to the best of our 
knowledge – the CatWalk system for gait analyses in a rat model of femoral fracture 
healing. Additionally, the post-traumatic course of muscle weight changes was 
evaluated.  
Our main results can be summarized as follows: 
1. Intramedullary stabilized femur fractures influence the gait pattern in the early 
fracture healing stages.  
2. Intramedullary stabilized femur fractures are associated with muscle atrophy in 
the early fracture healing stages.  
3. The changes in gait parameters according to the CatWalk system are associated 
with the progress of fracture healing. 
Complete bone bridging of a fracture in rats takes approximately 5 weeks, and 
torsional stiffness increases to 30–100 % in this period 2,18,19. In our study, we found 
a close association between the normal fracture healing process and the 
normalization of both gait parameters and muscle weight. In the first 2 weeks after 
fracture induction, all gait parameters (i.e. intensity, print area, stand duration, duty 
cycle, and swing speed) were reduced compared to the baseline measurements, but 
from the 3rd to 6th week of fracture healing, the gait parameters returned to baseline 
values. Archdeacon and colleagues showed similar results in a clinical study of 
patients with femoral fractures 4. This and other study groups, therefore, emphasized 
the importance of gait dysfunction in short- and long-term functional outcomes 4,20-
24. The values of intensity, print area, and swing speed even exceed the basic values 
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at DPO 28 – 84 and this could be due to new formed callus which has a bigger 
diameter and is possibly stronger than the original femur before fracture induction. 
 
Figure 5.3. Gait analysis in graphs. Percentage change to baseline values of gait parameters. 
Visualization of relative changes to baseline values of all 5 gait parameters (intensity, print area, stand 
duration, duty cycle, and swing speed) for the fractured hind leg (left column) and for the ratio of the 
fractured to unfractured side (R/L; right column). 
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Table 5.2. Comparison of the muscle weight of the fractured and unfractured side within the same animal. 
Significant differences between vastus lateralis muscle weight of the fractured and unfractured side of the 
same animal.   
 
With our study we are the first to demonstrate that the gait patterns of rats resemble 
those of patients with lower extremity fractures; only the healing process – and thus 
the impaired mobility – lasts longer in human beings. Because studies on small 
animal models are the most commonly used experimental models in fracture healing 
research, this observation can form an important basis for future fracture healing 
research. In the early fracture healing stages, the muscle weight of the fractured side 
was reduced in coherence with the impaired gait pattern. 
 
Figure 5.4. Muscle weight of the lateral vastus muscle. Muscle weight significantly decreases at the 
fractured side in the early fracture healing stages. 
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This was most likely caused by immobilization and, particularly at the very 
beginning, also by the impact of fracture induction and intramedullary stabilization. 
This is in line with clinical studies which showed significant muscle atrophy even 
after short periods of immobilization, with a negative influence on fracture 
biomechanics 5,25-27. In the later fracture healing stages, as the gait pattern of the 
animals normalized and the mobility improved, muscle atrophy decreased and 
muscle weight shows a tendency to return to normal values. This pattern of muscle 
atrophy is also demonstrated in literature 5. It is stated that the influence of this 
muscle atrophy goes beyond the direct effect on fracture healing, because it can 
impair gait patterns and general remobilization, thereby prolonging the 
rehabilitation process and even decreasing the functional outcome and quality of life 
of these patients 4,28-30. Overall, the CatWalk system adequately analyses and 
clinically reflects the gait pattern development in small animal models of fracture 
healing. It offers advantages over treadmills: First, the CatWalk system uses a 
walkway set-up, which matches the normal gait pattern of these animals much 
better. Second, both static and dynamic gait parameters can be evaluated at the same 
time. As Kappos and colleagues described earlier for functional nerve recovery in a 
small animal model, the CatWalk system is the only technique which can reliably 
analyse dynamic gait parameters, including swing speed, stand duration, and 
interlimb coordination 14. The improvement of gait parameters is especially 
important in rehabilitation after lower limb fractures, because it has been proved 
that an isolated femur fracture, and the subsequent impaired gait pattern, also 
influences the kinematics and kinetics of the adjacent joints, which is time dependent 
and can influence the long-term functional outcome 4. This underlines the 
importance of the described CatWalk system. Third, when the animals are trained 
well, the registration is accurate  and this system can provide clinically relevant and 
extensive data on gait patterns. The current study also has some limitations. 
Although we demonstrated a good correlation between our results and clinical 
findings, small animal models are not directly transferable to the human situation. 
However, more than50 % of experimental fracture healing studies are performed in 
small animal models. Therefore, our results are important as they confirm that gait 
analysis is a translationally relevant technique to gain information on the fracture 
healing process and posttraumatic mobilization. Moreover, we did not perform 
baseline measurements of the muscle weight in healthy animals of the same weight 
as a reference measurement. This was with intent, because muscle weight is 
extremely individual specific, and therefore, we were more interested in the 
differences in the muscle weight of the fractured against unfractured side in 1 animal. 
5.5. CONCLUSIONS 
We demonstrated for the first time that the CatWalk system is practicable and useful 
to assess both static  and dynamic gait parameters in a non-invasive, longitudinal 
manner in an experimental small animal model of fracture healing. Our pre-clinical 
findings are in line with clinical observations in patients with lower extremity 
fractures. Therefore, this system has the potential to become a standard gait analysis 
method in fracture healing research in experimental small animal models, thereby 
improving knowledge about behavioural and locomotor recovery after lower 
extremity fractures. 
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ABSTRACT 
Aims: Normal fracture healing and non-union development are influenced by a wide 
range of biological factors. Adequate concentrations of amino acids, especially arginine, 
are known to be important during normal bone healing. We hypothesize that the bone 
arginine availability in autologous bone marrow grafting by use of the reamer-irrigator-
aspirator (RIA) procedure is a marker of bone healing capacity in patients treated for 
non-union.  
Patients and methods: 17 patients treated for atrophic long bone non-union by 
autologous bone grafting by RIA procedure were included and divided into two groups: 
successful treatment of non-union and unsuccessful, and were compared to 8 control 
patients after normal fracture healing. Reamed bone marrow aspirate from an 
unaffected bone distant to the non-union was obtained and amino acids were measured 
using high-performance liquid chromatography. RNA was isolated for quantitative 
polymerase chain reaction analysis of relevant enzymes in the arginine metabolism. 
Results: Arginine and ornithine concentrations were higher in patients with successful 
bone healing after RIA in comparison with an unsuccessful healing. Ornithine 
concentrations were lower in all non-union patients compared to control patients, 
while citrulline concentrations were increased. Nos2 expression was significantly 
increased in all RIA treated patients, and higher in patients with a successful outcome 
when compared with unsuccessful outcome after RIA. Nos3 expression was not 
detectable in RIA treated patients. Arg1 was lower in all RIA treated patients when 
compared to control samples.  
Conclusions: The results indicate an influence of the arginine-nitric oxide metabolism in 
bone marrow, harvested using reamed intramedullary aspirate on the outcome of non-
union treatment, with indications for a prolonged inflammatory response in patients 
with unsuccessful bone grafting therapy. Determination of arginine concentrations and 
Nos2 expression could be used as predictor for successful treatment of autologous bone 
grafting in non-union treatment.   
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6.1. INTRODUCTION 
Non-union development occurs in 10-15% 1 of patients with long bone fractures. This 
incidence can increase up to 45% depending on risk factors such as fracture 
configuration and infection 2,3. Next to a major decrease in quality of life, non-union is 
accompanied by high socio-economic costs caused by multiple surgical interventions 
needed for adequate treatment 4. A regular treatment option for long bone non-unions 
is the use of autologous bone grafting by reamed-irrigation-aspiration (RIA) for 
harvesting of bone and bone marrow. This technique fulfils the requirements for 
adequate bone grafting stated in the Diamond Concept 5,6. The general risk of persisting 
failure of bone healing after bone grafting procedure for non-union using the RIA 
procedure is around 10-18% 7-9. Although the molecular pathogenesis of non-union 
remains unclear, a better understanding may provide better approaches for its 
diagnosis and treatment.  
It is known that disturbances in amino acid metabolism play a role in an inadequate 
bone healing response, especially amino acids related to the arginine-nitric oxide 
metabolism 10. Nitric oxide (NO, solely produced during conversion of arginine into 
citrulline by one of the nitric oxide synthases, NOSs) production is important during 
fracture healing because of its influence on stimulation of bone cells to regulate bone 
remodelling 11, vascularization 12 and a possible stimulation of polyamine production 
as a precursor for collagen synthesis 13,14. In vivo animal studies already showed a 
localized 15 and temporal 16 expression of the different NOS isoforms in fracture tissue. 
Next to this, absence of NOS isoforms results in diminished bone formation and non-
union development 17. In humans, NOS isoforms were also expressed in mRNA in callus 
samples 18, indicating an active role in the healing process.  
We hypothesize that the arginine-NO metabolism in the human body plays a role in the 
molecular pathogenesis of abnormal bone healing and that measuring the 
concentrations of these amino acids and its related enzymes from the bone harvested 
during RIA procedure is indicative of the success or failure of the non-union treatment.  
Hence, here we investigate amino acid concentrations and relevant enzyme expression 
in bone marrow obtained during the RIA procedure for autologous bone grafting in long 
bone non-unions, and comparing it between successful outcome and failure of this 
treatment. Patients with comparable fractures with normal fracture healing after 
fracture treatment were included as baseline control samples. 
6.2. PATIENTS & METHODS 
6.2.1. Patient inclusion 
This study was approved by the medical ethics committee of the Maastricht University 
Medical Center (permit METC04021). Written informed consent was obtained from all 
patients. Included were patients which were admitted for surgery on atrophic 
diaphyseal long bone non-unions at the Department of Surgery at the Maastricht 
University Medical Center and were the reamer-irrigator-aspirator (RIA) procedure 
was performed. Atrophic non-union was defined as a fracture which has, by opinion by 
the treating physician, no chance of healing without any further intervention. 17 
patients were included and retrospectively divided into two groups. In the first group 
9 patients achieved primary healing of the RIA procedure (bone healing within 6-9 
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months after surgery), and 8 patients in the second group either had secondary success 
(one or more re-interventions after the primary RIA procedure to obtain healing of the 
non-union) or persisting absence of healing. As control tissue, trabecular bone samples 
were obtained during regular elective surgery in which there was access to the bone 
marrow in patients with healed femur or tibia fractures in order to remove the 
osteosynthesis materials. Patient characteristics are presented in table 6.1. The non-
union scoring system (NUSS) was used to classify the non-union severity. 
Bone marrow samples were collected directly after harvesting the marrow and snap 
frozen in liquid nitrogen in the operating theatre. Samples were stored at -80 oC until 
analysis. 
 
Table 6.1. Patient characteristics. (BMI: body mass index, NSAID: non-steroidal anti-inflammatory drugs, 
NUSS: non-union scoring scale, DM: diabetes mellitus, NSAID: non-steroidal inflammatory drugs. Significance 
p < 0.05.  
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6.2.2. High-performance liquid chromatography amino acid analysis 
For measurement of relevant amino acids concentrations, tissue samples were crushed 
on liquid nitrogen, deproteinized, homogenized and centrifuged as described before in 
detail 17. The obtained supernatant was 100-fold diluted in water and 100 μl was placed 
in a WISP-style vial and placed in the chilled (4-8 oC) sample compartment from a 
Waters 717 plus Autosampler (Waters Chromatography BV, Etten-Leur, The 
Netherlands). The amino acid analysis was performed after pre-column derivatization 
using o-phthaldialdehyde (Thermo Fisher Scientific) as described previously 19. 
6.2.3. RNA isolation and qPCR 
Before RNA isolation, samples were crushed with pestle and mortar on liquid nitrogen. 
To isolate total RNA, crushed samples were incubated, precipitated and centrifuged as 
described before 17. Afterwards, pellets were washed and dried before dissolving in 
diethylpyrocarbonate treated water for subsequent cDNA synthesis.  
For quantitative PCR, iQ SYBR Green Supermix (Biorad Products, Hercules, CA, USA) 
and gene-specific forward and reversed primers were added to the cDNA. The cDNA 
was amplified using the MyiQ system (Biorad Products, Hercules, CA, USA) via a 3-step 
program: 40 cycles of denaturation (95 ºC, 10s), annealing (60 ºC, 20s) and elongation 
(70 ºC, 20s). Gene expression levels of Nos2, Nos3, and Arg1 were determined using IQ5 
software (Biorad Products, Hercules, CA, USA). The geometric mean of cyclophylin A 
(Ppia) and β-actin (ActB) expression levels was calculated and used as a normalization 
factor. All primers were acquired from Sigma-Aldrich (Zwijndrecht, The Netherlands). 
Primer sequences are depicted in table 6.2. 
 
Table 6.2. Primer sequences for quantitative polymerase chain reaction. (Fw = forward, Rev = reverse) 
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6.2.4. Statistical analysis 
Statistical analyses were performed using GraphPad Prism 6 (GraphPad, San Diego, CA, 
USA). Normality was checked using the Shapiro-Wilk test. All data are presented as 
means and standard error of the mean (SEM). Significance was calculated using one-
way ANOVA testing with post hoc Bonferroni correction. P-values below 0.05 were 
considered as statistical significant. For regression analysis, SPSS 25.0 was used (IBM, 
Armonk, NY, USA). A multivariate procedure was used to provide a regression analysis 
and analysis of variance for dependent variable group and with the factors BMI, age, 
NUSS and the arginine-metabolism related factors Nos- and Arginase 1-expression, and 
concentrations of ARG, CIT and ORN as covariates, presented as non-standardized 
regression coefficients (B) (with SE). 
6.3. RESULTS 
6.3.1. Patient characteristics 
Demographic characteristics of patients included within this study are presented in 
table 1. A significant age differences was observed between patients with primary 
success and patients with refractory non-union (p < 0.05). Although length and weight 
of the patients did not show significant differences, BMI from patients in the control 
group was significantly lower in comparison with both the primary and secondary 
success after RIA treatment groups (both p < 0.05). The NUSS score was significantly 
higher is patients with primary success after treatment when compared with refractory 
non-union patients. All other demographic factors (sex, smoking, alcohol and NSAID 
use, history of diabetes and the fracture location and Gustilo grade did not show any 
significant differences between the groups.  
6.3.1. Amino acid concentrations 
In Figure 6.1. concentrations of arginine, citrulline and ornithine measured in reamed 
intramedullary aspirate are shown.  
Arginine concentrations are significantly higher in patients in the primary success 
group when compared to patients with failure of the RIA treatment which needed one 
or more re-interventions (p < 0.05, respectively 225 ± 46.9 and 113 ± 17.2 μmol/mg 
wet tissue, Figure 6.1.A). No significant differences were found when concentrations in 
both patient groups treated with RIA were compared with control samples.  
Citrulline concentrations in samples of primary success patients (173 ± 50.3 μmol/mg 
wet tissue) and the secondary success or failure group (109 ± 26.7) were comparable. 
However, patients which achieved primary success of the RIA procedure showed 
significant higher citrulline levels when compared to the control group (45.3 ± 3.49, p 
< 0.05, Figure 6.1.B), while patients with a secondary success or failure had similar 
concentrations compared to control patients.  
Ornithine concentrations also showed different concentrations between the three 
study groups (Figure 6.1.C). Samples obtained from control patients showed significant 
higher ornithine concentrations (148 ± 7.38 μmol/mg wet tissue) when compared with 
primary success samples (102 ± 7.57, p < 0.001) as well as patients with failure of 
healing after RIA (71.5 ± 7.69, p < 0.0001). Next to this, patients with initial success of 
the RIA procedure also showed higher ornithine levels when compared to patients with 
failure of treatment or with the need of a secondary surgical intervention (p < 0.05). 
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6.3.2. qPCR analysis 
RNA-expression of enzymes relevant to the arginine-NO metabolism is shown in figure 
6.2. Measurements of Nos2 (inducible nitric oxide synthase) expression in trabecular 
bone from the reamed intramedullary aspirate showed a significant upregulation in 
patients with a successful RIA procedure as well as in patients where the procedure was 
not successful (both p < 0.05) when compared to samples obtained from control 
patients (Figure 6.2.A). Nos3, the enzymatic isoform present in the endothelium of bone 
vasculature, was not detectable in all patients who were treated with the RIA-procedure 
(data not shown). 
 
 
Figure 6.1. Concentrations of amino acids. Concentrations of arginine (6.1.A), citrulline (6.1.B) and 
ornithine (6.1.C) in reamed intramedullary aspirate, presented as µmol/mg wet tissue. Results in control 
tissues are presented in the white bars. Samples obtained from patients with a primary successful RIA 
treatment are shown in orange and with an unsuccessful treatment in dark blue. Statistical significance: * p < 
0.05, *** p < 0.001, **** p < 0.0001. 
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In Figure 6.2.B, the expression of Arg1 is shown in the three study groups. A significant 
downregulation (0.24 and 0.34 of the values in control patients) is visible in both RIA 
treated groups of patients when compared to control samples (p < 0.001 and p < 0.05 
for the primary success and the secondary success and failure group respectively).   
 
 
Figure 6.2 Relative expression of enzymes. Relative expression of iNOS (Nos2, inducible nitric oxide 
synthase, 6.2. A) and Arginase-1 (Arg1, 6.2. B). Results in control tissue are represented in white bars. Samples 
obtained from patients with subsequent successful RIA treatment are shown in orange. The failure of 
treatment group is presented in dark blue. Statistical significance: * p < 0.05, *** p < 0.001. 
 
6.3.3. Regression analysis 
All variables were subsequently used as independent variables in a logistic regression 
analysis. The dependent variables age, BMI, NUSS, arginine-, citrulline- and ornithine 
concentrations and arginase-1 and iNOS expression were included being significant 
predictors of outcome on univariate analysis. On multivariate analysis, iNOS was the 
only significant factor within these variables. Below the overview of the different 
significance levels and non-standardized regression coefficients (with SE): age (B 0.001, 
SE 0.215, p = 0.514), BMI (B -0.014, SE 0.006, p = 0.057), NUSS (B 0.003, SE 0.002, p = 
0.202), arginine concentration (B -0.001, SE 0.000, p = 0.179), citrulline concentration 
(B 0.000, SE 0.000, p = 0.357), ornithine concentration (B -0.003, SE 0.002, p = 0.146), 
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arginase-1 expression (B 0.421, SE 0.190, p = 0.057) and iNOS expression (B 0.025, SE 
0.002, p < 0.001). 
6.4. DISCUSSION 
This is the first study in which biomarkers of the arginine-nitric oxide metabolism are 
clinically evaluated in trabecular bone harvested during RIA from patients treated for 
non-union of the long bones. Both concentrations of the amino acids arginine and 
ornithine were higher in samples obtained from patients that had successful bone 
healing after bone grafting when compared with those that had an unsuccessful healing. 
Relevant enzymes, Nos2 and Arg1, showed differences in samples obtained from the 
reamed intramedullary aspirate when compared to bone marrow obtained from 
patients with an initial normal fracture healing, while Nos2 was able to differentiate 
between successful and primarily failed non-union treatment. This predictive value 
might lead towards a possible future use as biomarker in predicting non-union healing 
outcome.   
Generally, 10-15% of all long-bone fractures fail to heal adequately 1,20,21 with resulting 
development of non-unions with major functional impairment and a decrease in the 
quality of life for these patients, which is accompanied by a high socio-economic burden 
2,4. A wide range of possible biomarkers that can be used as a predictor for the 
development of non-unions have been investigated 22, however our current study 
shows, for the first time, the use of possible biomarkers as a predictor for a successful 
non-union treatment.  
One of the major components of the treatment for long bone non-union is autologous 
bone grafting. Bone grafting is used with proven effectiveness that the transplantation 
of sufficient cells, scaffold and growth factors from other, non-affected, locations to the 
non-consolidating bone can stimulate new bone healing. While this effectiveness of the 
autologous bone grafting in promoting consolidation of non-union is high, it can vary 
considerably among patients from 80 to 90% 20,23. Knowledge on predicting factors is 
limited, but encompass clinical and biological markers. A number of studies reported 
either specific (e.g. scaphoid or tibia) or general (e.g. NUSS score) clinical and 
radiological factors for predicting outcome after treatment of non-unions 24-26. In 
addition, Granchi et al shows a decrease in the biochemical bone turnover markers 
bone-specific alkaline phosphatase and C-terminal propeptide of type I procollagen 
were observed during treatment failure 27. The current study adds to the evidence that 
biomarkers can have prognostic value in the treatment of patients with a non-union in 
addition to clinical parameters. 
Differences in molecular patterns in bone grafts between patients with success and 
failure at a site distant from the non-union may indicate that systemic molecular 
pathologies are partly responsible for the failure of non-union treatment and that non-
union is not a purely local metabolic problem. The decreased concentrations of arginine 
in the non-union callus tissue in a previous study 10 and in the harvested bone in the 
patients with a failed response to the bone harvesting treatment seem to be an 
indication for this hypothesis. 
A sufficient formation of nitric oxide (NO), a free radical, influences vascular reactivity 
12 and stimulates bone cells to regulate bone remodelling during fracture repair 11. 
Through subsequent formation of ornithine, it also stimulates the production of 
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polyamines which are precursors for collagen synthesis 13. Previous studies already 
showed that callus tissue and plasma samples of patients with non-unions have 
abnormal low concentrations of amino acids arginine, citrulline and ornithine when 
compared to normal healed and acute fractures 10. The importance of the NOS isoforms 
during fracture healing have up till now mainly be investigated in in vivo models of 
fracture repair 15-18. Callus tissue of femoral fractures in rats showed a different 
temporal and spatial expression of these isoforms during the healing process. The 
inducible NOS (Nos2) is present during the first inflammatory reaction after sustaining 
the fracture and localized along the edge of the periosteal callus 15,18. Nos3, which is 
constitutively expressed is mainly present during later phases of fracture healing in 
cells lining the blood vessels 15,18. The fact that Nos1 is expressed during the remodelling 
stages 16 led us to not focus on this enzyme during the present study. The correlation of 
NOSs and fracture repair is further emphasized by experiments in which (non)-
selective NOS inhibitors are supplemented to animals after inducing a fracture leads to 
a decrease of cross-sectional callus area 18. Furthermore, genetic deletion of NOS2 or 
NOS3 leads to a decreased bone formation and subsequent non-union formation in mice 
17,28. 
In the current study, we found significantly increased Nos2 expression in RIA tissue 
obtained during the RIA procedure in patients were the bone grafting procedure had 
an unsuccessful outcome, when compared to patients with adequate bone healing after 
the RIA-procedure. An increased Nos2 expression suggests a prolonged inflammatory 
response (i.e. stimulation by NF-κΒ) resulting in the production of proinflammatory 
cytokines as IL-1, TNF-α and IFN-γ. Since a disturbed chronic inflammatory response 
during the fracture healing might result in delayed union or non-union formation, this 
can be the reason that the clinical response to the RIA treatment is inadequate 29,30. The 
significantly lower arginine concentrations that coincide with the higher Nos2 
expression may indicate depletion of this amino acid by an increased catabolic response 
of the patient 31. 
Arg1 is the enzyme converting arginine into ornithine subsequently leading to collagen 
synthesis. RIA procedures resulting in a successful bone healing as well as in 
unsuccessful healing showed a 3- to 4-fold lower expression of arginase 1 when 
compared to normal healed fractures. This might reflect the anabolic response of the 
bone during the healing process which initially was the cause of the non-union 
development and the need for surgical repair. This is also reflected by the lower 
ornithine concentrations measured in the reamed intramedullary aspirate in these 
patients.  
A number of factors are known predictors of development of non-union. While the 
NUSS score is a known factor in patients with a fracture to define the risk of 
subsequently developing a non-union, this study found the NUSS score also to be a 
predictor of the success rate of treatment for the non-union. Interestingly, compared to 
the NUSS score, the activity of the inflammatory response in the grafted material 
obtained by RIA was an even better predictor of therapy success. 
A limitation of this study is the heterogeneity of different characteristics in patients 
included in the current investigation. Especially defect size, NUSS 24,32 (non-union 
scoring scale), Gustilo classification and fracture localization show a wide range for a 
relative low number of patients. Ideally, a large cohort of patients with similar 
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characteristics in all groups is needed to minimalize the possible confounding effects, 
and this study should therefore be regarded a hypothesis generating pilot study to 
determine whether the underlying heterogeneity in our population influenced the 
amino acid concentrations. As for the amino acid concentrations and especially 
arginine, there are several conditions that can alter these concentrations of arginine 
and related amino acids in plasma, such as diabetes mellitus, inflammation are renal or 
hepatosplanchnic dysfunctions, due to the compromising function on the availability 
and conversion of citrulline into arginine 33-36. In addition, other host factors such as 
smoking or alcohol use, the use of NSAIDs, could possibly influence fracture healing 
negatively 2. As shown in table 1, these factors did not significantly differ between the 
control group and both non-union groups, supporting also the clinical relevance of the 
presented results.  
In conclusion, the results presented in the current study indicate an influence of the 
arginine-nitric oxide metabolism in bone grafts harvested by reamed intramedullary 
aspirate on the successful outcome of the autologous bone (marrow) grafting as 
treatment for long bone non-unions. The use of these biomarkers could add to the 
prediction of outcome in addition to the clinical parameters available.
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ABSTRACT 
The role of micro-vesicles (MVs) in transcellular signal transduction has been 
demonstrated in different studies. However, the potential modulatory role of MVs in 
fracture healing remains unclear. Therefore, we investigated the impact of plasma-
derived MVs after a femoral fracture on cranial osteoblasts.  
A femoral fracture with intramedullary stabilization was induced in Sprague Dawley 
rats. The animals were sacrificed 3 days (group A), 1 week (group B), or 2 weeks 
(group C) after trauma induction. Animals without trauma served as controls. 
Osteoblasts from the cranial bone of a neonatal Sprague Dawley rats were cultured 
and stimulated with either plasma-derived MVs or MV-free plasma of groups A–C. 
The effects of MVs on osteoblasts were analysed by growth assay, metabolic assay 
and quantitative real-time polymerase chain reaction (qRT-PCR) for osteocalcin, 
RUNX2 and collagen 1A to test differentiation of osteoblasts.  
MVs were time-dependently incorporated in osteoblasts and localized mainly 
around the nucleus. MVs increased the viability of osteoblasts, particularly in the late 
phase after femoral fracture (group A: 1.22 ± 0.09 absorbance (OD 405nM), p = 
0.0276; group B: 1.30 ± 0.12 absorbance (OD 405nM), p = 0.0295; group C 1.50 ± 
0.22 absorbance (OD 405nM), p = 0.0407) compared to the control group (0.98 ± 
0.02 absorbance (OD 405nM)). Late-phase differentiation of osteoblasts was not 
stimulated by MVs, but by MV-free plasma (Osteocalcin, groups C vs. control, p = 
0.0454). The levels of transforming growth factor β1 (TGF-β1) and insulin-like 
growth factor 1 (IGF-1) were significantly higher in MV-free plasma than in MVs.  
MVs seem to modulate the viability of osteoblasts but not to affect osteoblast 
differentiation. Further studies are warranted to determine the characteristics and 
interactions of MVs. Potentially, MVs might act as a diagnostic or therapeutic tool in 
cases of impairment of fracture healing. 
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7.1. INTRODUCTION  
Micro-vesicles (MV) represent a subset of extracellular vesicles secreted by blebbing 
and shedding from plasma membranes. They are thought to play a significant role in 
transcellular signal transduction 1,2.  
MVs contain diverse signalling factors (e.g., miRNAs, surface molecules, and 
proteins) and are of major importance in cell-to-cell communication 2. Different 
stimuli, such as cytokines, bacterial lipopolysaccharides, reactive oxygen species, 
thrombin, and C-reactive protein, result in significant changes in both the secretion 
patterns and contents of MVs 3. These alterations can result in a fundamental change 
in MV-related signalling transduction 4. Moreover, MVs selectively bind to cells via 
specific surface molecules rather than non-specifically interacting with various cell 
types 2,5.  
Due to the diversity of cell types (e.g., platelets, macrophages, endothelial cells, 
osteoblasts, and osteoclasts) involved in the complex process of fracture healing, 
synergistic interactions between these cells are essential. MVs are thought to play an 
important role in intercellular communication of the above-mentioned cells 6-8. For 
example, in vitro studies demonstrated that MVs originating from either endothelial 
cells or mesenchymal stem cells (MSCs) had the potential to stimulate angiogenesis 
9,10. In addition, studies showed that MVs secreted by osteoblasts contained the 
receptor activator of the nuclear factor-kappa B (NF-κB) ligand (RANKL), which is 
known to be involved in the regulation of osteoclast function 11. Furthermore, 
isolated MVs from bone marrow were shown to have the potential to stimulate the 
differentiation of osteoblasts 12.   
Despite the aforementioned findings, knowledge about the role of MVs during 
fracture healing remains sparse, especially the effects of systemically derived MVs 
on fracture healing. Therefore, in this study, we aimed to characterize the pattern of 
systemic release of MVs after induction of a femoral fracture and throughout the 
subsequent healing process. Furthermore, whether these MVs influence function of 
osteoblasts was investigated.  
7.2. MATERIALS AND METHODS  
7.2.1. General aspects   
This study was approved by the North Rhine-Westphalian State Agency for Nature, 
Environment and Consumer Protection (Reg. no.: 84-02.04.2015.A078). All the 
experiments were performed in accordance with “Guide for the Care and Use of 
Laboratory Animals” by the National Research Council (US) Committee for the 
Update of the Guide for the Care and Use of Laboratory Animals. In total, 24 female 
Sprague Dawley (SD) rats aged 8–10 weeks were used. Due to the protective effects 
of female hormones in cases of inflammatory stimuli, all the animals were in the same 
phase of the oestrous cycle as determined by vaginal swabs. An overview of the study 
protocol is provided in figure 7.1. 
7.2.2. Study groups  
The rats were randomly allocated into a control group and three treatment groups 
(group A, B, and C; 6 animals/group). The animals in group A were sacrificed 3 days 
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post-fracture, whereas those in groups B and C were sacrificed 1 week and 2 weeks 
post-fracture, respectively.   
 
 
Figure 7.1. Flow chart of the study. The animals were divided into four groups, with six animals in each 
group. They were randomly allocated into three treatment study groups (A, sacrificed after 3 d), (B, 
sacrificed after 1 week), and (C, sacrificed after 2 weeks) and a control group. Animals from study groups 
underwent femur fracture and fixation of right hind limbs under anaesthesia. Blood was taken from the 
animals by heart puncture after sacrifice. The micro-vesicle (MV) concentration within plasma was tested 
by nanoparticle tracking analysis. Then, MVs were isolated from plasma by centrifugation, and the TGF-
β1 and IGF-1 of both MV and MV-free plasma were tested by an enzyme-linked immunosorbent assay. To 
test the influence of the MVs from the animal model, primary osteoblasts were isolated from neonatal 
cultured with culture medium prepared from MV-containing plasma, MVs, and MV-free plasma 
respectively. The reactions of the osteoblasts to the MVs were tested by a growth assay, 3(4,5-
Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) tests, and quantitative real-time-
polymerase chain reaction (qRT-PCR).  
 
7.2.3. Animal fracture model  
The femur fracture model has been previously described 13 and was applied with 
minor changes. Briefly, the rats were anesthetized with an intraperitoneal (i.p.) 
injection of ketamine 100mg/kg i.p. (Pfizer, New York, USA) and xylazine 2% 
10mg/kg i.p (Xylapan, Vetoquinol, Ravensburg, Germany) before operation. 
Analgesia was induced with an additional subcutaneous (s.c.) application of 
buprenorphine hydrochloride (0.03-0.05mg/kg) (Reckitt Benckiser Healthcare Ltd., 
U.K.). Afterwards, isoflurane (2–2.5% by volume) was also given consistently via a 
nasal mask during operation. The adequate anaesthesia was assured by toe pinch 
reflex test. After anaesthesia, a Kirschner wire (1.4 × 26 mm) was inserted 
intramedullary in the right hind limb femur in treatment groups A, B, and C. A 
fracture of the femoral shaft was then induced by a 1 kg plumb-cuboid blunt 
guillotine, which was dropped from a height of 20 cm. Fracture induction and the 
correct position of the Kirschner wire were confirmed by X-rays (figure 7.2. A). 
Buprenorphine hydrochloride (0.03 mg/kg s.c. every 6–8 h for 48 h, subsequently 
every 12 h for 3 weeks) and Meloxicam (Metacam; Ingelheim, Germany, Boehringer 
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Ingelheim GmbH) (1ml/300ml into drinking water for 1 week) were given after 
fracture induction.   
At the end of the study period, the animals were sacrificed by cardiac puncture under 
adequate anaesthesia and analgesia. Blood was collected in ethylenediamine 
tetraacetic acid embedded tubes (SARSTEDT, Nürnbrecht, Germany) and centrifuged 
at 1,200 g for 5 min at 4° C. The plasma was then stored at -80° C.   
7.2.4. MV counts and sizes   
Analysis of the concentrations and sizes of MVs in plasma was performed by 
nanoparticle tracking analysis (NanoSight 300; NTA, NanoSight Ltd., Amesbury, 
U.K.). For the analysis, 100 μl of plasma was centrifuged at 5,000 g for 20 min to 
remove platelets and apoptotic bodies. The plasma was then diluted to 200 μl with 
phosphate buffered saline (PBS), which was filtered through a 0.2-μm sterile syringe 
filter (Corning, NY, USA). Samples were then analysed by NanoSight 300 in 
accordance with the manufacturer’s instructions.  
7.2.5. MV isolation and MV-free plasma generation  
MV isolation was performed according to a previously reported method 14. Briefly, 
the plasma obtained from each animal was centrifuged at 5,000 g for 20 min. The 
supernatant was then centrifuged again at 17,000 g for 90 min. The supernatant after 
second centrifuge was collected as MV-free plasma. The pellet (including the MVs) 
was resuspended in PBS. The MVs were washed a second time, centrifuged at 17,000 
g for 90 min, and dissolved in PBS.   
7.2.6. Transmission electron microscopy of MVs  
Unfixed isolated MVs were allowed to adsorb for 10 min on formvar-carbon-coated 
nickel grids (200 mesh), which was glow discharged for 2 min (Maxtaform; Plano, 
Wetzlar, Germany). After washing twice with Aqua Dest (Science Services GmbH, 
Munich, Germany), the samples on grids were stained using a drop of 0.5% uranyl 
acetate in Aqua Dest. After air drying, the samples were examined using a LEO 906 
(Carl Zeiss, Oberkochen, Germany) transmission electron microscope, operating at 
an acceleration voltage of 60 kV.  
7.2.7. Osteoblast isolation, culture, and identification  
Osteoblast isolation (rat cranial bone) and culture were performed from a neonatal 
SD rat according to a previously described protocol 15. The culture medium was 
changed every 3 days until the cells covered around 80% of the plate. After 
trypsinization (Gibco; Thermo Scientific), the cells were collected and seeded into 
culture flasks (Culturestar, Greine rbio-one GmbH, Frickenhausen, Germany). Third-
passage cells were used for further analyses.  
To identify osteoblasts, a bone formation assay was performed (Figure 2B). Isolated 
osteoblasts were cultured on a six-well plate with 2 mM β-GP (β-Glycerol phosphate, 
St. Louis, Missouri, USA. Sigma Aldrich), 10 nM dexamethasone (Merck Serono 
GmbH, Darmstadt, Germany), and 50 μg/ml of ascorbate (Sigma Aldrich). The pH was 
adjusted to 7.4, and 50% of the culture medium was changed every third day. After 
14 days, the cells were washed with PBS two more times, fixed in formaldehyde for 
15 min, and washed twice with PBS. After air drying, the cells were stained with 
7
153
CHAPTER 7 | 
154 
Alizarin Red S (Sigma Aldrich) for 5 min and washed with 50% ethanol (AppliChem, 
Darmstadt, Germany) three times.   
7.2.8. Imaging of fluorescently labelled MVs  
The MVs and the same volume of PBS as a control were incubated with WGA-Alexa 
Fluor™ 594 solution (0.5 µg/ml Wheat Germ Agglutinin, Alexa Fluor™ 594 conjugate; 
Thermo Fisher, Waltham, USA) for 10 min, washed twice with DMEM (Dulbecco's 
Modified Eagle Medium, Thermo Fisher) and after centrifugation at 17,000 g 
resuspended in DMEM (Dulbecco's Modified Eagle Medium, Thermo Fisher). The 
osteoblasts were cultured in a 24-well plate on sterilized cover slips. The cells were 
incubated with the stained MVs for 10 min, 30 min, and 1 h. The control plate was 
cultured for 1 h. Subsequently, the cover slips were washed with PBS, liquid was 
removed with blotting paper, and mounting medium (SlowFade™ Diamond Antifade 
Mountant with DAPI (4',6-diamidino-2-phenylindole); Thermo Fisher) was used to 
mount the cells and stain the nuclei. The samples were analysed by confocal 
microscopy (LSM 710; Carl Zeiss Microscopy GmbH, Jena, Germany). A Z-stack was 
generated, and a 3D image reconstructed using ZEN 2.3 software (Blue edition; Carl 
Zeiss Microscopy GmbH) to identify intracellular MVs.  
7.2.9. Transforming growth factor-β1 (TGF-β1) and insulin-like growth factor 
1 (IGF-1) analysis in MVs and MV-free plasma  
Commercialized enzyme-linked immunosorbent assay kits were used to determine 
the concentration of TGF-β1 (Boster Biological Technology, CA, USA) and IGF-1 
(Cloud Clone Corp., Wuhan, China). MVs were isolated from 100 µl plasma and lysed 
with 100 µl peqGOLD TriFast™ (peqlab, VWR International GmbH, Radnor, 
Pennsylvania, USA). The MV solution and MV-free plasma was then analysed 
according to the protocol.   
7.2.10. Experimental culture medium (CM)  
Four kinds of CMs were used, and for the following assays four kinds of culture 
medium were prepared: 
1. Normal culture medium was prepared with DMEM, 100 U/ml of penicillin, 50 
μg/ml of streptomycin sulphate, and 10% FBS (Foetal bovine serum, Thermo 
Fisher);  
2. Normal culture medium containing MVs isolated from plasma resuspended in a 
comparable amount of FBS (MV-contained culture medium, MVCM) was prepared 
with DMEM, 100 U/ml of penicillin, 50 μg/ml of streptomycin sulphate, and 10% FBS 
and MV;  
3. Culture medium containing plasma from groups A, B, C or the control (plasma 
contained culture medium, PCM) was prepared with DMEM, 100 U/ml of penicillin, 
50 μg/ml of streptomycin sulphate, 5% plasma from the animals from groups A, B, 
and C, and 5% FBS;  
4. MV-free plasma culture medium was prepared with DMEM, 100 U/ml of penicillin, 
50 μg/ml of streptomycin sulphate, 5% FBS, and 5% MV-free plasma from the 
animals in groups A, B and C.  
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7.2.11. Growth assay  
Osteoblasts (5,000 per well) were seeded in 24-well plates (TPP, Trasadingen, 
Switzerland) and cultured with 500 μl of PCM. For each test, triple wells were used 
as repeats. The medium was changed every third day. After 3, 5, and 8 days, the cells 
were digested with trypsin, and the total number of cells was counted with Neubauer 
chamber.   
7.2.12. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) 
assay   
An MTT assay was performed to evaluate the viability and proliferation of the 
osteoblasts 16. For the assay, 10,000 osteoblasts per well were seeded in 96-well 
plates and cultured in 200 μl of four kinds of CMs (1. to 4.) for 4 days. Each CM 
experiment was repeated three times. On the fourth day, 20 μl of 5 mg/ml of MTT 
(Sigma Aldrich) were added into each well and incubated for 4 h. The supernatant 
was then extracted, and 100 μl of dimethylsulfoxide (Sigma Aldrich) was added in 
each well and gently shaken in the dark for 10 min. The optical density value was 
measured with wavelengths of 490 nm and 690 nm (for correction).   
7.2.13. Quantitative real-time polymerase chain reaction (qRT-PCR)  
The osteoblasts were cultured with four kinds of CMs (1. to 4.) for 5 days and then 
dissolved with peqGOLD TriFast™. Total RNA was extracted, and cDNA was 
synthesized with cDNA kits (Thermo Scientific). The qRT-PCR was performed with 
SYBR Green real-time PCR Master Mix Reagent (Thermo Scientific) on a StepOne™ 
Real-Time PCR System (Applied Biosystems, Waltham, Massachusetts, USA). The 
expression of runt-related transcription factor 2 (RUNX2), osteocalcin, and collagen 
1A were analysed. Peptidylprolyl isomerase A (PPIA) was used as the housekeeping 
gene. The sequences of the primers are listed in table 7.1. The analysis of gene 
expression was performed using the 2 -ΔΔCT method (%PPIA) 17.  
 
Table 7.1. Primers of qRT-PCR 
 
 
7.2.14. Statistical analysis  
Excel 2016 (Microsoft, Redmond, Washington) and GraphPad Prism 7.0 (GraphPad 
Software, La Jolla, USA) were used for data collection and statistical analysis. The 
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Kolmogorov–Smirnov test was applied to test for a normal distribution. An analysis 
of variance, student’s t-test, and Kruskal–Wallis test were performed to test 
significance, and p < 0.05 was accepted as denoting statistical significance. 
7.3. RESULTS  
7.3.1. Animal model  
To obtain plasma from the trauma model, three groups of animals underwent femur 
fracture and fixation of right hind limbs under anaesthesia. All the animals survived 
until the end of the group-specific study period. Correct fixation by intramedullary 
pins was verified by an X-ray. Osteosynthesis resulted in appropriate stabilization of 
the femoral fracture (Figure 7.2.A). No sign of infections or other complications were 
observed. Animals were sacrificed after 3 days, 1 week and 2 weeks and blood 
plasma was collected through heart puncture.  
 
Figure 7.2. Fracture fixation and primary osteoblast isolation. A) Animals from study groups 
underwent femur fracture and fixation of right hind limb with a Kirschner wire under anaesthesia. A 
fracture of the right femur shaft and fixation were confirmed by an X-ray. B) Primary osteoblasts were 
isolated from the cranial bone of a neonatal rat. To certify the osteogenesis of these osteoblasts, a bone 
formation assay was performed. Osteogenic differentiation was assessed by Alizarin Red S staining, 
showing the presence of matrix mineralization in orange (× 60 magnification).  
 
7.3.2. Identification of MVs   
To identify MVs from the animal model, EM (electronic microscopy) was used. 
Figures 7.3.A and 7.3.B show representative EM images of MVs. Nanoparticle 
tracking analysis was used to assess size and amount of MVs. Figure 7.3.C shows a 
typical presentation of MVs obtained by nanoparticle tracking analysis (from 2 
weeks group). The average size of the MVs was 185.1 ± 4.7 nm. A typical size 
distribution is shown in Figure 3D. There was no significant difference in the MV 
concentrations of the control and study groups (Figure 7.3.E).  
7.3.3. MV uptake of osteoblasts  
To verify that MVs from the trauma model could be taken up by osteoblasts, 
fluorescently labelled MVs were co-cultured with primary cranial osteoblasts. 
Condensed red fluorescence was observed inside the osteoblasts indicating 
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incorporation of MVs (Figure 7.4.A). The amount of incorporated MVs increased with 
the time of incubation. No intracellular red fluorescence was observed in the control 
group without labelled MVs. The 3D reconstruction of confocal images (Figure 7.4.B) 
showed that the MVs were located around the nuclei. These results indicated that the 
cultured osteoblasts were able to incorporate MVs generated under trauma 
conditions located in the plasma. 
 
Figure 7.3. Identification of MVs by electronic microscopy and nanoparticle tracking analysis. A 
and B) To identify the MVs from plasma, a transmission electron microscopy was used (A, 27,800x 
magnification; B, 60,000x magnification). Arrows denote MVs. The marked MVs shown in B are 152.62 × 
197.14 nm and 169.11 × 148.62 nm in size. C, D and E) MVs were analysed with nanoparticle tracking 
system (NanoSight 300; NTA, NanoSight Ltd.). C shows a typical image of MVs observed by nanoparticle 
tracking analysis. D shows a typical size distribution of the MVs. No significant differences were found 
across study groups. E shows the MV count in plasma. There were no significant differences in the MV 
concentrations among the study groups. 
 
7.3.4. Concentrations of TGF-β1 and IGF-1 in MVs and MV-free plasma  
To locate and quantify osteogenic cytokines in the plasma, concentrations of TGF-β1 
and IGF-1 were measured with ELISA kits. Compared to the control group (TGF-β1 = 
64.98 ± 20.44 pg/ml; IGF-1 = 11,107 ± 885 pg/ml), TGF-β1 (24.03 ± 6.4 pg/ml) and 
IGF-1 (6,605 ± 996 pg/ml) concentrations in MV-free plasma were significantly 
lower at day 3 (group A) (p = 0.0320 and p = 0.0211, respectively). The levels of TGF-
β1 and IGF-1 within MVs were not significantly different between the control and 
study groups. In general, the levels of TGF-β1 and IGF-1 were significantly higher in 
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MV-free plasma than in MVs (Figure 7.5.), which proved that TGF-β1 and IGF-1 were 
mostly located within the MV-free plasma rather than in MVs.  
 
 
Figure 7.4. Imaging of fluorescently labelled MVs. A) Isolated and fluorescently labelled MVs were co-
cultured with primary osteoblasts for 10 min., 30 min. and 1 hour. Row 1 shows nuclei of osteoblasts in 
blue (stained with DAPI). Row 2 shows micro-vesicles (MVs) in red (labelled with WGA-Alexa Fluor™ 594). 
Row 3 shows merging of rows 1 and 2. As the incubation time was increased from 10 min to 1 h, the MVs 
accumulated within the cells. No MVs (red fluorescence) were found in the control group. The scale bar 
represents 50 µm. B) 3D representation of a z-stack recorded by confocal microscopy. The MVs are 
enriched around the nuclei. The scale bar represents 10 μm. 
 
7.3.5. Growth and differentiation of osteoblasts cultured in PCM  
To assess the influence of full trauma plasma on proliferation and differentiation of 
primary osteoblasts, osteoblasts were cultured in PCM, made by plasma from study 
animals. A growth assay was performed, and mRNA expression of osteogenic genes 
was analysed. As shown in figure 7.6., plasma from group B at day 5 after incubation 
(3.46 ± 1.59 x 104 vs. 2.06 ± 1.31 x 104 cell count, p = 0.0318) and from group C at 
day 8 after incubation (11.31 ± 4.77 x 104 vs. 4.02 ± 1.03 x 104 cell count, p = 0.009), 
significantly stimulated the growth of osteoblasts comparing with the control group. 
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Figure 7.5. Transforming growth factor- β1 (TGF-β1) and insulin-like growth factor 1 (IGF-1) in 
MVs and in MV-free plasma. MVs from 100 μl plasma were lysed with equal amount of peqGOLD 
TriFast™. Concentrations of TGF-β1 and IGF-1 were measured with by ELISA. Data from animals without 
fracture were set as control. In all groups, concentrations of TGF-β1 and IGF-1 differed significantly 
between MV and MV-free plasma. The concentration of TGF-β1 in group A (3 days) was significantly 
decreased compared to the control group (24.03 ± 6.4 vs. 64.98 ± 20.44 pg/ml, p = 0.032). The IGF-1 
concentration in group A (3 days) was significantly decreased compared to the control group (6,605 ± 996 
vs. 11,107 ± 885 pg/ml, p = 0.0211). # p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.  
Figure 7.6. Growth assay. Osteoblasts from the study and control groups (non-fracture) were cultured 
with plasma. Plasma from group B (1 week) significantly stimulated the proliferation of osteoblasts at 5 
days of incubation (p = 0.0318) and plasma from group C (2 weeks) significantly stimulated the 
proliferation of osteoblasts at 8 days of incubation (p = 0.009). 
 
PCM was associated with an increase in osteoblast viability over time, with 
significantly higher viability in group C as compared with that in the control group 
(1.13 ± 0.09 vs. 0.65 ± 0.12 absorbance (OD 405nM); p = 0.0393) (Figure 7.7.A). As 
previously reported, RUNX 2 and collagen 1A synthesis served as markers of early-
phase osteogenesis, and osteocalcin synthesis as late-phase osteoblastic 
differentiation markers 18. Osteocalcin mRNA expression of osteoblasts was reduced 
7
159
CHAPTER 7 | 
160 
in the early post-trauma phase (≤ 1 week) as compared with that in the controls 
(group B vs. control: 2.07 ± 2.47 vs. 7.14 ± 5.29 PPIA%, p = 0.0172, Figure 7.7.C). In 
the later phase (2 weeks) a significant increase occurred (group B vs. C: 2.07 ± 2.47 
vs. 10.31 ± 1.76 PPIA%, p = 0.0021). Comparisons of collagen 1A and RUNX2 revealed 
no significant differences in any of the groups (Figure 7.7.B and 7.7.D). These results 
indicated that, plasma from traumatized animals influences growth and 
differentiation of the primary osteoblasts.  
  
Figure 7.7. Influence of plasma from trauma animals on primary osteoblasts. Primary osteoblasts 
were cultured with medium containing plasma from fracture model (PCM). Data from animals without 
fracture were set as control. A) Osteoblast viability was tested by 3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT). Results showed significantly increased in group C (1.13 ± 0.09 vs. 
0.65 ± 0.12 absorbance (OD 405nM); p = 0.0393). B, C, and D) The osteogenesis mRNA expression of runt-
related transcription factor 2 (RUNX2), osteocalcin, and collagen 1A were measured by qRT-PCR. As 
compared within osteocalcin, mRNA expression was lower in group B as compared to the control group 
(2.07 ± 2.47 vs. 7.14 ± 5.29 PPIA%, p = 0.0172), and to group C (2.07 ± 2.47 vs. 10.31 ± 1.76 PPIA%, p = 
0.0021). There was no significant difference in RUNX2 and collagen 1A expression in any of the groups. (* 
compared with the control group, p < 0.05, ## p < 0.01). 
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Figure 7.8. Influence of plasma-derived micro-vesicles (MVs) from the fracture model on primary 
osteoblasts. Primary osteoblasts were cultured with medium containing MVs from fracture model 
(MVCM). Data from animals without fracture were set as control. A. Viability of osteoblasts was tested by 
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. A) Significant increases in 
osteoblast viability were observed (group A: 1.22 ± 0.09 absorbance (OD 405nM), p = 0.0276; group B: 
1.30 ± 0.12 absorbance (OD 405nM), p = 0.0295; group C 1.50 ± 0.22 absorbance (OD 405nM), p = 0.0407), 
compared to the control group  (0.98 ± 0.02 absorbance (OD 405nM). B, C, and D) The osteogenesis mRNA 
expression of runt related transcription factor 2 (RUNX2), osteocalcin, and collagen 1A were measured by 
qRT-PCR. Only osteocalcin mRNA expression was significantly reduced in group C (0.07 ± 0.04 PPIA%, p= 
0.0395) as compared with that in control (0.39 ± 0.14 PPIA%). There was no significant difference 
between groups in RUNX2 and collagen 1A expression. (*p < 0.05).  
 
7.3.6. Viability/proliferation and differentiation of osteoblasts cultured in 
MVCM  
The functions of MVs from trauma plasma on primarily cultured osteoblasts were 
assessed. MVs from trauma and control plasma were isolated, and co-cultured with 
the primary osteoblasts in culture medium made from FBS (MVCM). As depicted in 
figure 7.8.A, stimulation with MVs resulted in a significant increase in osteoblast 
viability in all the study groups (group A: 1.22 ± 0.09 absorbance (OD 405nM), p = 
0.0276; group B: 1.30 ± 0.12 absorbance (OD 405nM), p = 0.0295; group C 1.50 ± 
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0.22 absorbance (OD 405nM), p = 0.0407) compared to the control group  (0.98 ± 
0.02 absorbance (OD 405nM)). Osteocalcin was significantly reduced in group C 
compared to the control group (0.07 ± 0.04 vs. 0.39 ± 0.14 PPIA%, p = 0.0395) (Figure 
7.8. C). There expression of osteocalcin was also decreased in group A and B (p = 
0.0686, p = 0.0708), however they did not show statistical significance. Analysis of 
RUNX 2 and collagen 1A revealed no significant differences between the control and 
study groups (Figure 7.8.B and 7.8.D). These results showed the ability of MVs from 
trauma plasma to influence viability and differentiation of osteoblasts.  
 
 
Figure 7.9. Influence of micro-vesicle (MV)-free plasma from the fracture model on primary 
osteoblasts. Primary osteoblasts were cultured with medium containing MV-free plasma from fracture 
model. Data from animals without fracture were set as control. A) Viability of osteoblasts was tested by 3-
(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. MV-free plasma from 3 days 
(group A) post-fracture (0.93 ± 0.07 vs. 0.55 ± 0.11 absorbance (OD 405nM), p = 0.0171) significantly 
improved the viability of osteoblasts. No significance was found within the other groups. B, C, and D) The 
osteogenesis mRNA expression of runt-related transcription factor 2 (RUNX2), osteocalcin, and collagen 
1A were measured by qRT-PCR. The level of osteocalcin mRNA expression after 2 weeks (group C) was 
significantly higher than that in the control group (3.48 ± 2.91 vs. 1.09 ± 0.19 PPIA%, p = 0.0454). There 
was no significant difference in RUNX2 and collagen 1A expression in any of the fracture groups (*p < 
0.05). 
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7.3.7. Viability/proliferation and differentiation of osteoblasts cultured in MV-
free plasma culture medium   
To further distinguish the function of MVs and soluble components of the trauma 
plasma, a MTT assay and mRNA expression of osteogenic genes were also analysed 
on primary osteoblasts cultured with MV-free plasma from study animals. MV-free 
plasma from group A (0.93 ± 0.07 absorbance (OD 405nM), p = 0.0171)) significantly 
stimulated viability of primary osteoblasts, as compared with the control group (0.55 
± 0.11 absorbance (OD 405nM)). (Figure 7.9.A) However, no significant differences 
in viability of primary osteoblasts were found between all the other groups. 
Osteocalcin expression was significantly higher in group C as compared with that in 
the control group (3.48 ± 2.91 vs. 1.09 ± 0.19 PPIA%, p = 0.0454). No differences 
were detected in RUNX2 and collagen 1A expression (Figure 7.9.B, 7.9.C, and 7.9.D). 
Comparing  MVs in the trauma plasma, MV-free plasma stimulated viability and 
differentiation of the primary osteoblasts at certain time points. 
7.4. DISCUSSION   
Successful fracture healing involves a complex interaction between a variety of 
cellular components and signalling molecules 1. Dysfunction of any of these cellular 
components or disturbances of signalling mechanisms affects fracture healing. In this 
study, we aimed to investigate the interaction of systemic MVs from a rat fracture 
model with osteoblasts. Our main results can be summarized as follows:   
1. MVs isolated after a femoral fracture were time-dependently incorporated in 
osteoblasts and concentrated around the nucleus.   
2. The stimulatory effect of trauma plasma on osteoblast proliferation depends on 
the post-fracture time.  
3. MVs from trauma plasma increased the viability of osteoblasts, particularly in the 
late phase (i.e., 2 weeks post-fracture) after a femoral fracture.  
4. Late-phase differentiation of osteoblasts was not stimulated by the MVs in a high 
extent. In contrast, MV-free plasma seemed to have a stimulatory effect on 
differentiation in the late phase (2 weeks after fracture).   
Previous studies described increased osteoblast growth 2 weeks after a fracture 19,20. 
In accordance with this finding, in a rat model, we found enhanced growth of 
osteoblasts stimulated with plasma from 1 and 2 weeks after fracture. The 
stimulatory effect increased with the time elapsed since trauma. Therefore, plasma, 
specifically plasma mediators have the potential to modulate fracture healing. 
Among these mediators, studies reported that TGFβ and IGF-I represented important 
growth factors for osteoblasts 21. TGF-β and IGF-1 were secreted after different 
inflammatory stimuli and appeared to be good indicators of the fracture-healing 
process 21. In our study, both TGF-β1 and IGF-1 in MV-free plasma decreased in the 
first week post fracture. These findings are consistent with those of previous 
publications 21,22 and therefore indicate the reliability of our model. To the best of 
our knowledge, no other studies have described the characteristics and kinetics of 
TGF-β1 and IGF-1 concentrations in MVs after fractures. We found significantly 
lower levels of TGF-β1 and IGF-1 in MVs compared to MV-free plasma, with no 
relevant changes in intra-vesicular TGF-β1 and IGF-1 levels over the entire 
observation period.   
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MVs originate from a variety of cells and indicate the functional status of an organism 
at a specific time point. In previous studies, MVs were detected in the systemic 
circulation after diverse insults (e.g. severe trauma, stress) 23-25. Previous studies 
provided evidence that MVs seemed to be of major importance for intercellular 
communication in order to regulate bone metabolism 11,12,26,27. In this context, 
osteoblastic MVs were found to be important for cell-cell communication of 
osteoblasts with both osteoclasts 11 and MSCs 27, these MVs were able to incorporate 
into cells (e.g., integration of MV-derived osteoclasts into osteoblasts) 28-30. These 
findings are in line with those obtained in our study, which revealed the integration 
of plasma-derived MVs into osteoblasts and their aggregation around the nuclei. 
Based on the observed accumulation, it can be postulated that MV integration is 
faster than intracellular degradation of MVs. These results could explain both the 
potential impact of MVs on cellular function and the importance of MVs as mediators 
of intracellular communication.   
As indicated by the results of the MTT assay in our study, plasma-derived MVs 
seemed to have the potential to stimulate the viability and proliferation of 
osteoblasts, particularly in the late phase (i.e., 2 weeks) after fractures, whereas MV-
independent mechanisms appeared to be more relevant in the early phase after 
trauma. Accordingly, others also found stimulatory effects of both bone marrow-
derived MVs on osteoblast function 12 and effects of pluripotent stem cell-derived 
MVs on angiogenesis and osteogenesis 26.   
Previous studies have provided evidence that incorporated extracellular vesicles 
(e.g., originating from bone marrow stem cells or prostate cancer cell lines) affect 
osteoblast differentiation 12. In this context, several studies demonstrated that 
osteoblast-derived MVs had the potential to stimulate the differentiation of stem 
cells into osteoblasts 31,32. In contrast, we found that late-phase differentiation of 
osteoblasts, represented by osteocalcin synthesis 18 was almost exclusively 
stimulated by mediators located in plasma but not by plasma-derived MVs alone. 
These diverse findings might be explained by different factors. First, the low 
osteocalcin expression after plasma-derived MVs stimulation in our study might be 
associated with the stimulatory effects of these MVs on the viability and proliferation 
of osteoblasts. In this context, Owen et al. found low expression of osteocalcin mRNA 
during the proliferation phase of osteoblasts 33. Furthermore, studies observed that 
different factors (e.g., mediators and dynamic cell stretching) that promote the 
proliferation of osteoblasts simultaneously inhibited osteocalcin expression 34,35. 
Second, it is possible that the different origins of the investigated MVs (plasma vs. 
bone marrow stem cells) result in different effects on osteocalcin expression. 
Therefore, additional studies are needed to investigate the characteristics (e.g., 
content and receptor status) of MVs originating from diverse cell types.   
As determined by the analysis of RUNX 2 and collagen 1A synthesis (early-phase 
osteoblastic differentiation markers) 18, we observed no significant differences in the 
early phase differentiation of osteoblasts among the control and experimental 
groups following MVs and MV-free plasma stimulation. Several reason might explain 
this result. First, these findings may point to a comparable effect of both MVs and 
plasma on early osteoblastic differentiation. Second, as the synthesis of RUNX2 and 
collagen 1A in the trauma groups were not significantly different to that in the 
controls, the findings may indicate that the primary osteoblasts from this protocol 
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are in an early differentiation phase, with a stable expression of RUNX2 and collagen 
1A.   
Limitations. First, as our findings were derived from an animal model, they are not 
directly transferable to humans. However, the results from this study showed a 
potential role of osteoblast modulation by MVs, which may help in modulating 
osteogenesis after fracture or orthopaedic operations. Further in vivo and 
translational studies will be conducted in our lab in the future. Second, the amount 
of plasma harvested from this rat trauma model was limited, whereas the 
consumption of the cell culture and tests was high. This limited the possibility of 
further analyses, such as MV phenotype, miRNA analysis and in vivo studies. Thus, 
additional studies are needed to further elucidate the role of MVs in osteoblastic 
function post-fracture. In the following studies, larger animals may be needed in 
studies to increase both the availability of material for analysis, as well as the 
translational relevance. Finally, the centrifuge protocol for MV isolation does not 
exclude the presence of small amounts of other components (e.g., exosomes) that 
might have an impact on osteoblast functions 14.   
7.5. CONCLUSIONS  
The fracture healing process involves a complex network of signal transduction 
between a variety of cells. Our study showed a potential effect of MVs on regulating 
fracture healing, by modulating the viability and proliferation of osteoblasts. 
Therefore, MVs may possibly have potential therapeutic uses in cases of fracture 
healing disturbances. This should be clarified in further translational studies.  
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ABSTRACT 
Introduction: Excessive activation of the immune response after femoral fractures 
and fracture fixation is potentially associated with the development of systemic and 
local complications, particularly in multiple trauma patients. A dysregulated function 
of neutrophils, the most prevailing immune cells in circulation, has been discussed 
as a central pathophysiological background for these unfavourable post-traumatic 
courses. Our aim was to investigate alterations in activity and functionality as 
expressed by the cell surface receptor dynamics of circulatory neutrophils after 
femoral fracture and intramedullary stabilization. 
Material and Methods: After intramedullary stabilization, an isolated femur fracture 
was induced in 18 Sprague-Dawley rats. Animals were terminated at different time 
points, i.e. after 3 (n = 5, group 3d), 7 (n = 5, group 7d) and 14 (n = 5, Group 14d) 
days and grouped accordingly. Additionally, baseline measurements were 
performed in one control animal per study group (n = 3) after anaesthesia induction 
and termination, without prior intramedullary nailing and fracture induction. The 
numbers and cell surface expression of CD11b, CD11a, CD62L, and CD49d of 
circulating neutrophils were compared between groups. 
Results: Neutrophil numbers were significantly reduced at 3 days compared with 
baseline measurements (1.2 x105 vs. 6.3 x105 cells/ml, p < 0.01). By day 7, neutrophil 
counts significantly increased back to homeostatic levels (p < 0.05). At day 3, CD11b-
expression was significantly reduced, whereas CD11a-expression was increased 
compared with the baseline measurements (p < 0.05). At day 7, the circulatory 
neutrophil pool exhibited a unique CD11bhigh/CD11ahigh-neutrophil subset showing 
a significantly increased co-expression of CD49d. The expression of CD62L did not 
change significantly throughout the experiment compared with baseline 
measurements. 
Conclusions: This descriptive small animal fracture study is the first to show that an 
intramedullary stabilized femur fracture is associated with a temporary reduction in 
circulatory neutrophil count and concurrent changes in circulatory neutrophil 
function. Moreover, we demonstrated that the restoration to homeostatic neutrophil 
activation status occurs concomitantly with the appearance of a novel neutrophil 
subtype (CD11bhigh/CD11ahigh) in circulation.  
Our fundamental new findings of the changes in circulatory neutrophil count and 
functionality after trauma form an excellent basis for future studies to further 
elucidate the role of neutrophils as activators and regulators of different post-
traumatic processes, potentially resulting in local (e.g., fracture healing 
disturbances) or systemic (e.g., MODS) complications. This might result in the 
development of specific therapies to reduce adverse outcomes after trauma. 
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8.1. INTRODUCTION 
It is well-known that particularly in subgroups of multiple trauma patients, femur 
fractures and their intramedullary stabilization might result in a higher incidence of 
post-traumatic complications 1,2. Post-traumatic activation of the immune response 
has been shown to play a central role in these unfavourable events over the clinical 
course. It is assumed that neutrophils, the most prevailing immune cells in the 
human circulation system, play a central role in pathophysiological processes, 
potentially leading to systemic and local complications 3,4.  
At the local level at the fracture site, neutrophils are one of the first cells that 
permeate into the fracture hematoma. Here, they differentiate into different subsets, 
synthesize an “emergency extra cellular matrix,” and initiate the inflammation stage 
of fracture healing 2,5. At this stage, recruited immune cells clear the fracture area 
from pathogens and cell debris, restricting tissue damage 6. On the other hand, if this 
stage is not terminated adequately, damage of even uninjured tissue because of an 
excessive stimulation of neutrophils can occur 6. In this way, even systemic 
complications can occur because of the infiltration of neutrophils into lung 
parenchyma, with the subsequent formation of oedema, leading to tissue and, 
eventually, organ damage 7-9. 
Neutrophil tissue homing is regulated by alterations in the expression of cell surface 
receptors. Various selectins, including L-selectin (CD62L), are initially upregulated 
and later shed from the cell surface to enable vessel wall adherence and to initiate 
deceleration and rolling. In addition, integrin upregulation, including macrophage-1 
antigen (Mac-1 or CD11b) and lymphocyte function-associated antigen-1 (LFA-1 or 
CD11a), achieves actual neutrophil adhesion and extravasation 10. However, in vitro 
studies suggest that there is a functional overlap and that integrins are not only 
involved in adhesion and transmigration, but also in rolling 11.  
The aforementioned changes of the local release and/or differentiation of diverse 
neutrophil subsets have also been described after fractures 5. These subsets present 
with various surface receptor expressions, which, in turn, result in different 
neutrophil characteristics. However, knowledge of the specific influence of an 
isolated stabilized femoral fracture on the systemic neutrophil pool, especially 
throughout the later post-traumatic phases, is sparse. Indeed, the alterations in 
circulatory neutrophil number and their cell surface expression of selectins and 
integrins following fracture and intramedullary nailing have never been 
investigated. 
Knowledge of the time course and specific pattern of neutrophil surface receptor 
expression after trauma is of the utmost importance for the future development of 
therapeutic options to modulate the role and homing of neutrophils in injured tissue. 
Therefore, we investigated if femoral fractures and intramedullary nailing are 
associated with alterations in circulatory neutrophil counts and circulatory 
neutrophil surface receptor expression of selectins and integrins. 
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8.2. MATERIALS AND METHODS 
8.2.1. Housing 
Our study cohort consisted of 21 adult female Sprague-Dawley rats weighing 
approximately 250 g; the rats were obtained from Envigo B.V. (Horst, Netherlands).  
All the animals were specifically pathogen free according to the Federation of 
European Laboratory Animal Science Associations’ recommendations. The animals 
were housed and the experiments performed at the Institute 
of Laboratory Animal Science, University of Aachen Medical Center, Germany, with 
the approval of the Governmental Animal Care and Use Committee (Landesamt für 
Natur, Umwelt und Verbraucherschutz, North Rhine-Westphalia, Recklinghausen, 
Germany; Protocol No. 84-02.04.2015.A078). The animals were housed under 
controlled temperature (20 ± 2°C) and air humidity (45–65%), with a 12 hour light–
dark cycle and a light intensity of <200 lux. Food and water were offered ad libitum. 
Prior to study inclusion, all animals were kept in groups for 1 week in the laboratory 
premises to allow for acclimatization. Throughout the entire experiment, the rats 
underwent physical examinations according to a “score sheet” documentation 12 and 
the “body condition scoring” according to Hickman 13 to obtain the general health 
status.  
In order to optimize standardization of this long-term observation study, female 
animals were utilized, as variations in animal weight over time are smaller than 
observed in their male counterparts. Because of the protective effects of female 
hormones in cases of inflammatory stimuli, all animals were confirmed to be in the 
same “metestrus” phase of the menstrual cycle because this phase is characterized 
by low oestrogen and progesterone levels 14,15. The menstrual cycle phase was 
identified by the assessment of vaginal swabs according to Marcondes et al. 16. 
8.2.2. Experimental design and study groups 
In order to minimize usage of experimental animals in the current study, a baseline 
measurement was performed after anaesthesia and termination after 3 days (n = 1), 
7 days (n = 1), and 14 days (n = 1), without prior intramedullary nailing and fracture 
induction. Data of control animals was pooled and analysed as Group control.  
In all other animals (n = 18), after anaesthesia, an intramedullary Kirschner wire was 
inserted, and a standardized femoral fracture was induced at the right side. The 
animals were then randomly divided into three study groups according to the 
observation period:  
Group 3d : 3 days of observation after fracture induction  
Group 7d : 7 days of observation after fracture induction  
Group 14d : 14 days of observation after fracture induction  
The reasons for excluding animals were as follows: death from anaesthetic 
complications, open fracture, comminuted fracture, implant failure, wound 
dehiscence, or infection.  
8.2.3. Anaesthesia and pain management  
The animals received buprenorphine hydrochloride (0.03–0.05 mg/kg s.c.) as a 
multimodal analgesic at 30 minutes before operation. The operative procedures 
were performed under general anaesthesia induced with ketamine (100 mg/kg i.p.) 
and xylazine (2%; 10 mg/kg i.p.) and, if necessary, extended with isoflurane 
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inhalation (2.0–2.5 Vol.%). The toe pinch reflex was used to ensure adequate 
anaesthesia. Postoperative analgesia was ensured with buprenorphine 
hydrochloride (0.03–0.05 mg/kg s.c.) every 6 hours for the first 24–48 hours. 
Subsequently, it was given twice daily during the entire period of the experiment. All 
animals were allowed to mobilize freely directly after the operative procedure. The 
animals were evaluated  three times per day using the score sheet evaluation 12.  In 
the potential case of clinical signs of uncompensated/enhanced pain, animals are to 
be withdrawn from the study. Similar painkilling protocols were applied to control 
animals during the observation period. 
8.2.4. Standardized femoral fracture 
Sterilized implants (autoclave processing) and surgical equipment was used. 
Furthermore, procedures were performed using sterile gowns, gloves, surgical mask 
and theatre caps. After anaesthesia induction, the animals were placed on a heated 
pad (37 °C), and their eyes were covered with a moistening ointment. Their right 
hind leg was shaved, disinfected, and draped. Then, a para-patellar incision was 
made, the patella was everted laterally, and a 1 mm stainless-steel intramedullary 
Kirschner wire (Königsee Implantate GmbH, Allendorf, Germany) was inserted in a 
retrograde manner. Its placement was confirmed by fluoroscopy. The sharp end of 
the Kirschner wire was placed to the proximal end of the femur. The Kirschner wire 
was cut flush with the intercondylar notch, and the proximal end was bent over the 
greater trochanter, cut, and hidden subcutaneously. The distal end of the Kirschner 
wire was than shortened underneath the cartilaginous surface. The patella was 
repositioned, and the wounds were sutured (Ethicon Inc., Somerville, NJ, USA) in 
layers. Surgical procedures have been described in detail by Klueter et al. 17. A 
transverse fracture was induced with a blunt guillotine according to the method by 
Bonnarens and Einhorn 18. A fluoroscopic evaluation of the fractured side was 
performed directly after fracture induction. An example of fracture fixation adequacy 
and radiographic imaging is provided in figure 8.1. 
 
Figure 8.1. Fracture confirmation by X-ray and post-mortem micro-CT imaging. (a) X-ray 
confirmation of a non-displaced midshaft femur fracture and adequate nail positioning. (b) Post-mortem 
micro-CT analysis of the fractured femur to evaluate fracture healing, rotation and displacement of the 
fracture or the nail. 
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8.2.5. Blood collection and euthanasia 
In accordance with animal grouping, animals were euthanized at three different time 
points (3d, 7d, and 14d) by cardiac puncture with an ethylenediaminetetraacetic acid 
(EDTA)-coated syringe. Prior to cardiac puncture, animals were put under general 
anaesthesia induced with ketamine (100 mg/kg i.p.) and xylazine (2%; 10 mg/kg 
i.p.). After cardiac puncture, an overdose of Isoflurane was provided and manual 
cervical dislocation was applied.  
8.2.6. Sampling 
Blood samples were lysed twice in an ice-cold isotonic NH4Cl solution. Cells were 
then washed twice in a FACS (fluorescence-activated cell sorting) buffer solution 
(phosphate buffered saline supplemented with 0.5% bovine serum albumin and 0.5 
mM EDTA). Cell suspensions were then incubated with conjugated mouse anti-rat 
monoclonal antibodies. The following commercially available mouse anti-rat 
monoclonal antibodies were utilized: CD62L clone OX-85 (AbD Serotec, Düsseldorf, 
Germany) / fluorescein isothiocyanate (FITC), CD11b clone M1/70 (eBioscience 
Vienna, Austria) / R-phycoerythrin (RPE), CD49d (VLA-4) clone MRalpha4-1 (Becton 
& Dickinson, Mountain View, CA, USA) / peridinin-chlorophyll-protein-cyanine 5.5 
(PerCP-Cy5.5), CD11a clone WT.1 (AbD Serotec, Düsseldorf, Germany) / 
allophycocyanin (APC), and Granulocytes mouse anti-rat clone RP-1 (Becton & 
Dickinson, Mountain View, CA, USA) / allophycocyanin-cyanine 7 (APC-Cy7). Details 
on flow analyses are provided in figure 8.2. 
8.2.7. Neutrophil cell surface marker expression 
Neutrophil cell membrane receptor expression levels of CD62L (L-selectin), CD11b 
(macrophage-1 antigen (Mac-1)), and CD11a (lymphocyte function-associated 
antigen-1 (LFA-1)) were measured by flow cytometry with a Canto II-device (Becton 
& Dickinson, Mountain View, CA, USA) and FACS Diva software (Becton & Dickinson, 
Mountain View, CA, USA). Neutrophils were identified using a four-step gating 
strategy (Figure 8.2.). In steps one and two, debris and doublets were excluded. In 
step three, cells with a neutrophil specific forward scatter/side scatter-pattern were 
included. Finally, RP-1 positive cells were included. The utilized gating strategy has 
previously been validated for analysis of both blood and tissue neutrophils 19-22. 
From each sample, a minimum of 200,000 cells were measured. Cell viability was 
confirmed in separate pilot experiments. Because cells were stained and measured 
within 2 hours after blood collection, maximal neutrophil-viability was ensured, and 
cell fixation was not indicated. The dynamics of cell surface receptors was compared 
between the groups. Additionally, the current study aimed to identify novel subsets 
that play a role in the inflammatory response to trauma. 
8.2.8. Neutrophil count 
The total cell count of viable neutrophils was determined using a Neubauer improved 
grid haemocytometer (LW Scientific, Lawrenceville, USA). This device is optimized 
for leukocyte versus non-leukocyte differentiation of cell suspensions. Two 
independent samples were taken from lysed blood samples. Cell suspensions were 
stained with Tryptan blue (Thermo Fisher Scientific, Waltham, MA, USA) and then 
separately filled into two counting areas on the counting chambers. The total cell 
counts of large, viable cells were documented, and an average value was calculated. 
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Thereafter, total neutrophil counts were determined by the ratio of RP-1 (a specific 
neutrophil marker in rats) positive cells: total gated white blood cells (cells) as 
measured by flow cytometry. This method has been described and validated by 
Krajnar et al. 21. 
 
Figure 8.2. 4-step neutrophil identification and gating strategy in peripheral murine blood 
samples. Neutrophils were identified through a 4-step gating strategy including (1,2) exclusion of debris 
and doublets, (3) inclusion of cells with a neutrophil specific FSC/SSC-pattern, and (4) inclusion of RP-1 
positive cells. Cell viability was confirmed in separate pilot experiments. As cells were stained and 
measured within 2 hours after blood sampling there was maximal PMN-viability and no need for cell 
fixation. 
 
8.2.9. Endpoint and power analysis  
The primary endpoint of our study was an alteration in circulatory neutrophil 
numbers in the early fracture healing period of 14 days. A secondary endpoint was 
an alteration in neutrophil activity, as measured by neutrophil cell surface 
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expression of CD11a, CD11b, and CD62L. Our sample size calculation was based on 
alterations in circulatory neutrophil numbers over time in a rat study from McManus 
56, which demonstrates the raw data of circulatory neutrophil numbers from the 
control (1565 ± 387 cells / mm3) and intervention groups (3999 ± 787 cells / mm3) 
9 days after insult. According to our power analysis, groups with at least four animals 
will provide 90% power at an α-level of 0.05. To compensate for higher variability in 
our model and potential mortality, we decided to include six animals in each 
intervention group. 
8.2.10. Data analysis 
Statistical analysis was performed using SPSS (version 20.0; IBM Inc., Somers, NY, 
USA) and GraphPad Prism (version 7; San Diego, USA). All data are presented as the 
mean and standard deviation unless described otherwise. Comparison of the data 
with control values and between groups was performed using Mann-Whitney’s U-
test. In general, a two-sided p-value < 0.05 was considered significant. 
8.3. RESULTS 
All animals survived the observation period, and no animals had to be excluded 
according to our exclusion criteria. 
8.3.1. Circulatory neutrophil count 
The absolute neutrophil count significantly decreased in Group 3d compared with 
the baseline conditions (1.2 x 105 vs. 6.3 x 105 cells / ml, p < 0.01). However, 
circulatory neutrophil numbers returned to homeostatic levels after 7 days of 
observation (p < 0.05) and remained stable at day 14 (p < 0.05) (Figure 8.3.).  
 
Figure 8.3. Circulatory neutrophil count in early fracture healing. A significant difference was seen 
between the baseline measurement (control) and animals terminated 3 days after surgery (** p < 0.01). 
Furthermore, a significant rise in neutrophil count was observed between day 3 and day 7 (* p < 0.05). No 
differences were found between the baseline measurement (control) and counts at day 7 and day 14.  
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8.3.2. Neutrophil cell surface expression of L-selectin (CD62L) 
The expression of L-selectin (CD62L) at the surface of circulatory neutrophils 
decreased significantly in Group 7d and Group 14d compared with Group 3d, but no 
significant difference occurred between the baseline measurement and all three 
fracture groups (Figure 8.4.a). 
Figure 8.4. Cell surface expression of selectins/integrins in circulatory neutrophils. (a) L-selectin 
(CD62L) expression in circulatory neutrophils. Significant differences were seen between day 3 and day 
7, as well as day 14, after intramedullary nailing and fracture induction (** p < 0.01). No significant 
differences were found between the intervention groups and the baseline measurement. (b) Mac-1 
(CD11b) expression in circulatory neutrophils. A significant decrease of Mac-1 expression was seen at day 
3 compared with the baseline measurement (* p < 0.05). After 7 days, the expression returned to baseline 
values and remained at this level throughout day 14. (c) LFA-1 (CD11a) expression in circulatory 
neutrophils. Expression in mean fluorescence intensity (MFI) in arbitrary units (AU) over time. Statistical 
significance: * p < 0.05; ** p < 0.01. 
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8.3.3. Neutrophil cell surface expression of Mac-1 (CD11b) 
The expression of Mac-1 (CD11b) at the surface of circulatory neutrophils was 
significantly decreased in Group 3d compared with the baseline measurement (p < 
0.05). In Group 7d and Group 14d, the expression of Mac-1 (CD11b) returned to 
baseline values again. These values were significantly increased compared with the 
values at day 3 (day 7: p < 0.01, day 14: p < 0.05) (Figure 8.4.b). 
 
Figure 8.5. Flow cytometric analysis of changes in circulatory neutrophil integrin cell surface 
expression. Representative examples of alterations in LFA-1 (CD11a) and Mac-1 (CD11b) expression 
during fracture healing were selected. Histograms (left): These show the cell surface expression levels of 
either Mac-1 (CD11b) or LFA-1 (CD11a) on the x-axis and cell count on the y-axis. Dot plot (right): A two-
dimensional analysis was added to highlight the relationship between circulatory neutrophil Mac-1 
(CD11b) and LFA-1 (CD11a) expression. Here, Mac-1 (CD11b)-PE expression in mean fluorescence 
intensity (MFI) in arbitrary units (AU) is shown on the x-axis, and LFA-1 (CD11a)-APC mean fluorescence 
levels (AU) are plotted on the y-axis. 
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8.3.4. Neutrophil cell surface expression of LFA-1 (CD11a) 
The expression of LFA-1 (CD11a) at the surface of circulatory neutrophils 
significantly increased temporarily in Group 3d when compared with the baseline 
measurement (p < 0.05) and with Group 7d (p < 0.01). LFA-1 (CD11a) expression 
levels returned to homeostatic baseline levels by day 7 and remained at baseline 
until the end of the experiment (Figure 8.4.c). 
 
Figure 8.6. Fractions of neutrophil subtypes. Bar chart (left): The grey bars in the bar chart represent 
the percentage of regular non-CD11bhigh/CD11ahigh neutrophil subtypes, and the black bar represents the 
percentage (7.62%, range: 5.56–9.24%) of novel CD11bhigh/CD11ahigh cells in peripheral blood. The 
percentage of CD11bhigh/CD11ahigh neutrophils was significantly higher on postoperative day 7 compared 
with all other groups. Dot plot (right): A duplicate of a two-dimensional dot plot from a representative 
example provides an example of the utilized gating strategy. Statistical significance: ** p < 0.01. 
 
8.3.5. Co-expression patterns and the interplay between circulatory neutrophil 
LFA-1 (CD11a) and Mac-1 (CD11b) expression  
Several specific alterations in neutrophil cell surface receptor expression levels of 
integrins over time were identified. Histograms and two-dimensional plots at 
different time points of all individual samples were analysed, showing increased 
circulatory neutrophil heterogeneity upon intervention. This contrasts with the 
control group, which exhibited a homogeneous neutrophil population consisting of 
CD11bintermediate/CD11aintermediate-neutrophils only (Figure 8.5.). More specifically, a 
novel CD11bhigh/CD11ahigh-neutrophil subtype appeared in circulation on 
postoperative day 7 (Figure 8.5./8.6.). This neutrophil subset was encountered in 
five of six animals in the day 7 group, exhibiting a statistically significant fraction 
(average 7.62%, range: 5.56–9.24%, p < 0.01) of the overall circulatory neutrophil 
composition (Figure 8.6.). This subset was further characterized by a statistically 
significant increased co-expression of CD49d (VLA-4) on the cell surface compared 
with other regular neutrophils (p < 0.01). A back-gating analysis of the novel 
CD11bhigh/CD11ahigh -neutrophil population showed that all cells were spread across 
the neutrophil gate with respect to forward and side-scatter profiles. Finally, no 
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differences in L-selectin co-expression between CD11bhigh/CD11ahigh-neutrophils 
and regular neutrophils were seen (Figure 8.7.). 
 
 
Figure 8.7. Differences in cell surface co-expression of L-selectin (CD62L) and α4-integrin (CD49d) 
on CD11bhigh/CD11ahigh vs. regular neutrophil subtypes. The grey bars represent co-expression of cell 
surface receptors on regular, non-CD11bhigh/CD11ahigh -neutrophils, and the black bars represent co-
expression of cell surface receptors on novel CD11bhigh/CD11ahigh -neutrophils in Group 7d (n = 5). MFI: 
mean fluorescence intensity, AU: arbitrary units. Statistical significance * p < 0.05, ** p < 0.01. 
 
8.4. DISCUSSION 
Intramedullary nailing of long bone fractures represents a standard procedure in 
femoral shaft fractures and is performed 100,000-fold worldwide. Both the fracture 
itself and the surgical procedure for stabilization have been shown to be associated 
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with inflammatory changes, which are necessary for the normal fracture healing 
process. On the other hand, if these inflammatory changes are dysregulated, local 
and/or systemic hyper-inflammatory conditions can evolve, causing local and/or 
systemic complications, such as non-unions and acute respiratory distress syndrome 
(ARDS) 23,24. Because neutrophils are the most abundant immune cells in the 
circulation and the primary first responders to trauma 25,26, a dysregulation of the 
neutrophil response plays a key role in the pathogenesis of these complications 1,10,27. 
Indeed, severe trauma leads to changes in neutrophil counts and functionality 28; 
however, research on the influence of isolated trauma (i.e., fracture) on circulatory 
neutrophils is scarce and ambiguous 3,4. Especially, influences on the long-term 
course have not been investigated until now. Therefore, it is important to gain 
knowledge on the time course and the specific pattern of neutrophil surface receptor 
expression alterations in the circulatory neutrophil pool during the post-traumatic 
process.  
The present study focused on the circulatory neutrophil pool, and we were the first 
to describe changes in the circulatory neutrophil population in a standardized long-
term observation fracture model, primarily focusing on the later inflammatory phase 
(>48 hours after trauma) rather than the early/instant immune response. The results 
of the current study can be summarized as follows:  
1. The number and activation of circulatory neutrophils is temporarily decreased at 
3 days after femoral fracture and intramedullary nailing.  
2. During the subsequent restoration of neutrophil homeostasis, the heterogeneity 
of the circulatory neutrophil pool increases. In this context, a new subset of 
CD11bhigh/CD11ahigh-neutrophils with co-expression of CD49d (VLA-4) occurs in 
systemic circulation at day 7.  
One potential theory to explain this decrease in the number and activation of 
circulatory neutrophils 3 days after the described procedure is that homing of 
neutrophils into the fracture hematoma occurs. From the literature, it is known that 
in the very early phases of the inflammatory stage of fracture healing, the neutrophil 
concentrations in the circulation and within the fracture hematoma remain equal for 
the first few hours 29,30. However, within the first 24 hours after fracture, because of 
the release of mitochondrial DAMPs (damage-associated molecular patterns) and the 
subsequent release of different chemo-attractants in the surrounding tissue, the 
homing of circulatory neutrophils into the fracture hematoma occurs, which are later 
replaced by macrophages 3,31. Corresponding to our study, Grøgaard et al. find a 
depletion of the circulatory neutrophils in the first 2 to 5 days after fracture, 
demonstrating a correlation of this depletion with an enhanced fracture healing of a 
femur osteotomy in rats 4. This indicates, in accordance with other experimental 
rodent fracture studies, that accurate neutrophil recruitment and function in the 
fracture hematoma is crucial to initiate and coordinate the downstream responses 
leading to bone regeneration 3,6. The importance of neutrophil homing to the fracture 
hematoma is also demonstrated in the clinical situation in the study of Bastian et al., 
in which serum from human fracture hematoma significantly generates neutrophil 
chemotaxis during the inflammatory stage of fracture healing 1. Besides the extent of 
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the inflammatory response, its duration and the insufficient termination (hyper-
activated neutrophils) can impair the fracture healing process 2,6,32.  
In addition to the aforementioned recruitment into the fracture site, an enhanced 
migration of neutrophils into other organ systems after long bone fractures and 
intramedullary stabilization has also been described. In this context, the lungs have 
been identified as a primary target organ, in which neutrophils potentially damage 
parenchymal lung tissue 7 and cause complications such as acute lung injury and 
ARDS 8,9. Clinical and experimental trauma studies have demonstrated that this 
pulmonary neutrophil infiltration peaks at 72 hours after fracture fixation 8,33. This 
could be a second explanation for our discovered decrease of circulatory neutrophils. 
Besides neutrophil count, their functionality is also of the utmost importance to 
assess the competence of blood neutrophils. Neutrophil functionality is regulated by 
cell membrane receptor expression and is a complex, multistage process 34. These 
cell membrane receptors, which can detect different chemo-attractants (e.g., 
chemokines, complement) 35, define different neutrophil subsets or phenotypes.  
Among the neutrophil surface receptors, selectins and integrins are especially 
considered as essential for neutrophil activation and tissue migration. In the present 
study, the neutrophil surface expression of integrins and selectins was investigated 
for the first time in an experimental model of an isolated intramedullary stabilized 
femoral fracture. Previous studies focusing on the heterogeneity and function of 
circulatory neutrophils mainly focused on either the postoperative setting or on 
multiple trauma and found highly divergent results.  
The current study showed no significant differences in L-selectin (CD62L) surface 
expression levels compared with the control conditions. Similar findings can be 
found in clinical studies focusing on patients after elective surgery. After cardiac 
surgery, no significant shift in L-selectin expression was found in the first 5 days 
postoperatively 36. Also, Mommsen et al. find no significant difference in L-selectin 
expression of isolated neutrophils in the first 48 hours after elective lower limb 
surgery compared with preoperative expression levels. However, after stimulation 
with TNF-α, they show that there is a significant decrease of L-selectin expression in 
the first 24 hours after surgery, indicating a role for the pro-inflammatory cytokine 
TNF-α in the neutrophil surface expression of L-selectin 37. After multiple trauma, in 
contrast to our findings, Seekamp et al. find a significantly reduced level of L-selectin 
expression in the early phases (up to 24 hours) after trauma. This reduction is 
associated with the complicated post-traumatic course (i.e., the development of 
multi-organ dysfunction syndrome (MODS)) 38. Besides the differences of the 
underlying insults, time-related differences of the sample collection might explain 
the aforementioned differences. In this context, it is known that L-selectin mediates 
the very early stages (24–48 hours after trauma) of the adhesion of neutrophils to 
endothelial cells. Therefore, we might have missed the early alterations in L-selectin 
expression in our study with the first time point being at 3 days after trauma 37-39. 
For the current experiment only female animals have been utilized. This is of specific 
interest as L-selectin, in contrast to other receptors, responses in trauma are 
believed to be gender specific. Interestingly, in accordance with a study from Van 
Griensven et al on gender related dimorphism in L-selectin receptor responses on 
circulatory PMNs in trauma, we also found an initial drop of L-selectin expression 
182
| CIRCULATORY NEUTROPHIL POOL IN FRACTURE HEALING 
183 
 
upon insult and later restoration to baseline levels 40. This underlines the 
translational value of our model as well as the feasibility of our long-term fracture 
model in rats to perform proof-of-principle studies to test future immunomodulatory 
interventions. Future studies should focus on the occurrence of gender specific L-
selectin responses upon trauma in rats as well. 
In contrast to L-selectin, we demonstrated a relevant decrease of neutrophil CD11b 
expression 3 days after fracture induction. Thereafter, CD11b expression gradually 
increased for over 2 weeks after trauma. This recovery curve implies that restoration 
of CD11b-expression on the circulatory neutrophil pool takes at least 14 days. The 
results from a clinical study by Baehl et al. support our experimental findings, 
demonstrating that an isolated fracture is associated with reduced neutrophil cell 
surface expression of different integrins, such as CD11b, which are involved in 
binding and chemotaxis of neutrophils in the early phases after fracture. This 
decrease was followed by a gradual increase over 6 months of follow-up observation 
41. A decrease of CD11b expression in the initial phase after trauma has also been 
encountered in other clinical studies 42,43. In two clinical studies of severely injured 
patients, an initially decreased peripheral neutrophil-CD11b expression after three 
days followed by a gradual increase is found, which is in line with our results 43.  
We hypothesize that a transient decrease in neutrophil-CD11b expression is caused 
by a combination of (1) early extravasation of activated CD11bhigh-neutrophils into 
different tissue compartments (e.g., fracture and lung) directly after trauma and (2) 
an inadequate supply of new potent neutrophils in the circulation.  
The current investigation also showed that neutrophil-CD11a surface expression 
levels changed over time after fracture induction and intramedullary stabilization. In 
previous studies, the exact expression pattern of CD11a has been partly 
controversially discussed, mainly in clinical trauma studies. Our results of an 
increase in CD11a-expression on day 3 after fracture induction are supported by the 
findings of Maekawa et al., which also show an increased expression from 3 hours up 
to 96 hours after trauma. On the other hand, our results do not correspond with the 
findings from a clinical study in which no significant increase of CD11a expression 
was demonstrated at 3 days after severe trauma 43. Lo et al. even find a 
downregulation of CD11a expression although early at 24 hours after trauma 44. 
Although based on our results we cannot comment on the early data from Lo et al., 
both CD11a and CD11b exhibit transient changes in adhesion- and migration-
promoting activity. Because our first measuring time point was 3 days, we might 
have missed an early downregulation of CD11a expression. 
The aforementioned results of our and previous studies underline the results of a 
review of Mortaz et al. that focuses on neutrophil phenotyping in trauma patients. 
Here, specific post-traumatic expression patterns with various dynamics for surface 
receptors of neutrophils are described. In line with our results, the study shows that 
neutrophil CD11a and CD11b cell membrane expression levels do not rise 
synchronously in response to a traumatic insult, suggesting the existence of 
independent integrin regulation pathways 43,44. Both integrins, CD11a and CD11b, 
play a prominent role in regulating the trans-endothelial migration of neutrophils, 
which is essential for an adequate immune response. In this migration cascade, these 
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integrins partially have distinct roles 45-47, in that CD11a is critical at each step of the 
neutrophil extravasation and that CD11b is more involved in the adhesion of 
neutrophils to the endothelial cells 48. However, there seems to be an interplay, even 
an overlap, between these two integrins because they share the same heterodimeric 
component CD18 (integrin β-2) and partially bind to the same ligands 39,48. In this 
context, as an expression of this connection between both integrins, we were the first 
to identify a new subset of CD11bhigh/CD11ahigh-neutrophils in the circulation at day 
7. 
Because of the late post-traumatic appearance in peripheral circulation more than 3 
days after the insult, these neutrophils exhibit a unique pattern of mobilization 
compared with the other subtypes. Therefore, it has been suggested that they also 
might play a role in the regulation of the anti-inflammatory phase following trauma. 
Because neutrophils of this subset show a significantly higher co-expression with 
very late antigen-4 (VLA-4/CD49d) than regular neutrophils, it is most likely that 
they represent a unique phenotype.  
The expression of CD49d (VLA-4) has not been reported on circulating neutrophils 
under homeostatic conditions 49. On the contrary, CD49d expression has been 
identified on neutrophil progenitor cells in the bone marrow; therefore, it is tempting 
to hypothesize that these CD11bhigh/CD11ahigh-neutrophils are released from the 
bone marrow 49,50. CD49d (VLA-4) might play a significant role for the tissue 
migration of the new subset of neutrophils because it has been found to play a role 
in CD11b-independent neutrophil-adhesion pathways 51,52. Although it is not clear 
yet if these subsets definitively belong to separate developing lineages or embody 
certain activation states of a common precursor, the origin, characteristics, and 
functionality of the specific CD11bhigh/CD11ahigh- neutrophil subset should be the 
focus of further research.  
The current study also has some limitations. First, because our findings were derived 
from an animal model, they are not directly translatable to humans. We chose a rat 
model because this animal fracture model was established in our department, and it 
is suitable for this kind of research. Second, we used only one fixation method for the 
femur fractures, that is, intramedullary nailing; therefore, we cannot draw 
conclusions for other fixation methods based on these study results. Third, we 
planned to compare the data from the circulatory neutrophil pool with the 
neutrophils within the fracture hematoma, but we could not obtain enough fracture 
hematoma from the fracture site. Therefore, because the current descriptive study 
focused on the number and activation of neutrophils in the circulatory pool only, we 
could not make assertions about the functional relevance of the new subset of 
CD11bhigh/CD11ahigh-neutrophils or their morphological characteristics yet. These 
important factors are planned to be addressed in subsequent studies in a larger 
animal model. Fifth, our study design does not enable the usage of statistical testing 
by repeated measure methods as all experimental animals have been terminated 
after sampling. In fact, as a total of 2 ml blood per sample was required, we were not 
allowed to sample four times and thereby we would not have been able to determine 
long-term kinetics. To overcome this issue, we decided to perform termination after 
sampling and to group animal according to termination time point. By doing so we 
avoided potential confounding of the impact of withdrawal of relevant amounts of 
blood from rodents on metabolic 53, hormonal 54 and even immunological 55 
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homeostasis. In addition, we preferred to use female rats only, as they have relatively 
stable weight alterations in comparison with their male counterparts. As a 
consequence, extrapolation to the male situation in trauma is limited. Especially, as 
gender specific cellular immune response, and more specifically, L-selectin 
alterations upon severe trauma have been reported by Van Griensven et al. 40.  
8.5. CONCLUSIONS 
This descriptive, small animal fracture study is the first to show that an 
intramedullary stabilized femur fracture is associated with a temporary reduction in 
circulatory neutrophil count and concurrent changes in circulatory neutrophil 
function. Moreover, we demonstrated that the restoration to homeostatic neutrophil 
activation status occurs concomitantly with an increased heterogeneity of the 
circulatory neutrophil pool, which is accentuated by the appearance of a novel 
neutrophil subtype (CD11bhigh/CD11ahigh). Improved knowledge of neutrophil count 
and functionality after trauma form an excellent basis for future studies to further 
elucidate the role of neutrophils as activators and regulators of different post-
traumatic processes, potentially resulting in local (e.g., fracture healing 
disturbances) or systemic (e.g., MODS) complications. This might result in the 
development of specific therapies to reduce adverse outcomes after trauma.  
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ABSTRACT 
Purpose. Dysregulation of polymorphonuclear neutrophil (PMN) biology is associated 
with the development of inflammatory complications after trauma, such as acute 
respiratory distress syndrome (ARDS). Data about the influence of surgical procedures, 
such as intramedullary nailing (IMN) is sparse. This study aimed to characterize the 
remote neutrophil response in the lungs in case of a femur fracture and intramedullary 
nailing. 
Methods. A standardized rat model including intramedullary nailing and a femur 
fracture was utilized. Groups were terminated after observation times of 3, 7 and 14 
days. Neutrophils were isolated from lung parenchyma and broncho-alveolar lavage 
fluid (BALF) and analysed by flow cytometry. Absolute neutrophil numbers as well as 
membrane expression levels of CD11b, CD62L and CD11a were compared. 
Results. Pulmonary neutrophil numbers were increased 3 days after intervention. 
Membrane expression levels of CD11b (P<0.01), CD62L (P<0.01) and CD11a (p=0.06) 
on parenchymal PMNs increased as well after 3 days. Thereafter values restored 
gradually to physiological levels. Furthermore, neutrophil activation status between 
parenchymal and BALF-PMN pools did not correlate. 
Conclusions. The current study demonstrates that IMN and a femur fracture are 
associated with transient increased pulmonary PMN deposition, as well as a specific 
neutrophil activation pattern characterized by temporary increased selectin and 
integrin receptor expression on pulmonary neutrophils. This phenomenon might play 
an important role in the pathomechanism of ARDS after trauma. Moreover, we found 
striking differences between parenchymal and BALF-neutrophil populations, 
demonstrating the limited readout potential of BALF-analysis to investigate the entire 
pulmonary neutrophil pool. 
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9.1. INTRODUCTION   
Pulmonary complications such as acute lung injury (ALI) and adult respiratory distress 
syndrome (ARDS) occur after femoral fractures and intramedullary nailing (IMN). 
Additionally, a pulmonary entity called ‘fat embolism syndrome’ (FES) has been 
described as well. This syndrome is difficult to distinguish from ALI/ARDS and also 
occurs in septic patients 1-3. Current concepts emphasize that femoral fracture 
hematomas can alter, and more specifically, increase systemic levels of inflammatory 
mediators. These mediators could also activate circulating polymorphonuclear 
neutrophils (PMNs), that have the potency to damage parenchymal lung tissue upon 
extravasation and subsequent activation when residing in the lungs 4,5.  It has well been 
demonstrated that systemic neutrophil dysregulation is an important process in the 
development of ARDS 6,7. Histological studies after severe experimental trauma, and on 
patients who died from ARDS revealed substantial increased pulmonary neutrophil 
influx 8-10. Currently, the pathogenesis of these complications and their specific relation 
with IMN are unclear, but there appears to be a role for pulmonary polymorphonuclear 
neutrophils.    
Cell labelling studies performed by Wintrobe´s group established the concept of 
increased neutrophil deposition being associated with pulmonary inflammatory 
pathologies. In their studies on healthy individuals they demonstrated that only half of 
DFP32-labelled granulocytes, that were injected to volunteers, were later encountered 
in peripheral blood. These findings suggested that the non-circulating cells migrated 
instantly into the tissue compartment or adhered to a vessel wall (marginated pool) 11. 
With the development of ln111-cell labelling techniques, margination processes could 
be imaged more precisely. Animal experiments revealed that the pulmonary vascular 
bed was an important site of neutrophil margination. However, as a result of further 
studies in which labelling conditions of previous experiments were critically examined, 
it became clear that the observed effects did not reflect pure physiological conditions, 
as some form of injury/insult was implemented in the utilized models 12.  Circumstances 
in which neutrophil transit time in the lungs is prolonged include several pathologies 
as ALI/ARDS and fat embolism syndrome, and this affects pulmonary neutrophil 
deposition 11,13,14. According to experimental trauma studies, pulmonary PMN 
infiltration peaks at 72 hours after trauma 15. However, the characteristics (and specific 
alterations over time) of pulmonary PMNs upon trauma are unclear.   
Pulmonary tissue is not homogeneous and several compartments, namely lung 
parenchyma and the broncho-alveolar compartment, can be identified 16. Subsequently, 
neutrophils are situated in different lung compartments as well and different 
pulmonary neutrophil pools can be distinguished. In addition, large pools of neutrophils 
appear to be marginated to the vascular wall, and the lung neutrophil population 
consists, under homeostatic conditions, mainly of cells that adhere to the endothelium 
of pulmonary blood vessels 17. Upon activation, these marginated neutrophils can 
undergo rapid trans-endothelial and trans-epithelial migration into the interstitium 
and alveolar spaces. The insult-evoked influx of these cells into both lung parenchyma 
and broncho-alveolar spaces might alter the constitution and characteristics of the 
neutrophil pools in these compartments 18. This process might play a relatively 
unexplored role in the development of inflammatory complications in trauma.   
9
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Bronchoalveolar lavage was proposed as early as 1995 as a procedure to diagnose fat 
embolism syndrome. During this lavage, PMNs could be obtained for analysis 19,20. In 
2010, Blankstein described the combination of haemorrhagic shock, resuscitation, and 
fat embolism syndrome elicited neutrophil activation, infiltration of alveoli by PMNs, 
and inflammatory cytokine expression in bronchoalveolar lavage fluid 5. However, 
specific characteristics of neutrophils residing in different neutrophil compartments 
after trauma, as well as alterations over time have not been studied yet. Pulmonary 
neutrophil homing is a multistep process, orchestrated by alterations in cell-surface 
expression and affinity of mainly selectins and integrins. In order to obtain more insight 
into the pathogenesis of trauma-induced ARDS, we defined the following hypotheses:  
(1)  Intramedullary nailing and a unilateral femur fracture is associated with the 
expansion of the pulmonary neutrophil population and increased activation of 
both the parenchymal neutrophil pool and the broncho-alveolar neutrophil pool.  
 (2)  Cell-surface expression of activation markers on PMNs differs between distinct 
lung compartments (parenchymal vs. bronco-alveolar space).  
9.2. MATERIALS AND METHODS   
9.2.1. Ethical approval   
Prior to the start of the experiments the protocol was approved by the institutional 
animal committee and of the regulating authority: Landesamt für Natur, Umwelt und 
Verbraucherschutz (LANUV) Nordrhein-Westfalen, Recklinghausen, Deutschland 
(permit AZ 84-02.04.2015.A078). The utilized experimental animals are a part of a 
larger rodent study.   
9.2.2. Experimental model  
Adult female Sprague-Dawley rats (Harlan Industries, Indianapolis, Indiana, USA, 250-
350 grams) were subjected to standardized intramedullary nailing and a unilateral 
femur fracture, as previously described 21,22.  Subcutaneous premedication included: 
0.03 mg/kg buprenorphine hydrochloride (Reckitt Benckiser Healthcare Ltd., United 
Kingdom). General anaesthesia was induced by 100 mg/kg Ketamine (Pfizer, New York, 
USA) intraperitoneally and 2% 10 mg/kg Xylazine (Xylapan, Vetoquinol, Ravensburg, 
Germany) intraperitoneally. Anaesthesia was maintained by 2-2.5% Isoflurane 
inhalation. Postoperative animals received buprenorphine hydrochloride twice a day.  
9.2.3. Study groups  
Animals were sacrificed after 3, 7 and 14 days of observation (N=6). In addition, one 
control group was added to define homeostatic values (N=3). Animals were 
randomized for groups and terminated by cervical dislocation under isoflurane 
anaesthesia.   The following groups were included:   
Study group 1 : Intramedullary nailing + unilateral femur fracture, observation period: 
3 days.   
Study group 2 : Intramedullary nailing + unilateral femur fracture, observation period: 
7 days.   
Study group 3 : Intramedullary nailing + unilateral femur fracture, observation period: 
14 days.   
Control group : anaesthesia (in line with study groups) and direct termination.    
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9.2.4. Isolation of single-cell solutions from different pulmonary compartments 
Directly after termination a thoracotomy was performed and lungs (including trachea) 
were isolated for further analysis. First, the left main bronchus was clipped and a blunt 
syringe was utilized to flush the right lung. A total of three flushes with each 1mL of ice-
cold phosphate buffered saline (PBS) were performed. The solution was then filtered 
using a 100μl cell strainer (BALF-single cell solution).    
Thereafter the right caudal lobe was isolated. Lung tissue was crushed mechanically, 
and single cell solutions were collected in a 50mL Falcon-tube (lung parenchymal single 
cell solution). Then samples were lysed using a Red blood cell (RBC)-lysing buffer. After 
this lysis step, FACS-Buffer (phosphate buffered saline enriched with 0.5% bovine 
serum albumin and 0.5mM EDTA) was added to both samples and two washing steps 
were performed. Thereafter conjugated antibodies were added and allowed to incubate 
for 45 minutes. After staining the single cell solutions were washed twice and directly 
analysed by flow cytometry (within 1 hour). By doing so, neutrophil populations were 
isolated from two distinct compartments of uninjured lungs:   
1. Lung parenchymal neutrophils and,    
2. Broncho-alveolar neutrophils.  
9.2.5. Flow cytometry analysis and pulmonary neutrophil identification   
Neutrophils have been implicated as having a pivotal role in the development of acute 
lung injury. Neutrophils were identified and differentiated from other white blood cells 
by characteristic CD45 and RP-1 fluorescence and light scatter properties as measured 
by flow cytometry. The following gating strategy was utilized: isolation of viable 
leukocytes (CD45high), exclusion of doublets, inclusion of RP1high/SSChigh cells. From 
each sample a minimum of 10.000 RP1-positive cells were analysed. This protocol has 
been validated by pilot experiments and fluorescence levels were compared to negative 
control values as well as with fluorescence levels on blood and bone marrow cells.   In 
order to investigate characteristics of different pulmonary neutrophil populations and 
changes over time, membrane receptor expression levels of activation markers: 
integrin Mac-1 (CD11b), integrin LFA1 (CD11a) and L-selectin (CD62L) were measured. 
CD11b expression was used because it is an early indicator of the acute inflammatory 
reaction preceding lung injury. Moreover, CD11b expression on circulating neutrophils 
increases after major trauma. As neutrophil transmigration to the site of inflammation 
is a multistep process and dependent on the expression of cell-surface glycoprotein 
adhesion molecules we also studied cell-surface receptor expression dynamics of LFA-
1 and L-selectin. Counting beads were added in order to calculate absolute cells counts 
of broncho-alveolar lavage fluid samples. Absolute neutrophil numbers and the 
neutrophil fraction were determined as described by Skrajnar et al. 23. A Canto II-device 
(Becton & Dickinson, Mountain View, CA, USA) and FACS Diva Software (Becton & 
Dickinson, Mountain View, CA, USA) were utilized to analyse samples. In order to 
analyse differences between the tissue compartments we plotted correlations between 
all markers and calculated statistical significance.    
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9.2.6. Reagents  
RP-1 clone RUO (Becton & Dickinson, Mountain View, CA, USA), CD11b clone M1/70 
(eBioscience Vienna, Austria), CD62L clone OX-85 (AbD Serotec, Düsseldorf, Germany), 
CD11a clone WT.1 (AbD Serotec, Düsseldorf, Germany), CD45 clone 10558 (Abcam, 
Cambridge, Great Britain), CountBright counting beads (ThermoFisher Scientific, 
Waltham, United States). Phosphate buffered saline (PBS) (Sigma, Deisenhofen, 
Germany). RBC Lysis-Buffer (Bio-rad, Hercules, United States), FACS-Buffer (phosphate 
buffered saline enriched with 0.5% bovine serum albumin and 0.5mM 
Ethylenediaminetatraacetic acid (EDTA)).  
9.2.7. Statistical analysis  
Data are displayed as means and SEM, unless described otherwise. Groups were 
compared by using the Mann-Whitney U test. Differences were considered significant if 
p < 0.05. Data was analysed with the following software programs: SPSS version 20.0 
(SPSS Inc., Chicago, IL, USA) and GraphPad Prism (GraphPad Software Inc., La Jolla, CA, 
USA).  
9.3. RESULTS  
All animals survived the observation period and no signs of infection were seen. 
Furthermore, all animals were able to mobilize within 24 hours after the intervention. 
Single cell solutions from both the parenchymal compartment and the broncho-alveolar 
compartment were prepared and analysed as described previously. Pulmonary 
neutrophil numbers/deposition was determined by analysis of bronchoalveolar fluid. 
Additionally, specific characteristics of both the parenchymal as well as the broncho-
alveolar neutrophil populations were determined and compared.  
9.3.1. Intramedullary nailing is associated with temporarily increased 
pulmonary neutrophil deposition  
As displayed in figure 9.1.a, absolute neutrophil numbers in broncho-alveolar lavage 
samples were increased significantly 3 days post-insult (mean: 35,026 PMNs/ml). 
Neutrophil counts thereafter decreased and equalled those under control conditions 
after both 7 and 14 days. Furthermore, the percentage of PMNs out of total broncho-
alveolar lavage fluid (BALF) leukocytes also peaked at 33.3% of leukocytes in the 3-day 
observation group (Figure 9.1.b). This was  
significantly higher than the percentages encountered under control conditions (mean 
PMN-fraction: 7.4%, p = 0.036) and in both animals terminated at 7 and 14 days 
(respectively, mean PMN-fraction: 9.0%, p < 0.01 and mean PMN fraction: 5.4% p < 
0.01).  
9.3.2. Alterations in activation status of the parenchymal neutrophil pool over 
time  
A statistically significant increase in CD11b expression on parenchymal neutrophils 
was observed after 72 hours of observation compared with control conditions (p < 
0.01) (Figure 9.2.a). Thereafter, PMN Mac1 expression on the parenchymal PMN pool 
decreased gradually over time. However, Mac-1 expression did not recover fully to 
baseline levels within the first 14 days after surgery (p < 0.01).    
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Figure 9.1. Changes in neutrophil fraction and absolute neutrophil numbers in BALF between groups. 
Variations in absolute neutrophil numbers in BALF (a) and in neutrophil fraction in BALF-analysis (b). 
Significance between groups is displayed as *p<0.05, ** p<0.01. 
 
Membrane receptor expression of CD11a on parenchymal PMNs (Figure 9.2.b) did not 
change significantly over time. Nevertheless, a notable statistically non-significant 
trend towards temporary peaking of LFA1 expression levels at 3 days of observation 
was found (p = 0.061). Pulmonary neutrophil L-selectin expression (Figure 9.2.c) was 
significantly increased after 3 days of observation (p < 0.01). Neutrophil L-selectin 
expression levels thereafter returned to baseline levels, and no statistically significant 
difference between control conditions and the group observed for 14 days was 
encountered (p = 0.69).  
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9.3.3. Changes in cell-surface activation of the broncho-alveolar neutrophil pool 
following trauma  
In contrast to the observed alterations of PMN-CD11b expression levels in the 
parenchymal neutrophil pool, no statistically significant changes in BALF-PMN 
expression levels over time occurred (Figure 9.3.a). LFA-1 expression levels on 
broncho-alveolar neutrophils, on the other hand, were significantly lower at 3 days of 
observation compared with control conditions (P=0.02). However, at both 7 and 14 
days of observation, LFA-1 cell-surface expression levels equalled those under control 
conditions again (Figure 9.3.b). As displayed in Figure 3c, no statistically significant 
alterations in PMN-CD62L expression over time on BALF neutrophils were seen.   
9.3.4. Activation status of parenchymal and broncho-alveolar neutrophils do not 
correlate when measured by flow cytometry  
We also tested for differences between the cell-surface expression levels of relevant 
neutrophil activation markers on both parenchymal and BALF neutrophils. When 
pooling all measurements, we found no statistically significant correlation of neutrophil 
CD11b (p = 0.93), CD11a (p = 0.43) or CD62L (p = 0.20) cell-surface expression levels 
between parenchymal PMNs and BALF neutrophils (Figure 9.4.). 
9.4. DISCUSSION  
Previous studies on the inflammatory cellular response after trauma focused mainly on 
alterations in blood neutrophils. However, circulatory neutrophils are, in contrast to 
tissue neutrophils, not believed to be harmful by themselves 6,24. The current study is 
the first to determine the specific neutrophil response to intramedullary nailing in the 
pulmonary tissue compartment.   
1. The current study demonstrates that intramedullary nailing and a unilateral 
fracture are associated with transient increases in pulmonary neutrophil deposition 
and increases in the activation status of the pulmonary neutrophil pool.   
2. Moreover, this study revealed striking differences in the activation status of 
neutrophils belonging to the pulmonary parenchymal compartment and those 
belonging to the bronchoalveolar compartment and thereby demonstrates 
compartmentalization related to intrapulmonary neutrophil heterogeneity.  
 Dysregulation of neutrophil activation and deposition in end-organ tissue 
compartments causes collateral damage to parenchymal cells and thereby contributes 
largely to the development of (multiple) organ failure and ARDS/ALI. Experimental 
studies showed that trauma results in increased pulmonary neutrophil influx 8-10,16. In 
addition to these quantitative investigations of the pulmonary neutrophil response to 
trauma, we characterized the pulmonary parenchymal neutrophil pool and provided a 
qualitative description of pulmonary neutrophil activation patterns. We thereby 
revealed that cell-surface receptor expression levels of Mac-1, LFA-1 and L-selectin on 
pulmonary neutrophils temporarily increased after trauma, and after that returned 
back to baseline levels within the first two weeks after the trauma. 
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Figure 9.2. Changes in neutrophil cell surface expression of activation markers on parenchymal 
Neutrophils. Variations in cell surface expression levels of Mac-1 (a) and LFA-1 (b) and L-selectin (c). Data 
in mean fluorescence intensities; MFI in arbitrary units; AU. Significance between groups is displayed as, *, 
p<0.05; **, p<0.01. 
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Figure 9.3. Changes in neutrophil cell surface expression of activation markers on Broncho-alveolar 
neutrophils. Variations in cell surface expression levels of Mac-1 (a) and LFA-1 (b) and L-selectin (c). Data 
in mean fluorescence intensities; MFI in arbitrary units; AU. Significance between groups is displayed as, * 
p<0.05. 
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Neutrophil activation status is generally studied by comparing cell-surface expression 
levels of activation and migration markers. Relevant and validated markers include 
some that belong to the selectin and integrin receptor families 25.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9.4. Correlation between parenchymal and broncho-alveolar neutrophil activation. 
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Upon neutrophil activation, cells enter a primed state, and L-selectin expression 
decreases due to the shedding of the receptor from the cell membrane 26. On the other 
hand, neutrophil Mac-1 expression increases in response to cell activation. These 
typical effects upon priming, however, have been identified and validated mainly in in 
vitro studies of blood neutrophils 27,28. In line with the in vitro experiments on 
neutrophil activation, the current in vivo experiment also demonstrated a striking 
transient increase of Mac-1 cell-surface expression on parenchymal neutrophils after 
three days of observation. These findings are further in agreement with a previous 
trauma study by Van Wessem et al. in which hypovolemic shock caused an increase in 
CD11b expression on circulatory neutrophils 29. Interestingly, in the current 
investigation, the expression of CD11b on BALF-neutrophils decreased simultaneously 
with the encountered increase of CD11b on parenchymal neutrophils. This finding may 
be suggestive of a specific biological function of the PMN-Mac-1 receptor in pulmonary 
neutrophil compartmentalization and PMN migration processes between the 
interstitium and the alveolar space. We also encountered increased neutrophil CD62L-
expression in the lungs upon activation. Increased pulmonary neutrophil-CD62L cell-
surface expression levels can be explained either by decreased shedding of the receptor 
from the PMN membrane 26 or by increased tissue infiltration of specific subtypes of 
CD62Lhigh neutrophils into the lung compartment 30. In vivo studies on endotoxemia 
and trauma also demonstrated increased CD62L receptor expression on blood 
neutrophils 31,32. We hypothesize that the encountered increase in total PMN-CD62L 
expression was partly caused by alterations in the constitution of the pulmonary 
neutrophil pool due to the appearance of novel (CD16low/CD62Lhigh) subsets in the 
circulation and subsequent tissue migration 26,30-32. 
Unfortunately, we were unable to identify and characterize this specific subset in our 
model, as PMN Fcy-receptor (CD16) expression cannot be investigated properly in 
rodent models due to relevant biological differences with the human Fcy-receptor 
family 33,34. So, the increased CD62Lexpression on parenchymal neutrophils in our 
study might be explained by the increased selective pulmonary homing of this specific 
subset of neutrophils after trauma as well.   LFA-1 is also of great importance in 
neutrophil tissue migration upon inflammation 35. A trend towards higher parenchymal 
PMN-LFA-1-surface expression levels 72 hours after trauma was observed. 
Interestingly, a paradoxical effect was seen regarding LFA-1 expression on BALF 
neutrophils. This phenomenon suggests a potential specific biological role of the LFA 
receptor in neutrophil migration processes between the parenchymal compartment 
and the alveolar space.   
Following initial altered pulmonary neutrophil activation within the first three days 
after trauma, activation markers return to homeostatic levels. The gradual 
normalization of activation status of both the parenchyma and the broncho-alveolar 
compartments is seen over time. This observed process of transient neutrophil 
activation and later restoration during the first weeks after trauma is in line with a 
clinical trauma study from Hietbrink et al. 36.   
Broncho-alveolar lavage is a clinically useful and relatively non-invasive method to 
study the inflammatory milieu of distal airways and alveoli. Most studies in the field of 
pulmonology, however, have been performed on lung biopsy samples. Variations exist 
between both sampling techniques regarding the constitution of samples in chronic 
inflammation 37. In addition, we also found striking differences between both sampling 
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techniques in the cases of trauma-induced acute systemic inflammation. Cell-surface 
expression of both L-selectin and integrins differ largely between the parenchymal 
neutrophil pool and the broncho-alveolar pool. These differences can be explained by 
potential biological functions of both receptors in neutrophil migration and 
compartmentalization processes 27,28,35. As correlations between compartments were 
lacking in our standardized study, utilization of BALF to study the pulmonary 
compartment might not be an optimal method, and alternatives should be sought and 
further validated in upcoming studies.  
For this study, an ice-cold PBS solution was used in a standardized fashion to collect 
BALF as this method is utilized in the clinical situation as well. Furthermore, it has been 
described that the addition of EDTA to the flush solution can cause the detachment of 
sequestered neutrophils 38. Heparinized buffer solutions have the downside of 
potentially activating neutrophils due to in vitro-confirmed heparin-induced neutrophil 
activation 39. Nevertheless, testing altered BALF-flushing solutions should be a focus of 
further research as this may improve the readout potential and representability of the 
BALF procedure for studying the pulmonary neutrophil pool.   
This investigation has several limitations. Unfortunately, we were not able to 
investigate the functional capacities of different pulmonary neutrophil populations. It 
might be that the neutrophils residing in different compartments are in fact different 
phenotypes with specific functionality. Furthermore, it would be interesting to compare 
the formation potency of neutrophil extracellular traps (NETs) between populations 40. 
Neutrophil extracellular traps are characterized by an extracellular filamentous 
chromatin-histone matrix enriched with neutrophil granular proteins such as 
myeloperoxidase and lactoferrin 41. They were demonstrated to facilitate PMN 
extracellular bacterial killing. Initially it was believed that neutrophil cell death was 
required to form NETs. However, a more recent study from Yousefi et al. demonstrated 
that under specific conditions, neutrophils were capable to form NETs out of 
mitochondrial-DNA without subsequent loss of cell viability. Interestingly, ´NETosis´, 
the process of NET-formation, seems to be an important factor in the development of 
both acute and chronic inflammatory diseases 42. The interplay between pulmonary 
neutrophil deposition, compartmentalization, activation, and NET-formation following 
orthopaedic trauma and intramedullary nailing should be a focus of upcoming studies.   
9.5. CONCLUSION 
In conclusion, the current study was the first to describe alterations in pulmonary 
neutrophil compartmentalization and activation following intramedullary nailing. We 
demonstrated that our standardized rat model is feasible to study the long-term innate 
immune response to trauma in all tissue compartments. As neutrophil cell-surface 
activation levels between parenchymal and bronchoalveolar neutrophil pools in our 
study were not correlated, BALF might not be an optimal readout to analyse 
characteristics of the heterogeneous pulmonary neutrophils. Therefore, it would be 
interesting to study alternative minimally invasive techniques for collecting 
representative lung neutrophils.  Moreover, this standardized experiment revealed a 
specific pattern of transiently increased neutrophil deposition and increased PMN 
pulmonary activation. The encountered differences in integrin and selectin expression 
patterns between distinct pulmonary PMN pools imply a relevant biological role of 
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integrins and L-selectin in migratory lung processes. These insights might be 
interesting targets for upcoming therapies aimed to intervene in pulmonary neutrophil 
infiltration and compartmentalization mechanisms in patients at risk for inflammatory 
complications after orthopaedic trauma.
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10.1. PART I: INFLUENCE OF TBI ON FRACTURE HEALING 
TBI is recognised to induce both central and systemic changes, a number of which have 
the potential to affect bone and bone fracture healing. Clinical observations as well as 
expert opinions claim enhanced bone healing in patients with concomitant severe TBI, 
although the relationship between TBI and fracture healing is still poorly understood. 
Therefore, we aimed in part I of this thesis to find answers to the question of whether 
concomitant TBI definitely enhances fracture healing. And if so, what 
pathophysiological mechanisms are underlying this effect?  
The first review on this topic by Morley et al. 1 could not answer the question of whether 
there is positive interaction between TBI and fracture healing. More recently, in our 
review described in chapter 2, we observed a consensus of the scientific community 
over the positive influence of TBI on fracture healing, although the underlying 
pathophysiologic mechanisms of enhanced callus formation in patients with 
concomitant TBI remain unknown. Since the publication of our review in 2015, several 
new experimental as well as clinical studies have been published on this topic. 
Experimental studies. In the experimental research setting, several studies have been 
published after our review, which provide further evidence for the positive influence of 
TBI on fracture healing. These studies demonstrate the enhanced callus formation and 
superior mechanical integrity of the fracture site in murine TBI/fracture models 2-4. 
Several researchers have hypothesised that the enhanced callus volumes post-TBI may 
represent a form of heterotopic ossification (HO); however, no gross morphological 
differences exist in the callus structure between the patients with and without 
concomitant TBI. Localised inflammation in combination with neurological injury is 
suggested to drive this abnormal bone formation 5. Although the callus formation at HO 
and fracture sites may be equal in composition and quality, the soft-tissue environment 
of HO, often peri-articular, may not be as favourable for bone formation as that of 
fracture sites. 
Moreover, studies have suggested that the central and peripheral nervous system plays 
a significant role in regulating bone homeostasis and that an injury-induced 
disturbance of neural pathways alters the bone regeneration response during fracture 
healing. According to this theory, several studies have shown a positive correlation 
between increased leptin concentrations after TBI and enhanced callus formation and 
bone healing 6-8. After TBI, the expression of leptin in the brain is upregulated and the 
leptin concentrations in both cerebrospinal fluid (CSF) and serum are increased, 
leading to faster callus formation 6. In leptin-deficient mice, the research group of Graef 
and Seemann showed decreased callus formation, impaired bony bridging of fractures 
and high non-union rates compared with wild type mice 7,8.  
Other studies 9-11 have demonstrated that the serum from brain-injured rats increased 
the proliferation of mesenchymal stem cells and that the serum and CSF from patients 
with TBI increased osteoblastic proliferation, indicating the role of humoral 
mechanisms. 
Building up on the observation in our review that many studies focus on the role of 
mesenchymal stem cells (MSCs), Liu et al. studied the influence of the stromal cell-
derived factor-1/CXC-Motiv-Chemokine receptor 4 (SDF-1/CXCR4) axis and its role in 
the ‘homing’ of MSCs at the fracture site during bone repair in a murine fracture model 
12. In post-TBI mice, an upregulation of the SDF-1/CXCR4 axis after TBI and enhanced 
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callus formation were shown. Inhibition of SDF-1 resulted in the decrease of callus 
formation again. Therefore, they concluded that SDF-1, as a chemoattractant for MSCs 
during bone regeneration, is a factor that seems to play a pivotal role in the enhanced 
fracture healing after TBI.  
Clinical studies. In the clinical studies published after our review, the influence of 
neuroendocrine pathways on bone regenerations comes to the fore. The assumption 
that TBI has a substantial impact on skeletal regeneration and remodelling is 
reasonably based on the central role of the hypothalamic nuclei in managing 
neuroendocrine humoral outflow via the pituitary gland. The tissue damage after a TBI 
results in the release of tissue debris, prostaglandins and reactive oxygen and nitrogen 
elements, which in turn cause a response of resident immune cells, an upregulation of 
leukocyte migration and recruitment and the release of inflammatory mediators, such 
as cytokines and chemokines. This systemic and local immune response is accompanied 
by a neurogenic inflammation process in which different neuro-humors, 
neurotransmitters or neuro-hormones with osteogenic characteristics are systemically 
and locally released at the fracture site, thus playing a crucial role in bone regeneration 
13-16. 
This vision was supported by a prospective controlled study performed by Khallaf et 
al., who showed an accelerated fracture healing process in patients with concomitant 
TBI based on the involved neuro-hormonal mechanisms 17. The healing time was 
shorter, the callus volume was larger and the concentrations of parathyroid and growth 
hormone were elevated in this group of patients; moreover, the (nor-)adrenaline level 
was lower, reflecting a relative inhibition of nerve signalling of the sympathetic nervous 
system via neuromediators in the hypothalamus after TBI. This in turn could lead to the 
substantial mobilisation of undifferentiated mesenchymal stem cells and 
osteoprogenitor cells to the peripheral circulation to induce accelerated abundant 
healing of long-bone fractures, indicating the combined neuro-hormonal mechanism 
that explains this accelerated healing. The normal level of corticosteroids in patients 
with severe head injury and associated long-bone fractures could reflect a relative 
neuronal inhibition of the suprarenal cortex in producing anti-osteogenic 
corticosteroids, thus inducing an inflammatory condition, which is mandatory to bone 
healing 17. 
Wang et al. also showed enhanced osteogenesis in patients with a combination of 
fractures and spinal cord injury – namely, increased callus volumes and shorter healing 
times. However, in this study, all patients were classified as Frankel grade A, meaning 
they had no motor or sensory function, which could be a reason for the reduced 
mobilisation and subsequent callus formation in these patients 18. 
The research groups of both Zhuang and Li and Zhang et al. found evidence for the role 
of nerve growth factor (NGF) in the acceleration of fracture healing 19,20. This 
polypeptide hormone plays an important role in the survival of nerve centres and 
peripheral neurons by adjusting their growth, development and differentiation 21. The 
concentration of NGF was demonstrated to significantly increase after injury in patients 
with limb fractures and TBI compared with the patients with only limb fractures. The 
proposed mechanism of action was that NGF increases the nerve ingrowth into the 
callus, stimulates the local angiogenesis and thereby promotes bone regeneration. 
Supportive to this theory, Zhuang and Li demonstrated an increased concentration of 
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epidermal growth factor, which simultaneously acts on vascular endothelial cells, 
fibroblasts and osteoblasts to promote the formation of bone tissue and to accelerate 
the synthesis and deposition of the matrix 19. Furthermore, Zhang et al. demonstrated 
an increased level of vascular endothelial growth factor (VEGF), which mediates local 
angiogenesis at the fracture site 20. Zhang et al. also demonstrated that the percentages 
of M2 macrophages significantly increased during fracture healing, especially in 
patients with concomitant TBI who showed larger callus volumes and shorter healing 
times. These M2 macrophages are recruited to the fracture site in the later 
inflammatory stage of fracture healing, and they secrete tissue repair factors such as IL-
10, TGF-β, BMP 2 and VEGF to initiate the anti-inflammatory response; moreover, they 
attract mesenchymal stem cells and induce osteochondral differentiation and 
angiogenesis 22. 
In summary, there are strong indications, both experimental and clinical, for an 
influence of TBI on fracture healing via different neuro-humoral and neuro-hormonal 
pathways. Because the above described underlying pathomechanisms are far from 
uniform, these provide us with multiple leverage points to base future studies on. In our 
retrospective clinical study described in chapter 3, we demonstrated that the fracture 
stabilisation strategy has more impact on fracture healing and non-union development 
than concomitant injuries, such as TBI and chest injury. Moreover, we did not identify 
TBI as an independent factor for non-union development. Furthermore, the clinical 
studies supporting the expert opinion that TBI positively influences fracture healing are 
ambiguous and have low comparability and extent of the patient population. Therefore, 
it would be of immense interest to set up a large prospective multicentre study on 
patients with long-bone fractures and concomitant TBI to clinically endorse or reject 
the hypothesis that TBI positively influences fracture healing. 
The results of part I of this thesis emphasise the importance and potential of further 
clinical as well as experimental research on the topic of fracture healing and its 
pathomechanisms.  
Overall, over the last decades, evidence for the relationship between neural and 
humoral pathways and fracture healing has been increasingly provided in experimental 
studies, but the exact pathophysiological mechanisms are not yet clear. In part II of this 
thesis, we further elaborated on some of these issues; however, because the 
pathophysiological complex of fracture healing contains multiple influencing factors, 
which are also intertwined with each other, there will be much to be gained in this field 
of research in the next years. Further research will provide knowledge on 
pathophysiologic mechanisms, which can eventually be used to diagnose patients at 
risk for non-unions or delayed unions and to alter their treatment strategy. 
10.2. PART II: NEURO-HUMORAL MODULATION OF FRACTURE HEALING 
Attempts to modulate the inflammatory response of the body in stress situations, such 
as organ dysfunction or sepsis, to improve survival are often unsuccessfully 
undertaken. The innate immune system appears to be barely responsive to the 
immunosuppressive drugs used in current treatment strategies. Besides the evidence 
that the use of immunosuppressive agents is counterproductive for bone healing, the 
modulation of fracture healing remains difficult. Part of the aims of this thesis was to 
expound some leverage points in the normal neuro-humoral modulation mechanism of 
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bone regeneration, which could possibly influence the fracture healing process. In part 
II of this thesis, these aspects are studied and described. 
As mentioned before, a significant role in regulating bone homeostasis and fracture 
healing is also imputed to the central and peripheral nervous system and to injury-
induced disturbances of neural pathways. 
On this basis, in chapter 4, we studied the influence of the blockage of substance P, a 
neurotransmitter released by the sensory nerve-endings in bone tissue, on fracture 
healing. 
We demonstrated that this blockage impaired not only the expression of osteogenic 
genes but also the quality of the callus formed and the biomechanical strength in 
fracture healing. These results, together with the results of previous studies on this 
topic by Offley et al. 23 and Apel et al. 24, provide strong indications for the connection 
between neural pathways and bone regeneration.  
Although these results may not have direct consequences for the current treatment of 
patients with fractures or disturbed fracture healing, they provide a sound basis for 
further research on the influence of substance P on fracture healing. A next step in 
research could be to study the influence of the local or systemic administration of 
substance P on fracture healing in small animal fracture models. Another possibility, 
with the results of our study in mind, is a study in which the influence of substance P 
blockage on fracture healing is investigated in a combined small animal fracture and 
TBI model. Apel et al. have already shown that the blockage of both neurotransmitters 
(i.e. substance P and CGRP) from sensory nerves results in impaired fracture healing; 
therefore, further research on the role of CGRP in fracture healing is also promising. The 
results of such studies could eventually lead to the use of specific neurotransmitters as 
diagnostic markers or therapeutic agents in clinical situations. 
For the clinical outcome of patients with lower extremity fractures, in addition to the 
biomechanical strength of the healed bone, the quality of the mobility of patients is very 
important and significantly determines the quality of life after fracture healing. 
Therefore, being capable to perform an adequate evaluation of the gait of patients is 
crucial in the clinical setting as well as in the experimental setting of fracture research. 
Therefore, we wanted to implement a method for gait analysis in small animal fracture 
models because these models constitute about 50% of experimental fracture healing 
research.  
In chapter 5, we evaluated – to the best of our knowledge – for the first time the 
CatWalk gait analysis system for gait analyses in a femur fracture rat model. Our results 
showed that the CatWalk system is suitable for gait analysis in small animal fracture 
models and that the evaluated gait patterns have high correlation with the osteogenesis 
of fracture healing in these models. Because clinical interest in gait analyses is 
increasing and gait disturbances have a significant impact on the quality of life of 
patients with lower extremity fractures, we presume that the use of this gait analysis 
system in fracture healing research meets a need and the expectations of researchers 
in this field. Moreover, we suppose that the CatWalk system will be preferred above 
other methods, such as treadmill measurements, because in this system, the ranges of 
both static and dynamic parameters, which can be evaluated at the same time, are more 
comprehensive. For instance, using this system, the pressure exerted by each paw, the 
10
209
CHAPTER 10 | 
210 
swing and stand phase of each leg and the percentage of the time spent bearing weight 
in each walk cycle for the given paw can be evaluated. Furthermore, these data can be 
simultaneously compared with the healthy side. We therefore expect the CatWalk gait 
analysis system to be increasingly used in small animal fracture research, which we 
strongly advocate because it can provide a considerable amount of data and knowledge 
for gait analysis development after lower extremity fractures. 
To date, the most important tools for diagnosing disturbed fracture healing are clinical 
and radiological findings. Although research on the possible biomarkers that can be 
used as predictors for non-union development is promising, achieving consensus is 
very difficult because the evidence available is heterogeneous 25. Moreover, when a 
non-union is diagnosed, the exact treatment and the time point of this non-union 
treatment are still under discussion. Because the socio-economic impact of disturbed 
fracture healing is immense, finding biomarkers, which can predict the prognosis of the 
fracture healing process and the outcome of certain procedures performed in cases of 
non-unions, would be very valuable. 
The results of our study described in chapter 6 most importantly indicate a 
significantly lower ornithine concentration and arginase-1 expression in the bone 
marrow of patients developing non-unions. Moreover, this was the first study to 
recognise the possible biomarkers that could be used as predictors of the outcome of 
the autologous bone grafting procedure by reamer-irrigator-aspirator (RIA) in cases of 
non-union. These possible biomarkers include arginine, ornithine and iNOS.  
Therefore, this study could be a starting point to further investigate these biomarkers 
in the fracture healing process and to determine certain cut-off points for the different 
biomarkers, based on which the prognosis of fracture healing and non-union treatment 
could be estimated. 
The concentrations and expressions of these supposed ‘biomarkers’ give an indication 
on the prognosis of the non-union treatment in the case when the non-union has 
already occurred. Knowing the level of these concentrations and expressions at the time 
of the initial fracture would be more interesting so as to be able to say something on 
non-union development. 
In multivariate analysis, iNOS was the only significant factor within the included 
variables (i.e. age, BMI, NUSS, arginine-, citrulline- and ornithine concentrations and 
arginase-1 and iNOS expression). Differences in the molecular patterns in bone grafts 
between patients with success and failure at a site distant from the non-union may 
indicate that systemic molecular pathologies are partly responsible for the failure of 
non-union treatment and that the non-union is not a purely local metabolic problem. 
Previous studies have shown that the callus tissue and plasma samples of patients with 
hypertrophic and atrophic non-unions have abnormal low concentrations of amino 
acids arginine, citrulline and ornithine when compared with those of patients with 
normal healed and acute fractures 26.  
Increased iNOS expression suggests a prolonged inflammatory response (i.e. 
stimulation by NF-κΒ) that results in the production of pro-inflammatory cytokines 
such as IL-1, TNF-α and IFN-γ. A disturbed chronic inflammatory response during 
fracture healing might result in delayed union or non-union development and this could 
be a reason that the reaction of the bone tissue to the RIA treatment is inadequate 27,28. 
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The significantly lower arginine concentrations that coincide with the higher iNOS 
expression in patients with refractory non-unions may indicate the depletion of this 
amino acid by an increased catabolic response of the patient 29.  
Arg1 is the enzyme that converts arginine into ornithine, which can subsequently lead 
to collagen synthesis. RIA procedures resulting in successful non-union healing as well 
as in unsuccessful healing showed a 3–4-fold lower arginase-1 expression than normal 
healed fractures. This might reflect the inadequate anabolic response of the bone during 
the healing process, which initially was the cause of the non-union development and 
the need for surgical repair. This is also reflected by the lower ornithine concentrations 
measured in the reamed intramedullary aspirate in these patients.  
Although the NUSS score is a known factor in patients with a fracture that defines the 
risk of subsequent non-union development, this study found the NUSS score to be a 
predictor of the success rate of the non-union treatment. In addition, compared with 
the NUSS score, the activity of the inflammatory response in the grafted material 
obtained by RIA was a better predictor of therapy success. 
A limitation of this study is the heterogeneity of different patient characteristics in a 
relatively small patient population. Ideally, a large cohort of patients with similar 
characteristics in all groups is needed to minimise the possible confounding effects; 
therefore, this study should be regarded as a hypothesis generating pilot study. 
Owing to the diversity of the cell types involved in the complex process of fracture 
healing, synergistic interactions between these cells are essential; moreover, it is 
reasonable and proven that micro-vesicles (MVs) play an important role in this 
intercellular communication 30-33. However, the knowledge on the role of MVs and 
especially of systemically derived MVs in fracture healing is still sparse. 
In chapter 7, we demonstrated that systemically released MVs isolated after a femoral 
fracture were time-dependently incorporated in osteoblasts and concentrated around 
their nucleus. Further, we showed that these MVs modulated the viability but not the 
differentiation of osteoblasts after trauma.  
Although we do not detail in our study the exact pathophysiological mechanisms of 
action or the content of these MVs, it is known from literature that these MVs are active 
in many physiological and pathophysiological processes in the human body and that 
they play an important role in intercellular communication during fracture healing, 
between cells locally or at a distance through receptor-mediated interactions or by 
delivering their protein, lipid and genetic contents 34-38. 
The role of MVs and related vesicles (i.e. exosomes), which can be generated by various 
cell types, has gained interest over the last years. Different studies have demonstrated 
that exosomes have the potential to induce regenerative processes during bone 
formation, accomplished by activating the native cells (especially mesenchymal stem 
cells), upregulating growth factor genes, regulating osteogenesis, enhancing 
angiogenesis and increasing the expression levels of specific proteins involved in matrix 
mineralisation 33,39-42. 
In the literature, the important role of paracrine signalling of MSCs that differentiate to 
regenerate bone defects is emphasised 43-45. Therefore, the proliferating and migrating 
capacity of MSCs is crucial for fracture healing. Osteoblasts, as a differentiated product 
10
211
CHAPTER 10 | 
212 
from MSCs, are important for the mineralisation process of callus because they produce 
calcium- and phosphate-based minerals 46. The pivoting role of the regulation of 
osteoblast proliferation and osteogenic differentiation in bone regeneration is 
supported by the results of our study presented in chapter 8 of this thesis.  
Micro-vesicles incorporate various components from the originating cells, including 
lipids, proteins, mRNA, miRNA and other components 38,47,48; in particular, miRNAs are 
supposed to have a central role in bone regeneration. In the review by Hao et al., the 
upregulation of certain miRNAs in exosomes and their modulatory effect on the target 
genes and pathways in the regulation of osteogenic differentiation is substantiated by 
the studies of multiple authors 39. 
In another possible pathway, mentioned in the review by Hao et al., other contents of 
the vesicles, such as cytokines [monocyte chemoattractant protein 1 (MCP-1) and 
stromal cell-derived factor 1 (SDF-1)], activate or are delivered to the target cells at the 
fracture site as mode of action of the MVs 39. 
In short, the pathway of MVs from resident cell to target cell and the exact consequences 
of the release of their content at the fracture site are very complex and regulated by 
multiple factors, which are still to be elucidated by future research.  
The biological characteristics and structure of exosomes and MVs make them 
appropriate to act as a diagnostic or therapeutic tool in cases of fracture healing or 
delayed fracture healing. Encapsulation by the lipid bilayer of the exosomal membrane 
protects the proteins and miRNAs of exosomes from degradation in the body fluid, 
contributing to their ability to deliver the content across the cell membrane into the 
cytosol of the recipient cells 49,50. Compared with biomaterial treatment, the 
composition of these vesicles resolves the problems of immunogenicity and toxicity. In 
addition, exosomes are considerably stable and can be preserved for approximately six 
months in vitro at −20 °C without loss of potency 51. Nevertheless, the process from 
formation to effect is fairly complex and is regulated by multiple factors. The related 
mechanisms are still at an early stage of comprehension and require further 
investigations 48,52.  
In addition, the exact mechanisms of the enhanced bone formation after exosome 
treatment remain elusive. Thus, exosomes from different sources may exhibit diverse 
effects on fracture healing. 
Future research therefore needs to investigate the characteristics of the process in 
which MVs play the key role in influencing fracture healing, including the origin and 
composition of the MVs, the mechanism of action of different constituents within the 
MVs, the exact target cells of the MVs, etc.  
If these questions are answered, the way in which the responsible contents of MVs can 
be used to help in the diagnostics or treatment of fractures should be addressed. 
Possible applications could be the adjustment of the content or local application of MVs 
to alter the fracture healing process. Because the current exosome isolation methods 
such as ultracentrifugation and ultrafiltration only provide a low exosome yield 53, the 
challenge of obtaining sufficient amounts of exosomes has to be overcome 39. 
In the field of cellular immune response to trauma, neutrophils play an important role. 
In addition to their role as eliminator of detrimental stimuli, they modulate the function 
of multiple components of the innate and adaptive immune system. The functionality of 
neutrophils is reflected by the cell-surface expression of selectins and integrins.  
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In the study described in chapter 8, we demonstrated the changes in the circulatory 
neutrophil population in a standardised long-term observation fracture model, 
primarily focusing on the later inflammatory phase (>48 h after trauma) rather than 
the early/instant immune response. A temporary decrease in the number and 
activation status of the circulatory neutrophils was shown three days after femoral 
fracture and intramedullary nailing. The decreased activation was characterised by a 
reduced αMβ2-integrin (MAC-1 or CD11b/CD18) and an increased αLβ2-integrin (LFA-1 
or CD11a/CD18) expression. The transient decrease in neutrophil numbers could be 
caused by the homing of neutrophils into the fracture hematoma, regulated by the 
release of mitochondrial damage-associated molecular patterns (DAMPs) and the 
subsequent release of different chemoattractants. This homing of neutrophils into the 
fracture haematoma is in line with the results of several experimental and clinical 
studies that describe this phenomenon after fracture 54-58.  
Other important features of the inflammatory response after fracture are the extent, 
duration and sufficient termination of this response because enhanced migration of 
neutrophils into other organ systems after long-bone fractures and intramedullary 
stabilisation has also been described and could justify our finding of decreased 
circulatory neutrophil numbers. In this context, the lungs have been identified as a 
primary target organ, in which neutrophils potentially damage parenchymal lung tissue 
59 and cause complications such as acute lung injury and ARDS 60-62. Moreover, in the 
case of insufficient termination of the immune response, excessive homing of 
neutrophils into the fracture haematoma can occur and this could be damaging to the 
fracture healing process as well 63-65.  
The total range of functions of neutrophils as activators and regulators of different cells 
and processes within the non-specific as well as specific immune response is still to 
discover. 
The functionality of neutrophils is regulated by the neutrophil surface receptor 
expression, which can detect different chemoattractants and define different neutrophil 
subsets or phenotypes. We examined the expression of selectins and integrins; 
moreover, we demonstrated an increase in heterogeneity and thereby a change in the 
functionality of the circulatory neutrophil pool during the restoration of neutrophil 
homeostasis after fracture.  
We proved that a new subset of unique CD11bhigh/CD11ahigh neutrophils was present in 
the post-inflammatory neutrophil pool. This demonstrates a post-traumatic cell surface 
receptor dynamic in circulating neutrophils and an increased heterogeneity of the 
blood neutrophil pool during the restoration phase after trauma. Owing to the wide 
range of functions of neutrophils, it is reasonable that phenotypic and functional 
diversity exists within the neutrophil pool and that subpopulations of neutrophils are 
identified 66. Because the neutrophils of this CD11bhigh/CD11ahigh subset have a 
significantly higher co-expression with very late antigen-4 (VLA-4/CD49d) than regular 
neutrophils, as we have shown, they most likely represent a unique phenotype.   
The expression of CD49d has been identified on neutrophil progenitor cells in the bone 
marrow; therefore, it is tempting to hypothesise that these CD11bhigh/CD11ahigh 
neutrophils are released from the bone marrow 67,68. 
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On the contrary, whether these neutrophils with distinct functions belong to separate 
developing lineages or embody certain activation states of a common precursor is still 
not proved 69. In the last years, increasing attention is being paid to neutrophil 
heterogeneity 70 because this could be very interesting for future selective 
interventions. Certain therapies applicable to all neutrophils are mostly accompanied 
by the aggravating complications of neutropenia; therefore, the possibility to modulate 
specific subsets of neutrophils opens a wide range of possibilities in all kinds of 
treatments. Moreover, in fracture healing, the presence of different phenotypes of 
neutrophils, such as those demonstrated in our study, could offer opportunities in the 
treatment of disturbed fracture healing. Because our study was the first to describe 
these changes in the blood neutrophil pool in a standardised femoral fracture model, it 
can form the basis for the further research of novel immunotherapeutic strategies to 
modulate neutrophil homeostasis after fractures. 
Besides the influence of an intramedullary treated femoral fracture on the circulating 
neutrophils, in chapter 9, we studied the explicit influence of this pathology on the 
pulmonary neutrophil pool in rats. In line with the decreased circulating neutrophil 
numbers and activation three days after fracture induction, we found an increased 
pulmonary neutrophil deposition as well as a specific neutrophil activation pattern, 
characterised by increased selectin and integrin receptor expression in this period of 
fracture healing. 
As described by Deniset et al., the lungs, besides the skin and the spleen, function as a 
reservoir for neutrophils 70. One theory on the function of these pulmonary neutrophils 
is that they reside in the pulmonary capillaries and perform a kind of immune 
surveillance 71. Another theory is that older neutrophils eventually return to the lungs 
to de-prime and express novel homing receptors for migration to the bone marrow to 
undergo apoptosis 72. A third theory is that the intrapulmonary neutrophils form an 
original, different subset with a distinct function 73. 
Although a novel subset of neutrophils within the pulmonary tissue is not verified until 
now, the results of our study on the pulmonary neutrophil pool in chapter 9 show a 
certain compartmentalisation related to intrapulmonary neutrophil heterogeneity, 
with impressive differences between the neutrophils belonging to the pulmonary 
parenchymal and broncho-alveolar compartments. This could indicate a limited 
readout potential of broncho-alveolar lavage fluid (BALF) analysis to evaluate the 
pulmonary neutrophil pool. 
We further demonstrated a substantial increase of the cell-surface expression of both 
the integrin MAC-1 and the selectin CD62L on pulmonary neutrophils after an isolated 
femur fracture. These findings might be explained by the increased selective pulmonary 
homing of a specific subset of neutrophils after trauma. 
These phenomena could also increase the possibility of neutrophil NET production 
leading to tissue damage within the lungs, thus causing inappropriate inflammatory 
situations such as ARDS in poly-traumatised patients 69. Overall, future research to 
dispose the identity of neutrophil subpopulation or phenotypes should be propagated 
because more questions about the activities, functions and roles of neutrophils in 
fracture healing continuously originate. 
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10.3. CONCLUSIONS OF THIS THESIS 
As demonstrated throughout this thesis, fracture healing is still a very complex, 
kaleidoscopic process, many aspects of which are still not clear. The process has 
multiple influencing factors, which relate and influence each other and sometimes have 
opposing effects depending on the phase in which the fracture healing process is 
situated. 
In chapter 2 and 3, we demonstrated that the evidence for the positive influence of TBI 
on fracture healing and bone regeneration is increasing, especially in experimental 
studies. On the contrary, prospective clinical trials to support these experimental data 
are still missing. 
In chapter 4, we showed the negative effects of neurokinin-1-receptor blockage on the 
expression of different osteogenic proteins and on the biomechanical strength of bone 
healing. This means that substance P is important for a normal bone healing process 
and that this neurotransmitter offers great potential for future research related to 
fracture healing. 
In chapter 5, we successfully introduced the CatWalk system for gait analysis in 
fracture healing studies in small animal models. The gait analysis with this system is 
accurate, and the system provides clinically relevant and extensive static as well as 
dynamic data on gait patterns in a non-invasive, longitudinal manner during fracture 
healing in small animal models. The CatWalk system has the potential to become a 
standard gait analysis method in fracture healing research in experimental small animal 
models, thereby improving knowledge about behavioural and locomotor recovery after 
lower extremity fractures. 
In chapter 6, we investigated the influence of amino acid metabolism in fracture 
healing and found that the arginine-NO metabolism in the bone marrow influences the 
outcome of non-union treatment, with indications for a prolonged inflammatory 
response in patients with unsuccessful bone grafting therapy. The determined arginine 
concentrations and Nos2 expression could be used as predictors for the successful 
treatment of autologous bone grafting in non-union treatment. 
In chapter 7, we demonstrated that MVs from trauma plasma increased the viability 
but did not stimulate the differentiation of osteoblasts, particularly in the late phase of 
fracture healing. These acknowledgements, together with the growing scientific 
interest in exosomes, MVs and apoptotic bodies, will contribute to a better 
understanding of the intercellular communication processes in fracture healing. 
In chapter 8 and 9, we showed that in the fracture healing process, a transient decrease 
in circulating neutrophil numbers and a transient increase in the pulmonary deposition 
of neutrophils with a specific activation pattern occur. The latter phenomenon might 
play an important role in the pathomechanism of ARDS after trauma. Furthermore, we 
demonstrated the increased heterogeneity of the blood neutrophil pool during the 
restoration phase of neutrophil homeostasis by identifying a novel subset of 
CD11bhigh/CD11ahigh neutrophils appearing one week after the intramedullary nailing 
of a femur fracture. 
Finally, in this thesis, we contributed towards the further understanding of a few 
aspects of neuro-humoral modulation of the fracture healing process, although we may 
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have launched more questions than provided answers within this difficult but exciting 
subject matter. Therefore, this thesis forms an excellent basis for future research in this 
field, which will improve our understanding of fracture healing processes and their 
influencing factors. 
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In this thesis, we focused on several aspects of neuro-humoral modulation of fracture 
healing. We explored the literature, performed clinical studies and executed several 
experimental studies on small animal models.  
The aim of chapter 1 was to provide solid background information on the 
inflammatory and neuro-humoral responses to fracture healing and on fracture 
healing in general to equip the reader with a good basis to assimilate the information 
within this thesis. This is achieved by explaining the normal fracture healing process 
as well as its different stages and by clarifying the role of angiogenesis and different 
biologic factors in this process. Moreover, the disturbed fracture healing process 
along with its consequences and the influence of poly- and neuro-trauma on fracture 
healing are described. The literature on these topics clearly shows that fracture 
healing is an immense and complex phenomenon and many of its aspects are yet to 
be resolved. Therefore, the drive to write this thesis was the need to clarify little parts 
of the missing pieces in the realm of the fracture healing mechanism. 
11.1. PART I: INFLUENCE OF TBI ON FRACTURE HEALING 
In chapter 2 and 3, we aimed to provide an answer to the hypothesis that 
concomitant TBI enhances fracture healing.  
In the literature review presented in chapter 2, we included clinical, in vivo and in 
vitro studies to test this hypothesis, which is represented by expert opinions in the 
field. In these studies, performed in the last 50 years up to 2013, many different 
substances are investigated, such as cytokines, growth factors, mesenchymal stem 
cells, genes, hormones, proteins and enzymes, but a concrete pathomechanism to 
confirm the hypothesis was not find. However, the consensus of all published 
preclinical papers is that TBI indeed accelerates fracture healing via the 
osteoinductive factors in the serum and CSF released by the injured brain. On the 
contrary, the clinical studies with relatively small populations cannot fully support 
this hypothesis. 
In chapter 3, we performed a retrospective study to identify the roles of chest 
trauma, TBI and fracture stabilisation strategies on fracture healing. Although the 
results of this study could not confirm the relation between TBI or chest injury and 
fracture healing tendency, we demonstrated that the number of operations 
performed in patients with long-bone fractures was an independent predictor for 
non-union development.  
The results of these two studies were an incentive to further elaborate on our 
research on fracture healing with a focus on neuro-humoral pathways. 
11.2. PART II: NEURO-HUMORAL MODULATION OF FRACTURE HEALING 
In chapter 4, we aim to specify the proved influence of efferent sensory nerves on 
fracture healing by the selective blocking of the neurokinin-1-tachykinin (NK1) 
receptor for substance P as a neurotransmitter of these efferent sensory nerves. In 
this study, we showed that the blockage of this specific neurotransmitter impaired 
the gene expression of important osteogenic proteins (i.e. osteocalcin, collagen 1A2 
and collagen 2A1) in the early stages of fracture healing. Furthermore, we 
demonstrated that the blockage of the NK1 receptor resulted in the decreased 
biomechanical strength of the callus/bone throughout the fracture healing process 
in a small animal fracture model. 
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Chapter 5 reverts to a study we performed on gait pattern and muscle weight in a 
small animal femur fracture model. Because gait analysis is becoming increasingly 
important in the evaluation and rehabilitation of patients with lower extremity 
fractures, we wanted to establish a standard gait analysis method to investigate the 
gait parameters in the most used experimental fracture healing model: the small 
animal model. Normal gait pattern and muscle weight evolvement during fracture 
healing in rats was outlined in this chapter. We successfully introduced the 
CatWalkTM system for gait analysis in small animal models. Moreover, we 
demonstrated that this system could adequately register both static and dynamic 
gait parameters and that the gait pattern evolvement in this small animal model 
resembles that in patients with lower extremity fractures.  
In chapter 6, we clinically evaluated the biomarkers of the arginine-NO metabolism 
in trabecular bone harvested during RIA procedures for the non-union treatment of 
long bones. We demonstrated for the first time that arginine and NOS2 can be used 
as prognostic biomarkers to predict a successful outcome of non-union treatment. 
In chapter 7, 8 and 9, our focus shifted towards the role of cellular mechanisms 
within the inflammation response to femoral fracture in a small animal model. 
In chapter 7, the influence of MVs, which play an important role in intercellular and 
transcellular signal transduction, on osteoblasts was investigated. We showed that 
systemically derived MVs isolated after femoral fracture were time-dependently 
incorporated in osteoblasts and concentrated around their nucleus. Furthermore, we 
demonstrated that MVs potentially affect fracture healing regulation by increasing 
the viability of osteoblasts, particularly in the later inflammatory phases of fracture 
healing. 
In chapter 8, we demonstrated that three days after fracture induction, a temporary 
reduction in neutrophil count occurred, along with a concurrent increase of CD11a 
expression and a concurrent decrease of CD11b expression on circulatory neutrophil 
membranes. Moreover, we showed that during the subsequent restoration of 
neutrophil homeostasis, a novel subset of CD11bhigh/CD11ahigh neutrophils appears, 
with a co-expression of α4-integrin (CD49d). 
In chapter 9, we investigated the impact of an intramedullary stabilised femur 
fracture on the characteristics of the pulmonary neutrophil pool in a small animal 
model. Contrary to the decreased neutrophil activation in peripheral blood after 
trauma demonstrated in chapter 8, the number of neutrophils in the pulmonary pool 
and the expression of membrane receptors transiently increased in the early 
inflammatory phases of fracture healing. Thereafter, the values again normalised to 
physiological levels. 
Chapter 10 includes the general discussion and conclusions of this thesis, in which 
the results of the separate studies are discussed in view of the current knowledge 
represented in the scientific literature. In addition, the gaps in the obtained 
knowledge are identified, which could be explored in future studies. 11
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In dit proefschrift werden verschillende aspecten van neuro-humorale modulatie 
van fractuurheling onderzocht. We verkenden de literatuur en voerden zowel 
klinische als dierexperimentele studies uit.  
Het doel van hoofdstuk 1 was de lezer van voldoende achtergrond informatie 
betreffende de inflammatoire en neuro-humorale respons op fractuur heling te 
voorzien en een goede basis te verschaffen voor het verwerken van de informatie in 
dit proefschrift. Daarvoor hebben we ten eerste het normale proces van 
fractuurheling met zijn verschillende stadia verklaard en vervolgens de rol van 
angiogenese en verschillende biologische factoren aangehaald. Ook werd de invloed 
van poly- en neuro-traumata op de fractuur heling en het proces en de consequenties 
van een verstoorde fractuurgenezing belicht. Uit het literatuuronderzoek van deze 
onderwerpen is gebleken dat fractuurheling op zichzelf een immens complex 
fenomeen vormt, waarvan nog steeds vele aspecten niet zijn opgehelderd. Onze grote 
drijfveer voor dit proefschrift was dan ook het ophelderen van kleine vraagstukken 
betrekking hebbend op ontbrekende stukjes van het mechanisme van fractuurheling. 
DEEL I: INVLOED VAN TRAUMATISCH HERSENLETSEL OP FRACTUURHELING 
In hoofdstuk 2 & 3 hebben we getracht de hypothese dat begeleidend hersenletsel 
het proces van fractuurheling positief beïnvloed te toetsen. 
In de literatuurstudie, zoals beschreven in hoofdstuk 2, werden zowel klinische als 
ook in vivo en in vitro studies geïncludeerd, om deze hypothese, die door experts in 
de klinische medische wereld vertegenwoordigd wordt, te testen. In deze studies, 
uitgevoerd in de laatste vijftig jaar tot aan 2013, werden veel verschillende 
substanties onderzocht, zoals cytokinen, groeifactoren, mesenchymale stamcellen, 
genen, hormonen, proteïnen, enzymen, enzovoort. Ondanks dat we een concreet 
pathomechanisme om de hypothese te bevestigen niet konden vinden, is de 
consensus binnen de gepubliceerde preklinische studies dat traumatisch 
hersenletsel daadwerkelijk de fractuurheling positief beïnvloed via door het brein 
vrijgezette osteoinductieve factoren in het serum en de liquor. Aan de andere kant, 
wordt deze consensus niet gedeeld door de resultaten van de relatief kleine klinische 
studies, die we geëvalueerd hebben. 
In hoofdstuk 3 werd een retrospectieve klinische studie uitgevoerd om de invloed 
van thorax trauma, traumatisch hersenletsel en de fractuurstabilisatie-strategie op 
de fractuurgenezing te beoordelen. Ondanks dat de resultaten van deze studie geen 
relatie tussen traumatisch hersenletsel of thorax trauma en fractuurheling konden 
aantonen, kwam het aantal operaties uitgevoerd in patiënten met lange 
pijpbeenderfracturen naar voren als een onafhankelijke risicofactor voor het 
ontwikkelen van een non-union. 
De resultaten van deze twee studies waren een aanzet om ons onderzoek naar 
fractuurheling uit te breiden met een focus op de invloed van neuro-humorale 
regelsystemen. 
DEEL II: NEURO-HUMORALE MODULATIE VAN FRACTUURHELING 
Het doel van het onderzoek, beschreven in hoofdstuk 4 was de bewezen invloed van 
efferente zenuwsignalen op de botheling te specificeren. Daarvoor hebben we in een 
dierexperimenteel fractuurmodel de neurokinine-1-tachykinine receptor voor 
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substance P, als neurotransmitter van deze efferente sensibele zenuwbanen, 
geblokkeerd. In deze studie konden we aantonen dat deze selectieve blokkade de 
genexpressie van belangrijke osteogene proteïnen, te weten osteocalcine, collageen 
1A2 en collageen 2A1, in de vroege fase van de fractuurheling reduceert. Bovendien 
konden we aantonen dat deze blokkade de biomechanische sterkte van de callus / 
het bot verzwakt gedurende het gehele fractuurhelingsproces. 
Hoofdstuk 5 handelde over gang- en spieratrofie-analyses uitgevoerd in ons 
dierexperimenteel fractuurmodel. Omdat ganganalyses steeds belangrijker worden 
in de evaluatie en revalidatie van patiënten met fracturen aan de onderste 
extremiteiten, wilden we een standaard ganganalyse methode tot stand brengen en 
valideren voor het meest gebruikte dierexperimentele fractuurmodel binnen de 
wetenschap. We konden succesvol het CatWalkTM-system voor ganganalyses van 
klein diermodellen introduceren en demonstreren dat deze methode adequaat zowel 
statische als dynamische parameters kan registreren en dat het patroon van de 
ganganalyse binnen dit diermodel vergelijkbaar is met het patroon van de 
ganganalyses bij patiënten na fracturen van de onderste extremiteit. 
In hoofdstuk 6 hebben we een klinische evaluatie uitgevoerd van bio-markers van 
het arginine-stikstofoxide metabolisme in trabeculair bot. Het weefsel werd 
verkregen door middel van RIA-procedures voor de behandeling van non-unions in 
patiënten. We konden voor het eerst aantonen dat arginine en NOS2 voorspellende 
waarde hadden voor een succesvolle behandeling van non-unions. 
In hoofdstuk 7, 8 & 9 verschoof de focus van ons onderzoek naar de rol van cellulaire 
mechanismen binnen de inflammatoire reactie op femurfracturen in ons 
dierexperimenteel model. 
Het onderzoek naar de invloed van microvesikels, die een belangrijke rol vervullen 
in de inter- en transcellulaire signaal transductie, op osteoblasten werd beschreven 
in hoofdstuk 7.  We konden laten zien dat de na een femurfractuur vrijgezette 
systemische microvesikels tijdsafhankelijk geïncorporeerd werden in osteoblasten 
en dat zij zich concentreerden rondom de celkern. Verder konden we aantonen 
microvesikels potentieel de regulatie van de fractuurheling beïnvloeden kunnen, 
door de levensvatbaarheid van deze osteoblasten te vergroten, voornamelijk in de 
latere inflammatie-fases van de fractuurgenezing. 
In hoofdstuk 8 demonstreerden we dat 3 dagen na de fractuur inductie een tijdelijke 
afname van het aantal neutrofielen optrad, vergezeld van een stijging van de CD11a 
expressie en een daling van de CD11b expressie op de membraan van neutrofielen 
in de circulatie. Bovendien konden we aantonen dat gedurende het daaropvolgend 
herstel van de neutrofielen homeostase een nieuwe subset van CD11bhigh/CD11ahigh 
neutrofielen ontstaat, die een co-expressie met α4-integrin (CD49d) laten zien. 
Het onderzoek naar de impact van een intramedullair gestabiliseerde femurfractuur 
op de eigenschappen van de pulmonaire neutrofielen pool in ons dierexperimenteel 
model werd in hoofdstuk 9 beschreven. In tegenstelling tot de afname van 
neutrofielen-activiteit in het perifere bloed na het trauma, zoals beschreven in 
hoofdstuk 8, nam zowel het aantal neutrofielen in de pulmonaire pool, alsook de 
expressie van membraanreceptoren tijdelijk toe in de vroege inflammatoire fases 
&
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van het fractuurhelingsproces. Hierna normaliseerden deze waarden weer tot het 
fysiologische  niveau. 
Hoofdstuk 10 bevat de algehele discussie en de conclusies van dit proefschrift, 
waarin de resultaten van de afzonderlijke studies bediscussieerd worden in het licht 
van de huidige kennis uit de wetenschappelijke literatuur. Verder worden hiaten in 
de opgedane kennis geïdentificeerd, die mogelijk uitgediept kunnen worden in 
toekomstig onderzoek.
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Die vorliegende Dissertation untersuchte verschiedene Aspekte der 
neurohumoralen Modulation im Hinblick auf die Frakturheilung. Hierzu wurden 
sowohl klinische als auch experimentelle Studien vor dem Kontext der 
internationalen Kenntnislage durchgeführt. 
Kapitel 1 der vorliegenden Dissertation widmete sich dem zentralen Aspekt der 
Hintergrundanalyse der inflammatorischen als auch neurohumoralen 
Immunantwort hinsichtlich der Frakturheilung, um eine generelle 
Grundlageninformation zu bieten.  So werden der normale Ablauf der 
Knochenheilung als auch die unterschiedlichen Stadien in Abhängigkeit der 
Angiogenese und verschiedener biologischer Faktoren dargelegt. Gleichzeitig 
werden die gestörte Knochenheilung mit ihren Auswirkungen sowie die 
Beeinflussung durch Polytrauma oder Neurotrauma beschrieben. Im Kontext zur 
internationalen Literatur wird deutlich, dass die Frakturheilung ein umfassendes 
und komplexes Phänomen mit bislang zahlreichen, ungeklärten Aspekten darstellt.  
Zentrales Ziel dieser Dissertation war daher, bislang ungeklärte Zusammenhänge 
der Frakturheilungsmechanismen weiterführend zu untersuchen. 
TEIL I: EINFLUSSNAHME DES SCHÄDELHIRNTRAUMAS (SHT) AUF DIE 
FRAKTURHEILUNG 
In Kapitel 2 und 3 der vorliegenden Dissertation wurde die Hypothese überprüft, ob 
ein begleitendes SHT die Knochenheilung generell fördert.  
In Kapitel 2 wird nun eine Literaturanalyse im Sinne eines Reviews vorgelegt, die 
klinische, in vivo sowie in vitro Studien zur Überprüfung dieser Hypothese umfasste. 
Zahlreiche eingeschlossene Studien der letzten 50 Jahre bis einschließlich 2013, die 
Cytokine, Wachstumsfaktoren, mesenchymale Stammzellen, Geneuntersuchungen, 
Hormone, Proteine und Enzyme analysierten, konnten die aufgeführte Hypothese 
nicht belegen. Im Rahmen experimenteller Studien scheinen zentral ausgeschüttete 
osteoinduktive Faktoren, die im Serum und Liquor nach SHT nachweisbar sind, die 
Frakturheilung zu beschleunigen. Demgegenüber konnten klinische Studien einen 
solchen Effekt jedoch nicht belegen. 
Daher wurde in Kapitel 3 der Dissertation eine retrospektive, klinische Studie 
durchgeführt, um den Einfluss des Schädelhirntraumas, des Thorax-traumas sowie 
der operativen Frakturversorgung auf die Frakturheilung zu untersuchen. 
Wenngleich die Ergebnisse dieser Studie einen Zusammenhang zwischen SHT, 
Thorax-trauma und Frakturheilung nicht belegen konnten, so wurde die Anzahl an 
operativen Eingriffen an langen Röhrenknochen als unabhängiger Risikofraktur für 
die Entwicklung einer Pseudarthrose eruiert.  
Beide Studien dienten als Grundlage und Incentive im Hinblick auf die nachfolgenden 
Studien zur Frakturheilung. 
TEIL II: NEUROHUMORALE MODULATION DER FRAKTURHEILUNG   
Kapitel 4 der Dissertation galt der Spezifizierung der Einflussnahme efferenter 
sensorischer Nerven auf die Frakturheilung, wobei der Neurokinin-1-Tachykinin 
Rezeptor für den Neurotransmitter Substanz P blockiert wurde. Aus dieser Blockade 
resultierte eine nachgewiesene Beeinträchtigung der Genexpression bedeutsamer 
osteogener Proteine (z.B. Osteocalcin, Kollagen 1A2 und 2A1) während der 
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Frühphase der Frakturheilung. Darüber hinaus führte die Blockade des NK1-
Rezeptors im Kleintiermodell zu einer biomechanischen Schwächung des Kallus 
über den gesamten Knochenheilungsprozess hinaus.   
Kapitel 5 stellte eine Studie des Kleintiermodells an Ratten dar, welche im Rahmen 
eines Femur-Frakturmodells Gang- und Muskelanalysen durchführte. Basierend auf 
der Tatsache, dass Ganganalysen im rehabilitativen Behandlungsbereich bei 
Patienten mit Verletzungen der unteren Extremitäten zunehmend an Bedeutung 
gewinnen, sollte diese Studie eine Standardmethode zur Ganganalyse nach 
Femurfraktur im Kleintiermodell etablieren. Sowohl eine normale Entwicklung des 
Gangbildes als auch die regelhafte Zunahme der Muskelmasse während der 
Frakturheilung im Kleintiermodell werden in diesem Kapitel dargelegt.  Die 
Einführung des CatWalk™-Systems zur Ganganalyse konnte zuverlässig sowohl 
statische als auch dynamische Parameter erfassen und somit eine experimentelle 
Option zum zukünftigen Vergleich der Gangentwicklung bei Patienten mit 
Verletzungen der unteren Extremitäten bieten. 
In Kapitel 6 der vorliegenden Dissertation wurden in einer klinischen Studie 
Biomarker des Arginin-Stickstoffmonoxid Metabolismus aus dem intramedullären 
Knochen analysiert, die während der Markraumbohrung (RIA-Verfahren) in der 
Pseudarthrosenversorgung gewonnen wurden. Es gelang hierbei erstmals der 
Nachweis, dass Arginin, Ornithin und NOS2 als Prognosemarker im Hinblick auf die 
Pseudarthrosenheilung valide genutzt werden können. 
Kapitel 7, 8 und 9 legten den Fokus auf die zellulären Regulationsmechanismen der 
inflammatorischen Reaktion nach Femurfraktur im Kleintiermodell. 
In Kapitel 7 wurde der Einfluss von Mikrovesikeln, die eine bedeutsame Rolle in der 
inter- und transzellularen Kommunikation einnehmen, auf Osteoblasten analysiert. 
So konnte nachgewiesen werden, dass die abgeleiteten Mikrovesikel nach 
Femurfraktur zeitabhängig vermehrt in Osteoblasten aufgenommen und 
konzentriert um den Zellkern gelagert vorlagen. Zudem scheint die Viabilität der 
Osteoblasten durch die Inkorporation der Mikrovesikel beeinflusst zu werden, was 
insbesondere in der späten inflammatorischen Phase die Frakturheilung begünstigt. 
In Kapitel 8 wurde dargelegt, dass drei Tage nach Frakturinduktion eine temporäre 
Reduktion Neutrophiler unter gleichzeitiger Zunahme einer CD11a Expression bei 
Abfall einer CD11b Expression auf den Zelloberflächen der zirkulierenden 
Neutrophilen auftrat. Zudem imponierte eine neue Untergruppe von 
CD11bhigh/CD11ahigh Neutrophilen mit Co-Expression von α4-Integrin (CD49d) 
während der darauffolgenden Wiederherstellung der Neutrophilen-Hämostase.  
Kapitel 9 widmete sich dem Einfluss einer intramedullär stabilisierten 
Femurfraktur auf Charakteristika pulmonaler Neutrophiler im Kleintiermodell. Im 
Gegensatz zu der in Kapitel 8 beschriebenen, reduzierten Aktivität Neutrophiler im 
peripheren Blut stieg die Anzahl Neutrophiler und die Expression der 
Membranrezeptoren im pulmonalen Pool während der frühen Phase der 
Frakturheilung deutlich an. Abschließend fielen diese wieder auf das Normalniveau 
ab. 
&
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Kapitel 10 beinhaltet letztlich eine umfassende Diskussion und Schlussfolgerung 
der vorgelegten Dissertation. Die Ergebnisse der einzelnen Untersuchungen werden 
vor dem Hintergrund der international etablierten Studien ausführlich diskutiert. 
Zudem können bestehende Diskrepanzen für zukünftige Studien aufgezeigt werden. 
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As presented in the introduction of this thesis, the process of fracture healing and 
bone regeneration is an extremely complex process in which, besides the 
musculoskeletal system, other systems such as the neurological, vascular and 
immune systems play an important role. An immense amount of biological factors 
from each of these systems interact with each other and contribute to the 
regeneration of bony defects. With this thesis, we aimed to evaluate the influence of 
neuro-humoral modulation in the fracture healing process, without pretending that 
the evaluation is complete, hence to just lift a tip of the veil. 
The valorisation of results from experimental research, in the way Karl Marx 
originally conceptualised this theoretical concept of ‘Verwertung’ in his critique of 
political economy, is not that obvious because the results of experimental studies 
often cannot directly be implemented in daily lives or in medical treatments and thus 
will not generate money. Therefore, in this valorisation, we describe the value our 
results have or could have for further research and possibly in the long run for 
clinical applications. 
The results from our review described in chapter 2, the retrospective study 
described in chapter 3 and the results of the literature study described in the general 
discussion (chapter 10) about newer studies on the impact of TBI on fracture 
healing are all concerned with the influence of TBI on the fracture healing process. 
On one hand, we could demonstrate that the majority of the experimental studies 
tend to provide evidence for the positive influence of TBI on fracture healing; on the 
other hand, the clinical studies, most of which are retrospective, could not generally 
subscribe these findings. The value of these results should be such that the scientific 
community is triggered to further investigate this phenomenon and discover the 
pathophysiologic mechanisms that explain the relation between certain biologic 
factors released after TBI and the bone regeneration process. Moreover, the results 
shown in our studies could be an impulse to instigate a large randomised, 
prospective, clinical study to find clinical support for these experimental findings. 
In chapter 4, we demonstrated that the blockage of the NK1-receptor for substance 
P has a considerable influence on gene expression and bone strength throughout the 
fracture healing process. A logical next step in the research on the influence of 
neurotransmitters in fracture healing would be to administer substance P in small 
animal fracture healing and/or disturbed fracture healing models to evaluate its 
direct influence on the fracture healing process. Substance P is a biomarker, which is 
set free after TBI; in addition to causing pro-inflammatory effects, it causes increased 
vascular permeability, brain oedema and functional deficits after TBI 1. Lorente et al. 
showed that the substance P levels in serum are correlated to the severity and 
mortality of TBI 2. In this context, it would be very interesting to evaluate the 
dynamics of substance P and fracture healing in a small animal fracture model with 
concomitant TBI. After further experimental research on the function of substance P, 
it also could become a biomarker for fracture healing in patients because the 
concentration of substance P might be associated with the quality of fracture healing.  
In chapter 5, we proved the CatWalk gait analysis system to be an outstanding tool 
to assess both static and dynamic gait parameters in a non-invasive, longitudinal 
manner in an experimental small animal model of fracture healing. In our opinion, 
the CatWalk system has the potential to become the gold standard for gait analyses 
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in small animal fracture models. Because more than 50% of experimental animal 
fracture models are performed with mice and rats, the use of this system would 
significantly improve the knowledge about behavioural and locomotor recovery 
after lower extremity fractures. 
To date, the most important tools for diagnosing disturbed fracture healing are 
clinical and radiological findings. Although research on possible biomarkers that can 
be used as predictors for non-union development is promising, achieving consensus 
is very difficult because the evidence available is heterogeneous 3. The results of our 
study described in chapter 6 most importantly indicate a significantly lower 
ornithine concentration and arginase-1 expression in the bone marrow of patients 
developing non-unions. This was the first study to recognise these possible 
biomarkers (i.e. arginine, ornithine and iNOS) that could be used as predictors of the 
outcome of the autologous bone grafting procedure by RIA in cases of non-union. As 
the exact treatment and the time point of this non-union treatment are still under 
discussion, and the socio-economic impact of disturbed fracture healing is immense, 
finding biomarkers, which can predict the prognosis of the fracture healing process 
and the outcome of certain procedures performed in cases of non-unions, will be very 
valuable. Therefore, this study could be an excellent starting point to further 
investigate these biomarkers in the fracture healing process and to determine 
certain cut-off points for the different biomarkers, based on which the prognosis of 
fracture healing and non-union treatment could be estimated. 
During the last years, the intercellular communication through vesicles loaded with 
different proteins, mRNAs and miRNAs, known as exosomes, MVs, and apoptotic 
bodies, is gaining interest in fracture healing research. In this context, we showed in 
an in vitro study, described in chapter 7, that MVs isolated after a femoral fracture 
were time-dependently incorporated in osteoblasts and concentrated around the 
nucleus. These MVs from trauma plasma increased the proliferation and viability of 
osteoblasts, particularly in the late phase (i.e. two weeks post-fracture) of fracture 
healing. The fracture healing process involves a complex network of signal 
transduction between a variety of cells. Demonstrating the regulating effect of MVs 
on fracture healing by increasing the proliferation and viability of osteoblasts is just 
a first step in understanding the role that MVs might play in the fracture healing 
process. The characteristics of the exact role of MVs in the intercellular 
communication between cells in the fracture healing process are still to be 
discovered in future research, including the origin, the composition and the target 
cells of these MVs as well as the mechanism of action of the different constituents 
within these MVs. If these questions are answered, the way in which the responsible 
contents of MVs can be used to help in the diagnostics or treatment of fractures 
should be addressed. Possible applications could be the adjustment of the content or 
local application of MVs to alter the fracture healing process. Because the current 
exosome isolation methods such as ultracentrifugation and ultrafiltration only 
provide a low exosome yield 4, the challenge of obtaining sufficient amounts of 
exosomes should be overcome.  
In our small animal neutrophil studies, demonstrated in chapter 8 and 9, we showed 
that three days after intramedullary nailing and fracture induction, the concentration &
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of circulating neutrophils as well as the neutrophil activation, characterised by a 
change of integrin expression on their surface, decreased. One theory explaining this 
decrease is that the decrease expresses the homing of neutrophils into the fracture 
haematoma during the inflammatory stage of fracture healing, wherein they clear 
fracture debris and initiate further steps in the normal fracture healing process. 
Another theory, supported by our findings in chapter 9, is that this decrease is 
attributable to an increased extravasation of neutrophils not only into the fracture 
haematoma but also into peripheral tissues, such as the lungs, potentially causing 
tissue damage (i.e. ARDS/ALI). In future studies the number of circulatory 
neutrophils should be compared to the number of neutrophils in the fracture 
haematoma and the pulmonary pool after fracture. All in all, the total range of 
functions of the neutrophils as activators and regulators of different cell processes is 
still to be discovered in future studies. 
We also demonstrated, in chapter 8, the increased heterogeneity of the blood 
neutrophil pool during the restoration phase after fracture, with a new subset of 
unique CD11bhigh/CD11ahigh neutrophils present in the post-inflammatory 
neutrophil pool. Because it is not yet clear if these subsets belong to separate 
developing lineages or embody certain activation states of a common precursor, this 
finding offers a basis for further research on the exact origin of this novel subtype 
and on novel immunotherapeutic strategies to modulate neutrophil homeostasis 
after fractures or in cases of disturbed fracture healing. 
Similarly to several former studies that have shown the increased pulmonary 
neutrophil influx after trauma, in chapter 9, we demonstrated a transient increase 
in pulmonary neutrophil deposition and a contemporary increase in the activation 
status of the pulmonary neutrophil pool after an intramedullary stabilised femur 
fracture. Furthermore, we showed the striking differences in the activation status of 
the neutrophils belonging to the pulmonary parenchymal compartment and those 
belonging to the broncho-alveolar compartment. This qualitative description of 
pulmonary neutrophil populations and their characteristics should incite further 
research on the influence of different neutrophil subsets on the development of 
pulmonary complications and on the possibility to use these neutrophil cell-surface 
receptors as markers for neutrophil activation status. 
REFERENCES
1. Donkin JJ, Nimmo AJ, Cernak I, Blumbergs PC, 
Vink R. Substance P is associated with the 
development of brain edema and functional deficits 
after traumatic brain injury. Journal of cerebral blood 
flow and metabolism : official journal of the 
International Society of Cerebral Blood Flow and 
Metabolism 2009; 29(8): 1388-98. 
2. Lorente L, Martin MM, Almeida T, et al. Serum 
substance P levels are associated with severity and 
mortality in patients with severe traumatic brain 
injury. Critical care 2015; 19: 192. 
3. Sousa CP, Dias IR, Lopez-Pena M, et al. Bone 
turnover markers for early detection of fracture 
healing disturbances: A review of the scientific 
literature. Anais da Academia Brasileira de Ciencias 
2015; 87(2): 1049-61. 
4. Peinado H, Aleckovic M, Lavotshkin S, et al. 
Melanoma exosomes educate bone marrow 
progenitor cells toward a pro-metastatic phenotype 
through MET. Nature medicine 2012; 18(6): 883-91
.
234
| APPENDIX III 
 
 
 
Acknowledgements 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
APPENDIX III | 
236 
Last but not least, the word of thanks for those people who supported, inspired, and 
helped me on my way to become a surgeon and finally, a Doctor of Philosophy. 
Prof. Dr. med. Frank Hildebrand, dear Frank, thank you very much for supporting 
me throughout the last years of this PhD-project and for giving me the opportunity 
to combine my research with my daily work as a trauma surgeon within your 
department. You were very important in critically reviewing and improving my 
manuscripts and providing ideas of how to design and mould the theme of this 
project. Thank you for your constructive cooperation and your attention. 
Prof. dr. Martijn Poeze, dear Martijn, you gave me the opportunity to become a PhD-
candidate at the MUMC+ and although it was sometimes difficult to organize our 
meetings due to our busy schedules, these meetings were always very gratifying. You 
were very helpful in structuring and outlining this thesis and I am grateful and proud 
to be the first Doctor of Philosophy derived from the bilateral co-operation of our 
two departments. Hopefully, in the near future, we can expand this collaboration 
both in the clinical and the research field. 
Priv. Doz. Dr. med. Hagen Andruszkow, dear Hagen, I would not have been able to 
adequately evaluate the results of all studies without your help and your enthusiasm 
about statistics and therefore, I thank you from the bottom of my heart. You always 
made time for me and you patiently revised every version of my manuscripts with 
me, even when we reached ‘versie 29’ of a single manuscript.  
Johannes Greven. As head of the research laboratory of our department, you were 
the spider in the web of all studies within my PhD-project. Thank you for your co-
operation, your perseverance and your coordinating role in this project.  
Furthermore, I want to thank Michel Teuben, Zhi Qiao, Dennis Meesters and all 
other research colleagues for their collaboration, help and support, especially at the 
beginning and end of this PhD-project. 
dr. Heinrich Janzing, dear Heinrich, maybe you are not aware of the great impact 
you had on me as a person and the role model you were to me as a surgeon. For me, 
you were the founding father of the way I would like to be as a physician, a surgeon 
and a tutor and therefore I am truly grateful that I had the privilege to work with and 
learn from you. Thank you for being a great inspiration and motivation for me to 
become a trauma surgeon. 
dr. Jan Verbruggen, dear Jan, thank you for introducing me in Aachen with PD. Dr. 
med. Hans-Josef Erli, so I could still aspire to become a trauma surgeon, which was 
one of my dreams, after all. Until now, I have no regrets! 
Dr. med. Mathias Nossek, dear Mathias, I have never met a colleague who worked 
so hard and was as correct to patients and colleagues as you were. In that, you were 
a great example to me and besides that, I have learned a lot from you operatively.  
Prof. Dr. med. Bernhard Schmidt-Rohlfing, dear Bernhard, during my residency 
you enabled me to operate a lot and therefore I could gather a lot of experience, for 
which I am truly thankful. 
Dr. med. Achim Dohmen, dear Achim, I got to know you during my orthopaedic 
rotation at the St. Elisabeth Hospital Geilenkirchen, where you teached me how to 
236
| ACKNOWLEDGEMENTS 
237 
 
implant an endoprosthesis properly and efficiently. Furthermore, I greatly 
appreciate your drive to expand your department and to warrant the quality of 
patient care. Thank you for the great time I had in Geilenkirchen with you. 
Priv. Doz. Dr. med. Richard Sellei, dear Richard, thank you for taking care of me 
during my first period in Germany and for being a great colleague to me throughout 
the years. I deeply respect you as a friend and as a surgeon and by the way, I still 
strive for a little piece of your patience.  
Prof. Dr. med. Philipp Kobbe, dear Philipp, thank you for being a sparring partner in 
discussions about the treatment of patients, future perspectives and other (less) 
important things in life. These discussions always force me to be on the alert, and 
that is a good thing. 
In addition, I would like to thank my dear friends and family, who provided a 
sympathetic ear, stimulating discussions as well as happy distractions to rest my 
mind outside of my research and work. Special thanks go out to…  
dr. Guido Koopmans, dear Guido, dear best friend, thank you for being my sounding 
board throughout this project, because that helped me a lot, just by talking about 
science. I greatly appreciate you as my best friend and I deeply respect your 
perseverance in organising and structuring your research projects at Algiax 
pharmaceuticals around your promising compound AP-325. I am really grateful that 
you are my friend and deep inside, I envy you for the time you spend on sports, of 
course! 
My dear brother, Jeroen, although we do not see each other very often, I know I can 
always rely on you and that is a comforting thought. Thank you. 
Dear dad, until now I have never met another person who is interested in so many 
fields of life, nature, sports, languages, countries, people, etc. You largely formed my 
character, which I have inherited from mom and I want to thank you that you always 
encouraged and supported me without conditions in everything I did! 
Dear mom, thank you for always covering my back and supporting me in whatever 
my goals were. Above all, to me, you are the one who gives unconditional motherly 
love to me and I am really grateful that my children receive the same! 
Dear Jente, Max, & Cato, my three precious ´kabouters´, although I work a lot, and I 
can be a little grumpy sometimes, you may never forget that I love all three of you 
just like you are and I will do anything to enable you to freely strive for your goals 
and to become a happy person. I could never wish for nicer, funnier, and sweeter 
children as you are! 
My dear Geertje, since I know you, my morning moodiness has nearly disappeared. 
I want to thank you that I could always rely on you as the base of our family. Honestly, 
without your support and the freedom you give to me, I could not have reached so 
far. You are the love of my life, whatever happens next, and I hope, some time I can 
make up for my absences and long working hours. I love you! 
&
237
 
238 238
| APPENDIX IV 
 
 
 
Curriculum vitae 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
APPENDIX IV | 
240 
Martijn was born on the 30th of September 1976 in Sittard, the 
Netherlands. He grew up in a sportive family and during the 
first 20 years of his life playing soccer was his greatest passion. 
Since a class `human biology` in the last year of his grammar 
school, he knew that if he did not manage to become a 
professional soccer player, he wanted to become a physician.  
In 1994 he finished his secondary school and started to study 
human medicine at the `Limburgs Universitair Centrum` in 
Diepenbeek, Belgium. He combined his part-time study with 
playing soccer and here, thanks to the outstanding anatomy 
courses, he decided that he wanted to work in a surgical 
specialty. In 1997 he switched from the Belgian university to the Maastricht 
University in the Netherlands, because there he could combine his sporting career 
with a full-time medical study. 
After his studies, he worked from 2003 – 2007 in different hospitals in the 
Netherlands, among others in the VieCuri Medical Centre in Venlo, where under 
supervision of dr. H.M.J. Janzing his basic surgical skills were formed. As he did not 
manage to get into the surgical residency program within the Netherlands, and he 
was determined to become a trauma surgeon, he diverted to the other neighbouring 
country, Germany. Here he completed his residency `Orthopaedics and Trauma 
Surgery` at the University Medical Center RWTH Aachen under the supervision of 
Priv. Doz. Dr. med. H.J. Erli und Prof. Dr. med. F.U. Niethard and the St. Elisabeth 
Hospital Geilenkirchen under supervision of Dr. med. A. Dohmen. 
Since 2011 he became an attending physician of the department of Orthopaedic 
Trauma and Reconstructive Surgery at the University Medical Center RWTH Aachen, 
Germany. He also became the head of the department of Sports Traumatology and 
Minimal-invasive Joint Surgery. Prof. Dr. med. H.C. Pape, as head of the department 
provided the circumstances for him to fully develop his traumatological skills and to 
extend the department freely. After Prof. Dr. med. F. Hildebrand took over the 
position as head of the department, Martijn gained a leading position within the 
department of Orthopaedic Trauma and Reconstructive Surgery at the University 
Medical Center RWTH Aachen in September 2018. 
In 2015 he started, parallel to his daily work as a physician, this Ph.D.-project in 
cooperation with the department of Trauma Surgery of the Maastricht University 
Medical Center (MUMC+). Supported by his colleagues of the research laboratory of 
the department of Orthopaedic Trauma and Reconstructive Surgery at the University 
Medical Center RWTH Aachen, he could complete his thesis in the summer of 2020. 
Also due to the obvious ups and downs of a scientific research project as this, Martijn 
worked on it with great pleasure. Nevertheless, he looks forward, after one and a half 
years of working up results and writing and correcting manuscripts, to spend more 
time on operating patients and sporting again. 
Hopefully, after the COVID-19 pandemic, a long-cherished dream of Martijn will 
come true and he will perform developmental work in Africa. 
Altogether, he is still convinced that he has the greatest job in the world!
240
| APPENDIX V 
 
 
 
List of publications 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
APPENDIX V | 
242 
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